Serial	O
measurements	O
of	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
in	O
patients	O
with	O
systemic	O
vasculitis	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
value	O
of	O
serial	O
determinations	O
of	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
(	O
ANCA	O
)	O
for	O
monitoring	O
disease	O
activity	O
in	O
patients	O
with	O
systemic	O
vasculitis	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
three	O
patients	O
with	O
histologically	O
proven	O
vasculitis	O
(	O
21	O
with	O
Wegener	O
's	O
granulomatosis	O
,	O
17	O
with	O
microscopic	O
polyangiitis	O
,	O
and	O
5	O
with	O
renal	O
-	O
limited	O
vasculitis	O
)	O
were	O
studied	O
for	O
a	O
median	O
follow	O
-	O
up	O
of	O
22	O
months	O
.	O

Disease	O
activity	O
was	O
prospectively	O
assessed	O
and	O
quantified	O
by	O
the	O
Birmingham	O
Vasculitis	O
Activity	O
Score	O
.	O

A	O
total	O
of	O
347	O
sera	O
were	O
analyzed	O
for	O
ANCA	O
determination	O
.	O

RESULTS	O
:	O
Relapses	O
occurred	O
in	O
23	O
(	O
54%	O
)	O
of	O
43	O
patients	O
.	O

Diagnostic	O
category	O
(	O
Wegener	O
's	O
granulomatosis	O
vs	O
micropolyangiitis	O
and	O
renal	O
-	O
limited	O
vasculitis	O
)	O
,	O
severity	O
of	O
initial	O
symptoms	O
(	O
mean	O
vasculitis	O
activity	O
score	O
,	O
mean	O
number	O
of	O
organs	O
involved	O
)	O
,	O
and	O
ANCA	O
pattern	O
[	O
cytoplasmic	O
-	O
ANCA	O
(	O
c	O
-	O
ANCA	O
)	O
vs	O
perinuclear	O
-	O
ANCA	O
(	O
p	O
-	O
ANCA	O
)	O
]	O
did	O
not	O
significantly	O
differ	O
between	O
relapsers	O
and	O
nonrelapsers	O
.	O

Lung	O
involvement	O
was	O
more	O
frequent	O
at	O
onset	O
among	O
relapsers	O
[	O
16	O
of	O
23	O
(	O
70%	O
)	O
vs	O
6	O
of	O
20	O
(	O
30%	O
)	O
;	O
P	O
=	O
0.02	O
]	O
.	O

Relapses	O
were	O
slightly	O
,	O
but	O
not	O
significantly	O
,	O
more	O
frequent	O
in	O
patients	O
with	O
Wegener	O
's	O
granulomatosis	O
or	O
a	O
c	O
-	O
ANCA	O
pattern	O
.	O

The	O
percentage	O
of	O
relapsers	O
was	O
greater	O
in	O
patients	O
with	O
persistently	O
positive	O
ANCA	O
than	O
in	O
patients	O
with	O
negative	O
or	O
decreasing	O
ANCA	O
titers	O
(	O
86%	O
vs	O
20%	O
,	O
P	O
=	O
0.0001	O
)	O
.	O

However	O
,	O
the	O
predictive	O
value	O
of	O
an	O
increase	O
in	O
ANCA	O
titers	O
for	O
the	O
occurrence	O
of	O
a	O
subsequent	O
relapse	O
was	O
only	O
28%	O
(	O
4	O
of	O
14	O
)	O
for	O
c	O
-	O
ANCA	O
,	O
12%	O
(	O
2	O
of	O
17	O
)	O
for	O
anti	O
-	O
proteinase	O
3	O
-	O
ANCA	O
,	O
and	O
43%	O
(	O
6	O
of	O
14	O
)	O
for	O
anti	O
-	O
myeloperoxidase	O
-	O
ANCA	O
.	O

An	O
increase	O
in	O
ANCA	O
occurred	O
before	O
or	O
during	O
relapse	O
in	O
33%	O
(	O
10	O
of	O
30	O
)	O
of	O
cases	O
for	O
c	O
-	O
ANCA	O
/	O
anti	O
-	O
proteinase	O
3	O
antibodies	O
,	O
and	O
73%	O
(	O
11	O
of	O
15	O
)	O
of	O
cases	O
for	O
anti	O
-	O
myeloperoxidase	O
antibodies	O
.	O

CONCLUSION	O
:	O
The	O
persistence	O
of	O
ANCA	O
positivity	O
is	O
strongly	O
associated	O
with	O
relapses	O
.	O

However	O
,	O
an	O
increase	O
in	O
ANCA	O
titers	O
has	O
a	O
poor	O
value	O
for	O
the	O
early	O
prediction	O
of	O
a	O
subsequent	O
relapse	O
and	O
should	O
not	O
be	O
used	O
as	O
a	O
sole	O
parameter	O
for	O
therapeutic	O
intervention	O
.	O

In	O
addition	O
,	O
our	O
results	O
suggest	O
that	O
serial	O
anti	O
-	O
myeloperoxidase	O
determination	O
may	O
be	O
useful	O
as	O
a	O
prognostic	O
marker	O
in	O
patients	O
who	O
are	O
p	O
-	O
ANCA	O
positive	O
.	O

The	O
synthesis	O
of	O
a	O
range	O
of	O
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinones	I-IUPAC
with	O
potential	O
for	O
the	O
chelation	O
of	O
iron	I-TRIVIAL
(	I-TRIVIAL
III	I-TRIVIAL
)	I-TRIVIAL
is	O
described	O
.	O

The	O
pKa	O
values	O
of	O
respective	O
ligands	O
and	O
the	O
stability	O
constants	O
of	O
their	O
iron	I-TRIVIAL
(	I-TRIVIAL
III	I-TRIVIAL
)	I-TRIVIAL
complexes	I-MODIFIER
are	O
presented	O
.	O

The	O
distribution	O
coefficient	O
values	O
of	O
a	O
range	O
of	O
48	O
hydroxypyridinones	I-FAMILY
and	O
their	O
corresponding	O
iron	I-TRIVIAL
(	I-TRIVIAL
III	I-TRIVIAL
)	I-TRIVIAL
complexes	I-MODIFIER
between	O
1	I-TRIVIAL
-	I-TRIVIAL
octanol	I-TRIVIAL
and	O
MOPS	O
buffer	O
(	O
pH	O
7.4	O
)	O
are	O
reported	O
.	O

The	O
range	O
of	O
log	O
Dcomplex	O
values	O
covers	O
7	O
orders	O
of	O
magnitude	O
.	O

The	O
results	O
suggest	O
the	O
existence	O
of	O
a	O
biphasic	O
relationship	O
between	O
the	O
distribution	O
coefficient	O
values	O
of	O
the	O
chelator	O
and	O
the	O
corresponding	O
iron	I-TRIVIAL
(	I-TRIVIAL
III	I-TRIVIAL
)	I-TRIVIAL
complexes	I-MODIFIER
.	O

For	O
ligands	O
with	O
a	O
log	O
Dligand	O
=	O
-	O
1	O
,	O
a	O
linear	O
relationship	O
exists	O
with	O
a	O
value	O
of	O
the	O
slope	O
2.53	O
,	O
whereas	O
with	O
ligands	O
with	O
a	O
log	O
Dligand	O
&	O
lt	O
;	O
-	O
1	O
,	O
a	O
linear	O
relationship	O
exists	O
with	O
a	O
slope	O
of	O
0.49	O
.	O

The	O
reduced	O
slope	O
for	O
the	O
more	O
hydrophilic	O
molecules	O
of	O
the	O
series	O
offers	O
some	O
advantage	O
for	O
this	O
type	O
of	O
hydroxypyridinone	I-FAMILY
as	O
the	O
distribution	O
coefficients	O
for	O
such	O
complexes	O
do	O
not	O
change	O
so	O
rapidly	O
with	O
increasing	O
ligand	O
hydrophilicity	O
.	O

The	O
ability	O
of	O
selected	O
3	I-IUPAC
-	I-IUPAC
hydroxypyridinones	I-IUPAC
to	O
facilitate	O
the	O
excretion	O
of	O
iron	O
in	O
bile	O
was	O
investigated	O
in	O
non	O
-	O
iron	O
-	O
overloaded	O
,	O
bile	O
duct	O
-	O
cannulated	O
rats	O
and	O
in	O
a	O
[	I-IUPAC
59Fe	I-IUPAC
]	I-IUPAC
ferritin	I-IUPAC
-	O
loaded	O
rat	O
model	O
.	O

Both	O
systems	O
compare	O
the	O
ability	O
of	O
chelators	O
to	O
remove	O
iron	O
from	O
the	O
liver	O
,	O
the	O
prime	O
target	O
organ	O
in	O
thalassemia	O
.	O

The	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
are	O
demonstrated	O
to	O
be	O
orally	O
active	O
under	O
the	O
in	O
vivo	O
conditions	O
adopted	O
.	O

Thus	O
both	O
1	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
hydroxyalkyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carboxyalkyl	I-IUPAC
)	I-IUPAC
pyridinones	I-IUPAC
are	O
able	O
to	O
remove	O
iron	I-TRIVIAL
from	O
the	O
liver	O
.	O

Although	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carboxyalkyl	I-IUPAC
)	I-IUPAC
hydroxypyridinones	I-IUPAC
are	O
active	O
,	O
they	O
do	O
not	O
demonstrate	O
any	O
clear	O
advantage	O
over	O
Deferiprone	I-TRIVIAL
(	O
1,2	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
)	O
.	O

Indeed	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkyl	I-IUPAC
)	I-IUPAC
hydroxypyridinones	I-IUPAC
which	O
are	O
known	O
to	O
be	O
rapidly	O
converted	O
to	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carboxyalkyl	I-IUPAC
)	I-IUPAC
hydroxypyridinones	I-IUPAC
are	O
also	O
marginally	O
superior	O
to	O
Deferiprone	I-TRIVIAL
.	O

In	O
contrast	O
,	O
2	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
which	O
is	O
not	O
metabolized	O
to	O
the	O
corresponding	O
(	I-TRIVIAL
carboxyalkyl	I-TRIVIAL
)	I-TRIVIAL
hydroxypyridinone	I-TRIVIAL
,	O
was	O
found	O
to	O
be	O
superior	O
to	O
Deferiprone	I-TRIVIAL
and	O
therefore	O
deserves	O
further	O
consideration	O
as	O
an	O
orally	O
active	O
iron	O
chelator	O
with	O
potential	O
for	O
the	O
treatment	O
of	O
iron	I-TRIVIAL
overload	O
associated	O
with	O
transfusion	O
-	O
dependent	O
thalassemia	O
.	O

A	O
series	O
of	O
analogues	O
of	O
the	O
analgesic	O
dipeptide	O
derivative	O
H	O
-	O
Lys	O
-	O
Trp	O
(	O
NPS	O
)	O
-	O
OMe	O
has	O
been	O
designed	O
to	O
determine	O
the	O
influence	O
of	O
the	O
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
nitrophenyl	I-PARTIUPAC
)	I-PARTIUPAC
sulfenyl	I-PARTIUPAC
(	O
NPS	I-ABBREVIATION
)	O
moiety	I-MODIFIER
on	O
the	O
activity	O
.	O

The	O
syntheses	O
and	O
antinociceptive	O
effects	O
of	O
these	O
analogues	O
of	O
general	O
formula	O
H	O
-	O
Lys	O
-	O
Trp	O
(	O
R	O
)	O
-	O
OMe	O
[	O
R	O
=	O
phenylsulfenyl	I-PARTIUPAC
(	O
PS	I-ABBREVIATION
)	O
(	O
9	O
)	O
;	O
R	O
=	O
(	O
2	I-PARTIUPAC
-	I-PARTIUPAC
carbomethyoxyphenyl	I-PARTIUPAC
)	I-PARTIUPAC
sulfenyl	I-PARTIUPAC
(	O
CmPS	I-ABBREVIATION
)	O
(	O
10	O
)	O
;	O
R	O
=	O
(	O
4	I-PARTIUPAC
-	I-PARTIUPAC
nitrophenyl	I-PARTIUPAC
)	I-PARTIUPAC
sulfenyl	I-PARTIUPAC
(	O
pNPS	I-ABBREVIATION
)	O
(	O
11	O
)	O
;	O
R	O
=	O
(	O
2,4	I-PARTIUPAC
-	I-PARTIUPAC
dinitrophenyl	I-PARTIUPAC
)	I-PARTIUPAC
sulfenyl	I-PARTIUPAC
(	O
DNPS	I-ABBREVIATION
)	O
(	O
12	O
)	O
;	O
R	O
=	O
[	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
acetylamino	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
carbomethoxyethyl	I-PARTIUPAC
]	I-PARTIUPAC
sulfenyl	I-PARTIUPAC
(	O
AacCmES	I-ABBREVIATION
)	O
(	O
13	O
)	O
;	O
R	O
=	O
[	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
acetylamino	I-PARTIUPAC
)	I-PARTIUPAC
phenyl	I-PARTIUPAC
]	I-PARTIUPAC
sulfenyl	I-PARTIUPAC
(	O
AacPS	I-ABBREVIATION
)	O
(	O
17	O
)	O
;	O
R	O
=	O
tert	I-PARTIUPAC
-	I-PARTIUPAC
butylsulfenyl	I-PARTIUPAC
(	O
t	I-ABBREVIATION
-	I-ABBREVIATION
BuS	I-ABBREVIATION
)	O
(	O
23	O
)	O
;	O
R	O
=	O
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
carbomethoxyethyl	I-PARTIUPAC
)	I-PARTIUPAC
sulfenyl	I-PARTIUPAC
(	O
CmES	I-ABBREVIATION
)	O
(	O
24	O
)	O
]	O
are	O
described	O
.	O

Reaction	O
of	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
-	O
OMe	O
(	O
3	O
)	O
with	O
PS	I-ABBREVIATION
-	O
,	O
CmPS	I-ABBREVIATION
-	O
,	O
pNPS	I-ABBREVIATION
-	O
,	O
DNPS	I-ABBREVIATION
-	O
,	O
and	O
AacCmES	I-ABBREVIATION
-	I-ABBREVIATION
Cl	I-ABBREVIATION
afforded	O
the	O
corresponding	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
sulfenyl	I-IUPAC
)	I-IUPAC
tryptophan	I-IUPAC
derivatives	I-MODIFIER
,	O
which	O
on	O
treatment	O
with	O
boron	I-IUPAC
-	I-IUPAC
tris	I-IUPAC
(	I-IUPAC
trifluoroacetate	I-IUPAC
)	I-IUPAC
/	O
trifluoroacetic	I-IUPAC
acid	I-IUPAC
or	O
trimethylsilyl	I-IUPAC
iodide	I-IUPAC
in	O
acetonitrile	I-TRIVIAL
(	O
Me3SiI	I-SUM
/	O
CH3CN	I-SUM
)	O
provided	O
9-13	O
,	O
respectively	O
.	O

Sulfenylation	O
of	O
3	O
with	O
NPS	I-ABBREVIATION
-	I-ABBREVIATION
Cl	I-ABBREVIATION
gave	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
NPS	O
)	O
-	O
OMe	O
,	O
which	O
,	O
on	O
catalytic	O
hydrogenation	O
of	O
the	O
nitro	O
group	O
using	O
10%	O
Pd	O
/	O
C	O
followed	O
by	O
acetylation	O
of	O
the	O
resulting	O
amino	O
function	O
and	O
removal	O
of	O
the	O
protecting	O
Z	O
groups	O
,	O
gave	O
17	O
.	O

Condensation	O
of	O
2	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
tert	I-PARTIUPAC
-	I-PARTIUPAC
butylsulfenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbomethoxyethyl	I-IUPAC
)	I-IUPAC
sulfenyl	I-IUPAC
]	I-IUPAC
tryptophan	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
,	O
obtained	O
by	O
reaction	O
of	O
methyl	I-IUPAC
3a	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1,2,3,3	I-IUPAC
a	I-IUPAC
,	I-IUPAC
8,8	I-IUPAC
a	I-IUPAC
-	I-IUPAC
hexahydropyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxyla	I-IUPAC
te	I-IUPAC
with	O
the	O
corresponding	O
thiol	O
,	O
with	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
OSu	O
afforded	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
t	O
-	O
BuS	O
)	O
-	O
OMe	O
and	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
CmES	O
)	O
-	O
OMe	O
,	O
which	O
on	O
treatment	O
with	O
Me3SiI	I-SUM
/	O
CH3CN	I-SUM
provided	O
23	O
and	O
24	O
,	O
respectively	O
.	O

Intracerebroventricular	O
administration	O
of	O
10	O
elicited	O
a	O
naloxone	I-TRIVIAL
-	O
reversible	O
antinociceptive	O
effect	O
in	O
mice	O
similar	O
to	O
that	O
of	O
H	O
-	O
Lys	O
-	O
Trp	O
(	O
NPS	O
)	O
-	O
OMe	O
.	O

No	O
analgesia	O
was	O
however	O
found	O
with	O
the	O
phenylsulfenyl	I-PARTIUPAC
or	O
acyclic	I-IUPAC
sulfenyl	I-IUPAC
substituted	I-IUPAC
dipeptides	I-IUPAC
9	O
,	O
11	O
,	O
and	O
17	O
or	O
13	O
,	O
23	O
,	O
and	O
24	O
.	O

The	O
Trp	I-ABBREVIATION
(	I-ABBREVIATION
DNPS	I-ABBREVIATION
)	I-ABBREVIATION
-	O
containing	O
analogue	O
was	O
neurotoxic	O
.	O

Structure	O
-	O
activity	O
studies	O
indicate	O
that	O
the	O
role	O
of	O
the	O
NPS	I-ABBREVIATION
and	O
CmPS	I-ABBREVIATION
moieties	B-MODIFIER
could	O
be	O
related	O
to	O
the	O
adoption	O
of	O
a	O
preferential	O
active	O
conformation	O
.	O

A	O
series	O
of	O
substituted	O
1,4	I-IUPAC
-	I-IUPAC
dihydronaphthoquinones	I-IUPAC
,	O
hydroindoloquinones	I-TRIVIAL
,	O
benzofuran	I-IUPAC
-	I-IUPAC
4,7	I-IUPAC
-	I-IUPAC
dihydroquinones	I-IUPAC
,	O
and	O
benzothiophene	I-IUPAC
-	I-IUPAC
4,7	I-IUPAC
-	I-IUPAC
dihydroquinones	I-IUPAC
were	O
synthesized	O
and	O
evaluated	O
for	O
inhibitory	O
activity	O
against	O
5	O
-	O
lipoxygenase	O
.	O

These	O
compounds	O
were	O
found	O
to	O
be	O
active	O
in	O
vitro	O
for	O
LTC4	O
/	O
D4	O
inhibition	O
with	O
the	O
potencies	O
(	O
IC50	O
's	O
)	O
ranging	O
from	O
0.2	O
to	O
85	O
microM	O
.	O

Active	O
1,4	I-IUPAC
-	I-IUPAC
dihydronaphthoquinone	I-IUPAC
acetates	I-IUPAC
(	O
IC50	O
less	O
than	O
20	O
microM	O
)	O
were	O
evaluated	O
in	O
an	O
ex	O
vivo	O
LTB4	O
inhibition	O
assay	O
.	O

The	O
acetates	I-FAMILY
of	O
1,4	I-IUPAC
-	I-IUPAC
dihydronaphthoquinones	I-IUPAC
containing	O
the	O
alkyl	I-PARTIUPAC
substituent	B-MODIFIER
(	I-MODIFIER
s	I-MODIFIER
)	I-MODIFIER
(	O
2	I-PARTIUPAC
-	I-PARTIUPAC
n	I-PARTIUPAC
-	I-PARTIUPAC
butyl	I-PARTIUPAC
,	O
11	O
,	O
and	O
2,3	I-PARTIUPAC
-	I-PARTIUPAC
diethyl	I-PARTIUPAC
,	O
15	O
)	O
exhibited	O
the	O
best	O
activity	O
in	O
LTC4	O
/	O
D4	O
inhibition	O
(	O
IC50	O
=	O
0.2-0.4	O
microM	O
,	O
in	O
vitro	O
)	O
as	O
well	O
as	O
in	O
LTB4	O
inhibition	O
(	O
60-75%	O
inhibition	O
)	O
.	O

The	O
regulation	O
of	O
total	O
creatine	I-TRIVIAL
content	O
in	O
a	O
myoblast	O
cell	O
line	O
.	O

Total	O
cellular	O
creatine	I-TRIVIAL
content	O
is	O
an	O
important	O
bioenergetic	O
parameter	O
in	O
skeletal	O
muscle	O
.	O

To	O
understand	O
its	O
regulation	O
we	O
investigated	O
creatine	I-TRIVIAL
transport	O
and	O
accumulation	O
in	O
the	O
G8	O
cultured	O
skeletal	O
myoblast	O
line	O
.	O

Like	O
other	O
cell	O
types	O
,	O
these	O
contain	O
a	O
creatine	O
transporter	O
,	O
whose	O
activity	O
,	O
measured	O
using	O
a	O
radiolabelling	O
technique	O
,	O
was	O
saturable	O
(	O
Km	O
=	O
110	O
+	O
/	O
-	O
25	O
microM	O
)	O
and	O
largely	O
dependent	O
on	O
extracellular	O
[	O
Na+	O
]	O
.	O

To	O
study	O
sustained	O
influences	O
on	O
steady	O
state	O
creatine	I-TRIVIAL
concentration	O
we	O
measured	O
total	O
cellular	O
creatine	I-TRIVIAL
content	O
using	O
a	O
fluorimetric	O
method	O
in	O
48	O
h	O
incubations	O
.	O

We	O
found	O
that	O
the	O
total	O
cellular	O
creatine	I-TRIVIAL
content	O
was	O
relatively	O
independent	O
of	O
extracellular	O
creatine	I-TRIVIAL
concentration	O
,	O
consistent	O
with	O
high	O
affinity	O
sodium	I-TRIVIAL
-	O
dependent	O
uptake	O
balanced	O
by	O
slow	O
passive	O
efflux	O
.	O

Accordingly	O
,	O
in	O
creatine	I-TRIVIAL
-	O
free	O
incubations	O
net	O
creatine	I-TRIVIAL
efflux	O
was	O
slow	O
(	O
5	O
+	O
/	O
-	O
1%	O
of	O
basal	O
creatine	I-TRIVIAL
content	O
per	O
day	O
over	O
6	O
days	O
)	O
,	O
while	O
creatine	I-TRIVIAL
content	O
in	O
48	O
h	O
incubations	O
was	O
reduced	O
by	O
28	O
+	O
/	O
-	O
13%	O
of	O
control	O
by	O
the	O
Na+	O
,	O
K	O
(	O
+	O
)	O
-	O
ATPase	O
inhibitor	O
ouabain	I-TRIVIAL
.	O

Creatine	I-TRIVIAL
accumulation	O
after	O
48	O
h	O
was	O
stimulated	O
by	O
treatment	O
with	O
the	O
mixed	O
alpha	O
-	O
and	O
beta	O
-	O
adrenergic	O
agonist	O
noradrenaline	I-TRIVIAL
,	O
the	O
beta	O
-	O
adrenergic	O
agonist	O
isoproterenol	I-TRIVIAL
,	O
the	O
beta	O
2	O
-	O
agonist	O
clenbuterol	I-TRIVIAL
and	O
the	O
cAMP	I-TRIVIAL
analogue	B-MODIFIER
N6	B-IUPAC
,	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
dibutyryladenosine	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
cyclic	I-IUPAC
monophosphate	I-IUPAC
,	O
but	O
was	O
unaffected	O
by	O
the	O
alpha	O
1	O
adrenergic	O
agonist	O
methoxamine	I-TRIVIAL
.	O

The	O
noradrenaline	I-TRIVIAL
enhancement	O
of	O
creatine	I-TRIVIAL
accumulation	O
at	O
48	O
h	O
was	O
inhibited	O
by	O
the	O
mixed	O
alpha	O
-	O
and	O
beta	O
-	O
antagonist	O
labetalol	I-TRIVIAL
and	O
by	O
the	O
beta	O
-	O
antagonist	O
propranolol	I-TRIVIAL
,	O
but	O
was	O
unaffected	O
by	O
the	O
alpha	O
2	O
antagonist	O
phentolamine	I-TRIVIAL
;	O
greater	O
inhibition	O
was	O
caused	O
by	O
the	O
beta	O
2	O
antagonist	O
butoxamine	I-TRIVIAL
than	O
the	O
beta	O
1	O
antagonist	O
atenolol	I-TRIVIAL
.	O

Creatine	I-TRIVIAL
accumulation	O
at	O
48	O
h	O
was	O
increased	O
to	O
230	O
+	O
/	O
-	O
6%	O
of	O
control	O
by	O
insulin	O
and	O
by	O
140	O
+	O
/	O
-	O
13%	O
by	O
IGF	O
-	O
I	O
(	O
both	O
at	O
3	O
nM	O
)	O
.	O

Creatine	I-TRIVIAL
accumulation	O
at	O
48	O
h	O
was	O
also	O
increased	O
to	O
280	O
+	O
/	O
-	O
40%	O
of	O
control	O
by	O
3,3	I-IUPAC
'	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
triiodothyronine	I-IUPAC
(	O
at	O
70	O
microM	O
)	O
and	O
to	O
220	O
+	O
/	O
-	O
35%	O
of	O
control	O
by	O
amylin	I-TRIVIAL
(	O
60	O
nM	O
)	O
.	O

As	O
3,3	I-IUPAC
'	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
triiodothyronine	I-IUPAC
,	O
amylin	I-TRIVIAL
and	O
isoproterenol	I-TRIVIAL
all	O
stimulate	O
the	O
Na+	O
,	O
K	O
(	O
+	O
)	O
-	O
ATPase	O
,	O
we	O
suggest	O
that	O
they	O
stimulate	O
Na	I-SUM
(	I-SUM
+	I-SUM
)	I-SUM
-	O
creatine	I-TRIVIAL
cotransport	O
indirectly	O
by	O
increasing	O
the	O
transmembrane	O
[	O
Na+	I-SUM
]	O
concentration	O
gradient	O
and	O
membrane	O
potential	O
.	O

Attenuation	O
of	O
cerebral	O
vasospasm	O
in	O
rabbits	O
using	O
clonidine	I-IUPAC
hydrochloride	I-IUPAC
,	O
a	O
central	O
adrenergic	O
agonist	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
,	O
firstly	O
,	O
if	O
exclusion	O
of	O
central	O
noradrenergic	O
areas	O
in	O
the	O
hypothalamus	O
and	O
brain	O
stem	O
with	O
the	O
central	O
sympathetic	O
blocker	O
clonidine	I-IUPAC
hydrochloride	I-IUPAC
could	O
prevent	O
the	O
development	O
of	O
chronic	O
vasospasm	O
following	O
experimental	O
subarachnoid	O
haemorrhage	O
in	O
rabbits	O
and	O
,	O
secondly	O
,	O
if	O
,	O
parallel	O
with	O
the	O
effect	O
on	O
cerebral	O
arteries	O
,	O
changes	O
in	O
dopamine	O
beta	O
-	O
hydroxylase	O
concentration	O
in	O
the	O
hypothalamus	O
and	O
brain	O
stem	O
could	O
also	O
be	O
detected	O
.	O

Experimental	O
subarachnoid	O
haemorrhage	O
,	O
in	O
concentrations	O
of	O
1	O
ml	O
of	O
autologous	O
arterial	O
blood	O
/	O
1	O
kg	O
of	O
body	O
weight	O
was	O
carried	O
out	O
on	O
18	O
New	O
Zealand	O
rabbits	O
.	O

Histological	O
specimens	O
were	O
obtained	O
by	O
the	O
method	O
of	O
perfusion	O
fixation	O
after	O
the	O
rabbits	O
were	O
sacrificed	O
on	O
day	O
8	O
after	O
subarachnoid	O
haemorrhage	O
.	O

The	O
spastic	O
effect	O
of	O
experimentally	O
induced	O
subarachnoid	O
haemorrhage	O
was	O
determined	O
by	O
assessing	O
the	O
intensity	O
of	O
corrugation	O
of	O
the	O
intima	O
of	O
the	O
rabbit	O
basilar	O
artery	O
by	O
the	O
previously	O
developed	O
method	O
of	O
corrugation	O
coefficient	O
and	O
computer	O
image	O
analysis	O
.	O

The	O
concentration	O
and	O
localization	O
of	O
dopamine	O
beta	O
-	O
hydroxylase	O
in	O
noradrenaline	I-TRIVIAL
-	O
containing	O
neurons	O
was	O
immunohistochemically	O
assessed	O
(	O
semiquantitatively	O
as	O
0	O
,	O
1	O
and	O
2	O
)	O
with	O
anti	O
-	O
dopamine	O
beta	O
-	O
hydroxylase	O
,	O
at	O
precisely	O
defined	O
sites	O
of	O
the	O
hypothalamus	O
and	O
brain	O
stem	O
of	O
the	O
same	O
rabbit	O
.	O

The	O
results	O
revealed	O
less	O
corrugated	O
and	O
smoother	O
intima	O
in	O
the	O
basilar	O
artery	O
and	O
significantly	O
lower	O
dopamine	O
beta	O
-	O
hydroxylase	O
concentration	O
in	O
the	O
control	O
group	O
of	O
rabbits	O
with	O
sham	O
subarachnoid	O
haemorrhage	O
and	O
without	O
any	O
additional	O
interventions	O
(	O
mean	O
corrugation	O
coefficient	O
=	O
1.123	O
+	O
/	O
-	O
0.024	O
,	O
P	O
=	O
0.35	O
x	O
10	O
(	O
-	O
3	O
)	O
;	O
mean	O
dopamine	O
beta	O
-	O
hydroxylase	O
=	O
0.350	O
+	O
/	O
-	O
0.071	O
,	O
P	O
=	O
0.22	O
x	O
10	O
(	O
-	O
3	O
)	O
)	O
,	O
and	O
smoother	O
intima	O
in	O
the	O
basilar	O
artery	O
with	O
significantly	O
lower	O
concentration	O
of	O
dopamine	O
beta	O
-	O
hydroxylase	O
in	O
the	O
clonidine	I-TRIVIAL
group	B-MODIFIER
(	O
rabbits	O
with	O
subarachnoid	O
haemorrhage	O
and	O
central	O
alpha	O
(	O
2	O
)	O
-	O
blocker	O
clonidine	I-IUPAC
hydrochloride	I-IUPAC
at	O
a	O
daily	O
dose	O
of	O
0.03	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
for	O
8	O
days	O
;	O
mean	O
corrugation	O
coefficient	O
=	O
1.177	O
+	O
/	O
-	O
0.058	O
,	O
P	O
=	O
1.7	O
x	O
10	O
(	O
-	O
3	O
)	O
;	O
mean	O
dopamine	I-TRIVIAL
beta	O
-	O
hydroxylase	O
=	O
0.583	O
+	O
/	O
-	O
0.175	O
,	O
P	O
=	O
1.1	O
x	O
10	O
(	O
-	O
3	O
)	O
)	O
.	O

In	O
comparison	O
,	O
the	O
haemorrhage	O
only	O
group	O
(	O
rabbits	O
with	O
subarachnoid	O
haemorrhage	O
and	O
without	O
medication	O
;	O
mean	O
corrugation	O
coefficient	O
=	O
1.370	O
+	O
/	O
-	O
0.101	O
;	O
mean	O
dopamine	O
beta	O
-	O
hydroxylase	O
=	O
1.214	O
+	O
/	O
-	O
0.313	O
)	O
displayed	O
intensive	O
corrugation	O
of	O
the	O
intima	O
of	O
the	O
basilar	O
artery	O
and	O
a	O
significantly	O
more	O
intensive	O
accumulation	O
of	O
dopamine	O
beta	O
-	O
hydroxylase	O
than	O
did	O
the	O
control	O
group	O
and	O
the	O
clonidine	O
group	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrated	O
that	O
the	O
central	O
alpha	O
(	O
2	O
)	O
-	O
blocker	O
clonidine	I-IUPAC
hydrochloride	I-IUPAC
effectively	O
prevents	O
vasospasm	O
,	O
and	O
diminishes	O
the	O
concentration	O
of	O
cerebral	O
dopamine	O
beta	O
-	O
hydroxylase	O
in	O
the	O
hypothalamus	O
and	O
brain	O
stem	O
after	O
experimental	O
subarachnoid	O
haemorrhage	O
in	O
rabbits	O
.	O

Heterologous	O
expression	O
of	O
lipoprotein	O
-	O
associated	O
phospholipase	O
A2	O
in	O
different	O
expression	O
systems	O
.	O

Lipoprotein	O
-	O
associated	O
phospholipase	O
A	O
(	O
2	O
)	O
(	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
)	O
is	O
a	O
key	O
enzyme	O
involved	O
in	O
atherosclerosis	O
,	O
and	O
has	O
been	O
considered	O
as	O
a	O
new	O
target	O
for	O
drug	O
discovery	O
.	O

The	O
major	O
difficulty	O
for	O
high	O
-	O
throughput	O
screening	O
of	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
inhibitors	O
and	O
for	O
functional	O
studies	O
was	O
their	O
fast	O
and	O
efficient	O
production	O
.	O

Purification	O
of	O
native	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
from	O
human	O
plasma	O
was	O
complicated	O
and	O
produced	O
a	O
very	O
low	O
yield	O
.	O

We	O
herein	O
examined	O
the	O
feasibility	O
of	O
expressing	O
and	O
purifying	O
recombinant	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
in	O
different	O
heterologous	O
expression	O
systems	O
.	O

The	O
fusion	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
was	O
expressed	O
at	O
high	O
levels	O
and	O
exhibited	O
strong	O
enzyme	O
activity	O
in	O
insect	O
cell	O
-	O
baculovirus	O
expression	O
system	O
.	O

The	O
functional	O
enzyme	O
could	O
also	O
be	O
produced	O
in	O
Pichia	O
pastoris	O
.	O

The	O
inclusion	O
of	O
a	O
Kozak	O
sequence	O
increased	O
greatly	O
the	O
expression	O
level	O
of	O
recombinant	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
in	O
insect	O
cells	O
,	O
but	O
had	O
little	O
effect	O
on	O
the	O
expression	O
of	O
recombinant	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
in	O
P	O
.	O

pastoris	O
and	O
Escherichia	O
coli	O
.	O

P	O
.	O

pastoris	O
-	O
produced	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
could	O
be	O
purified	O
rapidly	O
and	O
conveniently	O
through	O
a	O
one	O
-	O
step	O
procedure	O
,	O
while	O
baculovirus	O
-	O
produced	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
could	O
be	O
efficiently	O
purified	O
through	O
a	O
two	O
-	O
step	O
procedure	O
.	O

This	O
ability	O
to	O
readily	O
produce	O
recombinant	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
could	O
provide	O
a	O
screening	O
model	O
for	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
inhibitors	O
and	O
will	O
facilitate	O
further	O
studies	O
on	O
this	O
enzyme	O
.	O

A	O
series	O
of	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
thieno1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
ÃÂ	I-IUPAC
ÃÂ	I-IUPAC
xazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
s	O
was	O
synthesized	O
and	O
evaluated	O
in	O
vitro	O
for	O
inhibitory	O
activity	O
toward	O
human	O
leukocyte	O
elastase	O
(	O
HLE	O
)	O
.	O

The	O
Gewald	O
thiophen	I-TRIVIAL
e	O
synthesis	O
was	O
utilized	O
to	O
obtain	O
several	O
ethyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminothiophene	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
s	O
.	O

These	O
precursors	O
were	O
subjected	O
to	O
a	O
five	O
-	O
step	O
route	O
to	O
obtain	O
thieno2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
ÃÂ	I-IUPAC
ÃÂ	I-IUPAC
xazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
on	I-IUPAC
es	O
bearing	O
various	O
substituents	O
at	O
positions	O
5	O
and	O
6	O
.	O

Bot	O
h	I-PARTIUPAC
thieno2	I-PARTIUPAC
,	I-PARTIUPAC
3	I-PARTIUPAC
-	O
d	O
an	O
d	I-PARTIUPAC
thieno3	I-PARTIUPAC
,	I-PARTIUPAC
2	I-PARTIUPAC
-	O
d	O
fuse	O
d	I-IUPAC
oxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
on	I-IUPAC
es	O
possess	O
extraordinary	O
chemical	O
stability	O
,	O
which	O
was	O
expressed	O
as	O
rate	O
constants	O
of	O
the	O
alkaline	O
hydrolysis	O
.	O

The	O
kinetic	O
parameters	O
of	O
the	O
HLE	O
inhibition	O
were	O
determined	O
.	O

The	O
most	O
potent	O
compound	O
,	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
1benzothieno2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
ÃÂ	I-IUPAC
ÃÂ	I-IUPAC
xazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	O
,	O
exhibited	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
5.8	O
n	O
M	I-IUPAC
.	I-IUPAC

2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Diethylamino	I-IUPAC
)	I-IUPAC
thieno1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
ÃÂ	I-IUPAC
ÃÂ	I-IUPAC
xazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	O
act	O
as	O
acyl	O
-	O
enzyme	O
inhibitors	O
of	O
HLE	O
,	O
similar	O
to	O
the	O
inhibition	O
of	O
serine	O
proteases	O
by	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
3,1	I-IUPAC
-	I-IUPAC
benzoxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	O
.	O

The	O
isoste	O
ric	I-IUPAC
benzene	I-IUPAC
-	I-IUPAC
thiop	I-IUPAC
hene	O
replacement	O
accounts	O
for	O
an	O
enhanced	O
stability	O
of	O
the	O
acyl	O
-	O
enzyme	O
intermediates	O
.	O

Structure	O
-	O
activity	O
relationships	O
have	O
been	O
investigated	O
for	O
inhibition	O
of	O
DNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
)	O
and	O
ATM	O
kinase	O
by	O
a	O
series	O
of	O
pyran	I-FAMILY
-	I-FAMILY
2	I-FAMILY
-	I-FAMILY
ones	I-FAMILY
,	O
pyran	I-FAMILY
-	I-FAMILY
4	I-FAMILY
-	I-FAMILY
ones	I-FAMILY
,	O
thiopyran	I-FAMILY
-	I-FAMILY
4	I-FAMILY
-	I-FAMILY
ones	I-FAMILY
,	O
and	O
pyridin	I-FAMILY
-	I-FAMILY
4	I-FAMILY
-	I-FAMILY
ones	I-FAMILY
.	O

A	O
wide	O
range	O
of	O
IC50	O
values	O
were	O
observed	O
for	O
pyranones	I-FAMILY
and	O
thiopyranones	I-FAMILY
substituted	O
at	O
the	O
6	O
-	O
position	O
,	O
with	O
the	O
3	O
-	O
and	O
5	O
-	O
positions	O
proving	O
intolerant	O
to	O
substitution	O
.	O

Related	O
pyran	I-FAMILY
-	I-FAMILY
2	I-FAMILY
-	I-FAMILY
ones	I-FAMILY
,	O
pyran	I-FAMILY
-	I-FAMILY
4	I-FAMILY
-	I-FAMILY
ones	I-FAMILY
,	O
and	O
thiopyran	I-FAMILY
-	I-FAMILY
4	I-FAMILY
-	I-FAMILY
ones	I-FAMILY
showed	O
similar	O
IC50	O
values	O
against	O
DNA	O
-	O
PK	O
,	O
whereas	O
the	O
pyridin	I-FAMILY
-	I-FAMILY
4	I-FAMILY
-	I-FAMILY
one	I-FAMILY
system	O
proved	O
,	O
in	O
general	O
,	O
ineffective	O
at	O
inhibiting	O
DNA	O
-	O
PK	O
.	O

Extended	O
libraries	O
exploring	O
the	O
6	O
-	O
position	O
of	O
2	I-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
-	I-IUPAC
pyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
-	I-IUPAC
thiopyrano	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
identified	O
the	O
first	O
highly	O
potent	O
and	O
selective	O
ATM	O
inhibitor	O
2	I-IUPAC
-	I-IUPAC
morpholin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
thianthren	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
pyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
151C	O
;	O
ATM	O
;	O
IC50	O
=	O
13	O
nM	O
)	O
and	O
revealed	O
constrained	O
SARs	O
for	O
ATM	O
inhibition	O
compared	O
with	O
DNA	O
-	O
PK	O
.	O

One	O
of	O
the	O
most	O
potent	O
DNA	O
-	O
PK	O
inhibitors	O
identified	O
,	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
morpholin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
pyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
16	O
;	O
DNA	O
-	O
PK	O
;	O
IC50	O
=	O
220	O
nM	O
)	O
effectively	O
sensitized	O
HeLa	O
cells	O
to	O
the	O
topoisomerase	O
II	O
inhibitor	O
etoposide	I-TRIVIAL
in	O
vitro	O
.	O

Differential	O
effects	O
of	O
luteinizing	O
hormone	O
-	O
releasing	O
hormone	O
on	O
follicle	O
-	O
stimulating	O
hormone	O
-	O
dependent	O
responses	O
in	O
rat	O
granulosa	O
cells	O
and	O
Sertoli	O
cells	O
in	O
vitro	O
.	O

The	O
abilities	O
of	O
LHRH	O
and	O
a	O
potent	O
LHRH	O
agonist	O
(	O
[	O
D	O
-	O
Ser	O
-	O
(	O
But	O
)	O
,	O
6	O
,	O
des	O
-	O
Gly	O
-	O
NH210	O
]	O
LHRH	O
ethylamide	O
)	O
inhibit	O
FSH	O
responses	O
by	O
rat	O
granulosa	O
cells	O
and	O
Sertoli	O
cells	O
in	O
vitro	O
have	O
been	O
compared	O
.	O

Granulosa	O
cells	O
isolated	O
from	O
22	O
-	O
or	O
25	O
-	O
day	O
-	O
old	O
diethylstilbestrol	I-TRIVIAL
-	O
primed	O
rats	O
and	O
cultured	O
under	O
defined	O
conditions	O
for	O
48	O
h	O
with	O
NIH	I-TRIVIALVAR
-	I-TRIVIALVAR
FSH	I-TRIVIALVAR
-	I-TRIVIALVAR
S13	I-TRIVIALVAR
(	O
300	O
ng	O
/	O
ml	O
)	O
or	O
cholera	I-TRIVIAL
toxin	I-TRIVIAL
(	O
0.1	O
microgram	O
/	O
ml	O
)	O
showed	O
increased	O
aromatase	O
activity	O
,	O
as	O
determined	O
by	O
the	O
release	O
of	O
3H2O	O
from	O
[	I-IUPAC
1	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
testosterone	I-IUPAC
.	O

LHRH	O
(	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
or	O
th	O
agonist	O
(	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
added	O
simultaneously	O
with	O
FSH	O
or	O
cholera	I-TRIVIAL
toxin	I-TRIVIAL
inhibited	O
the	O
effects	O
on	O
the	O
release	O
of	O
3H2O	I-SUM
without	O
influencing	O
the	O
protein	O
content	O
of	O
the	O
cell	O
cultures	O
.	O

A	O
smaller	O
stimulation	O
of	O
3H2O	I-SUM
production	O
occurred	O
with	O
(	I-IUPAC
Bu	I-IUPAC
)	I-IUPAC
2cAMP	I-IUPAC
(	O
1.0	O
mM	O
)	O
plus	O
3	I-IUPAC
-	I-IUPAC
isobutyl	I-IUPAC
-	I-IUPAC
l	I-IUPAC
-	I-IUPAC
methylxanthine	I-IUPAC
(	O
0.1	O
mM	O
)	O
,	O
and	O
this	O
was	O
partially	O
suppressed	O
in	O
the	O
presence	O
of	O
LHRH	O
or	O
the	O
agonist	O
.	O

Parallel	O
studies	O
with	O
Sertoli	O
cells	O
from	O
15	O
-	O
or	O
20	O
-	O
day	O
-	O
old	O
rats	O
demonstrated	O
that	O
culture	O
under	O
appropriate	O
conditions	O
with	O
FSH	O
,	O
cholera	I-TRIVIAL
toxin	I-TRIVIAL
,	O
or	O
(	I-IUPAC
Bu	I-IUPAC
)	I-IUPAC
2cAMP	I-IUPAC
(	O
0.5	O
mM	O
)	O
for	O
24	O
h	O
caused	O
an	O
increase	O
in	O
cellular	O
aromatase	O
activity	O
and	O
enhanced	O
secretion	O
into	O
the	O
medium	O
of	O
plasminogen	O
activator	O
.	O

However	O
,	O
no	O
inhibition	O
by	O
LHRH	O
(	O
10	O
(	O
-	O
7	O
)	O
or	O
10	O
(	O
-	O
9	O
)	O
M	O
)	O
or	O
the	O
agonist	O
(	O
10	O
(	O
-	O
6	O
)	O
or	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
occurred	O
when	O
the	O
peptides	O
were	O
added	O
either	O
simultaneously	O
or	O
24	O
h	O
before	O
the	O
stimulatory	O
agent	O
.	O

Similarly	O
,	O
Sertoli	O
cells	O
from	O
11	O
-	O
day	O
-	O
old	O
rats	O
treated	O
daily	O
with	O
LHRH	O
agonist	O
for	O
5	O
days	O
in	O
culture	O
,	O
showed	O
no	O
inhibition	O
of	O
aromatase	O
activity	O
after	O
a	O
4	O
-	O
h	O
stimulation	O
with	O
FSH	O
or	O
(	I-IUPAC
Bu	I-IUPAC
)	I-IUPAC
2cAMP	I-IUPAC
.	O

FSH	O
dose	O
-	O
response	O
curves	O
(	O
0-300	O
ng	O
/	O
ml	O
)	O
for	O
aromatase	O
activity	O
were	O
shown	O
to	O
be	O
similar	O
after	O
5	O
days	O
of	O
culture	O
with	O
or	O
without	O
10	O
(	O
-	O
8	O
)	O
M	O
LHRH	O
agonist	O
,	O
indicating	O
that	O
the	O
LHRH	O
did	O
not	O
cause	O
a	O
shift	O
in	O
the	O
sensitivity	O
to	O
FSH	O
.	O

The	O
lack	O
of	O
inhibition	O
was	O
seen	O
in	O
Sertoli	O
cell	O
cultures	O
maintained	O
at	O
37	O
or	O
32	O
C	O
.	O

The	O
enzyme	O
digestion	O
method	O
used	O
to	O
isolated	O
Sertoli	O
cells	O
was	O
not	O
responsible	O
for	O
the	O
lack	O
of	O
effects	O
of	O
LHRH	O
,	O
since	O
cell	O
cultures	O
prepared	O
without	O
the	O
aid	O
of	O
proteolytic	O
enzymes	O
showed	O
similar	O
FSH	O
stimulation	O
of	O
aromatase	O
activity	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
(	O
-	O
8	O
)	O
M	O
agonist	O
.	O

Further	O
,	O
there	O
was	O
no	O
evidence	O
of	O
degradation	O
of	O
the	O
LHRH	O
agonist	O
when	O
incubated	O
with	O
Sertoli	O
cell	O
cultures	O
.	O

From	O
these	O
studies	O
,	O
we	O
conclude	O
that	O
1	O
)	O
granulosa	O
cells	O
and	O
Sertoli	O
cells	O
from	O
immature	O
rats	O
differ	O
in	O
their	O
responses	O
to	O
LHRH	O
,	O
and	O
2	O
)	O
the	O
immature	O
Sertoli	O
cell	O
is	O
an	O
unlikely	O
target	O
for	O
a	O
direct	O
inhibiting	O
influence	O
of	O
LHRH	O
on	O
spermatogenesis	O
.	O

We	O
have	O
previously	O
described	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
6H	I-IUPAC
-	I-IUPAC
cyclohepta	I-IUPAC
[	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
4	I-ABBREVIATION
-	I-ABBREVIATION
AHCP	I-ABBREVIATION
)	O
as	O
a	O
highly	O
effective	O
agonist	O
at	O
non	O
-	O
N	O
-	O
methyl	O
-	O
d	O
-	O
aspartate	O
(	O
non	O
-	O
NMDA	O
)	O
glutamate	O
(	O
Glu	O
)	O
receptors	O
in	O
vivo	O
,	O
which	O
is	O
more	O
potent	O
than	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	I-ABBREVIATION
)	O
but	O
inactive	O
at	O
NMDA	O
receptors	O
.	O

However	O
,	O
4	I-ABBREVIATION
-	I-ABBREVIATION
AHCP	I-ABBREVIATION
was	O
found	O
to	O
be	O
much	O
weaker	O
than	O
AMPA	I-ABBREVIATION
as	O
an	O
inhibitor	O
of	O
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
H	I-IUPAC
]	I-IUPAC
AMPA	I-IUPAC
binding	O
and	O
to	O
have	O
limited	O
effect	O
in	O
a	O
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
H	I-IUPAC
]	I-IUPAC
kainic	I-IUPAC
acid	I-IUPAC
binding	O
assay	O
using	O
rat	O
cortical	O
membranes	O
.	O

To	O
shed	O
light	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
underlying	O
this	O
quite	O
enigmatic	O
pharmacological	O
profile	O
of	O
4	I-ABBREVIATION
-	I-ABBREVIATION
AHCP	I-ABBREVIATION
,	O
we	O
have	O
now	O
developed	O
a	O
synthesis	O
of	O
(	I-ABBREVIATION
S	I-ABBREVIATION
)	I-ABBREVIATION
-	I-ABBREVIATION
4	I-ABBREVIATION
-	I-ABBREVIATION
AHCP	I-ABBREVIATION
(	O
6	O
)	O
and	O
(	I-ABBREVIATION
R	I-ABBREVIATION
)	I-ABBREVIATION
-	I-ABBREVIATION
4	I-ABBREVIATION
-	I-ABBREVIATION
AHCP	I-ABBREVIATION
(	O
7	O
)	O
.	O

At	O
cloned	O
metabotropic	O
Glu	O
receptors	O
mGluR1alpha	O
(	O
group	O
I	O
)	O
,	O
mGluR2	O
(	O
group	O
II	O
)	O
,	O
and	O
mGluR4a	O
(	O
group	O
III	O
)	O
,	O
neither	O
6	O
nor	O
7	O
showed	O
significant	O
agonist	O
or	O
antagonist	O
effects	O
.	O

The	O
stereoisomer	O
6	O
,	O
but	O
not	O
7	O
,	O
activated	O
cloned	O
AMPA	O
receptor	O
subunits	O
GluR1o	O
,	O
GluR3o	O
,	O
and	O
GluR4o	O
with	O
EC	O
(	O
50	O
)	O
values	O
in	O
the	O
range	O
4.5-15	O
microM	O
and	O
the	O
coexpressed	O
kainate	I-TRIVIAL
-	O
preferring	O
subunits	O
GluR6	O
+	O
KA2	O
(	O
EC	O
(	O
50	O
)	O
=	O
6.4	O
microM	O
)	O
.	O

Compound	O
6	O
,	O
but	O
not	O
7	O
,	O
proved	O
to	O
be	O
a	O
very	O
potent	O
agonist	O
(	O
EC	O
(	O
50	O
)	O
=	O
0.13	O
microM	O
)	O
at	O
the	O
kainate	I-TRIVIAL
-	O
preferring	O
GluR5	O
subunit	O
,	O
equipotent	O
with	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyisothiazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
[	O
(	I-ABBREVIATION
S	I-ABBREVIATION
)	I-ABBREVIATION
-	I-ABBREVIATION
Thio	I-ABBREVIATION
-	I-ABBREVIATION
ATPA	I-ABBREVIATION
,	O
4	O
]	O
and	O
almost	O
4	O
times	O
more	O
potent	O
than	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
[	O
(	I-ABBREVIATION
S	I-ABBREVIATION
)	I-ABBREVIATION
-	I-ABBREVIATION
ATPA	I-ABBREVIATION
,	O
3	O
]	O
.	O

Compound	O
6	O
thus	O
represents	O
a	O
new	O
structural	O
class	O
of	O
GluR5	O
agonists	O
.	O

Molecular	O
modeling	O
and	O
docking	O
to	O
a	O
crystal	O
structure	O
of	O
the	O
extracellular	O
binding	O
domain	O
of	O
the	O
AMPA	I-ABBREVIATION
subunit	O
GluR2	O
has	O
enabled	O
identification	O
of	O
the	O
probable	O
active	O
conformation	O
and	O
binding	O
mode	O
of	O
6	O
.	O

We	O
are	O
able	O
to	O
rationalize	O
the	O
observed	O
selectivities	O
by	O
comparing	O
the	O
docking	O
of	O
4	O
and	O
6	O
to	O
subtype	O
constructs	O
,	O
i.e.	O
,	O
a	O
crystal	O
structure	O
of	O
the	O
extracellular	O
binding	O
domain	O
of	O
GluR2	O
and	O
a	O
homology	O
model	O
of	O
GluR5	O
.	O

The	O
synthesis	O
of	O
aminoaceto	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidides	I-IUPAC
substituted	I-MODIFIER
on	O
the	O
amide	I-FAMILY
nitrogen	B-TRIVIAL
with	O
2	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
diethylamino	I-PARTIUPAC
)	I-PARTIUPAC
ethyl	I-PARTIUPAC
,	O
2	I-PARTIUPAC
-	I-PARTIUPAC
aminoethyl	I-PARTIUPAC
,	O
2	I-PARTIUPAC
-	I-PARTIUPAC
hydroxyethyl	I-PARTIUPAC
,	O
and	O
2	I-PARTIUPAC
-	I-PARTIUPAC
ethoxyethyl	I-PARTIUPAC
groups	I-MODIFIER
is	O
described	O
.	O

The	O
2	I-PARTIUPAC
-	I-PARTIUPAC
aminoethyl	I-PARTIUPAC
derivatives	I-MODIFIER
were	O
prepared	O
by	O
treatment	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phthalimidoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidine	I-IUPAC
with	O
chloroacetyl	I-IUPAC
chloride	I-IUPAC
,	O
followed	O
by	O
treatment	O
with	O
either	O
potassium	I-IUPAC
phthalmide	I-IUPAC
or	O
diethylamine	I-TRIVIAL
.	O

Hydrazinolysis	O
of	O
the	O
phthalimides	I-FAMILY
liberated	O
the	O
free	O
amines	I-FAMILY
.	O

The	O
remaining	O
target	O
compounds	O
were	O
produced	O
by	O
alkylation	O
of	O
lidocaine	I-TRIVIAL
or	O
of	O
2	I-IUPAC
-	I-IUPAC
phthalimidoaceto	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidide	I-IUPAC
with	O
the	O
appropriate	O
halide	I-PARTIUPAC
and	O
sodium	I-IUPAC
hydride	I-IUPAC
,	O
followed	O
by	O
hydrazinolysis	O
where	O
necessary	O
.	O

All	O
target	O
compounds	O
were	O
evaluated	O
for	O
antiarrhythmic	O
efficacy	O
against	O
chloroform	I-TRIVIAL
-	O
induced	O
ventricular	O
tachycardia	O
,	O
as	O
well	O
as	O
for	O
acute	O
CNS	O
toxicity	O
in	O
mice	O
.	O

Most	O
of	O
the	O
target	O
compounds	O
were	O
more	O
potent	O
than	O
the	O
corresponding	O
secondary	O
amides	O
and	O
had	O
improved	O
therapeutic	O
margins	O
toward	O
CNS	O
toxicity	O
.	O

The	O
diamines	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoaceto	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidide	I-IUPAC
(	O
13	O
)	O
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
aceto	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidide	I-IUPAC
(	O
29	O
)	O
are	O
especially	O
promising	O
in	O
this	O
respect	O
.	O

Several	O
compounds	O
were	O
tested	O
as	O
spinal	O
anesthetics	O
.	O

Some	O
novel	O
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
have	O
been	O
prepared	O
.	O

At	O
the	O
N	O
-	O
1	O
position	O
"	O
standard	O
"	O
substitution	O
was	O
employed	O
with	O
the	O
ethyl	I-PARTIUPAC
,	O
cyclopropyl	I-PARTIUPAC
,	O
and	O
p	I-PARTIUPAC
-	I-PARTIUPAC
fluorophenyl	I-PARTIUPAC
groups	I-MODIFIER
being	O
used	O
.	O

At	O
C	O
-	O
7	O
the	O
introduction	O
of	O
some	O
novel	O
piperazines	I-FAMILY
was	O
made	O
.	O

Most	O
notably	O
,	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoromethyl	I-IUPAC
)	I-IUPAC
piperazine	I-IUPAC
(	O
10	O
)	O
and	O
hexahydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
diazepine	I-IUPAC
(	O
16	O
,	O
fluorohomopiperazine	I-TRIVIAL
)	O
at	O
the	O
quinolone	I-TRIVIAL
C	O
-	O
7	O
position	O
produced	O
products	O
with	O
similar	O
in	O
vitro	O
antibacterial	O
activity	O
as	O
the	O
ciprofloxacin	I-TRIVIAL
reference	O
.	O

The	O
in	O
vivo	O
efficacy	O
of	O
1	I-IUPAC
-	I-IUPAC
cyclopropyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoromethyl	I-IUPAC
)	I-IUPAC
piperazinyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
20	O
)	O
was	O
excellent	O
with	O
better	O
oral	O
absorption	O
than	O
ciprofloxacin	I-TRIVIAL
(	O
2	O
)	O
.	O

The	O
thermal	O
Fischer	O
indolization	O
of	O
hydrazones	I-FAMILY
resulting	O
from	O
4	I-IUPAC
-	I-IUPAC
hydrazino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
one	I-IUPAC
and	O
various	O
beta	I-PARTIUPAC
-	I-PARTIUPAC
and	O
alpha	I-IUPAC
-	I-IUPAC
tetralones	I-IUPAC
led	O
to	O
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
,	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
e	I-IUPAC
]	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
and	O
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
,	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
g	I-IUPAC
]	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
respectively	O
.	O

After	O
aromatization	O
,	O
these	O
compounds	O
were	O
transformed	O
by	O
phosphorus	I-IUPAC
oxychloride	I-IUPAC
,	O
giving	O
1	I-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
-	I-PARTIUPAC
5H	I-PARTIUPAC
-	I-PARTIUPAC
pyrido	I-PARTIUPAC
[	I-PARTIUPAC
4,3	I-PARTIUPAC
-	I-PARTIUPAC
b	I-PARTIUPAC
]	I-PARTIUPAC
benzo	I-PARTIUPAC
[	I-PARTIUPAC
e	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
and	O
-	I-PARTIUPAC
benzo	I-PARTIUPAC
[	I-PARTIUPAC
g	I-PARTIUPAC
]	I-PARTIUPAC
indoles	I-PARTIUPAC
which	O
were	O
substituted	O
by	O
[	I-IUPAC
(	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
amines	I-IUPAC
.	O

The	O
resulting	O
1	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
dialkylamino	I-PARTIUPAC
)	I-PARTIUPAC
alkyl	I-PARTIUPAC
]	I-PARTIUPAC
amino	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
-	I-PARTIUPAC
5H	I-PARTIUPAC
-	I-PARTIUPAC
pyrido	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
4,3	I-PARTIUPAC
-	I-PARTIUPAC
b	I-PARTIUPAC
]	I-PARTIUPAC
benzo	I-PARTIUPAC
[	I-PARTIUPAC
e	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
and	O
-	I-PARTIUPAC
benzo	I-PARTIUPAC
[	I-PARTIUPAC
g	I-PARTIUPAC
]	I-PARTIUPAC
indoles	I-PARTIUPAC
,	O
as	O
well	O
as	O
hydroxy	I-PARTIUPAC
derivatives	B-MODIFIER
obtained	O
by	O
demethylation	O
of	O
methoxylated	O
compounds	O
with	O
hydrobromic	I-IUPAC
acid	I-IUPAC
,	O
were	O
tested	O
for	O
antitumor	O
activity	O
in	O
vitro	O
(	O
leukemic	O
and	O
solid	O
tumor	O
cells	O
)	O
and	O
in	O
vivo	O
on	O
various	O
experimental	O
tumor	O
models	O
using	O
the	O
standard	O
NCI	O
protocols	O
.	O

1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Dialkylamino	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
e	I-IUPAC
]	I-IUPAC
indoles	I-IUPAC
appeared	O
as	O
a	O
promising	O
new	O
class	O
of	O
antineoplastic	O
agents	O
.	O

[	O
Synthesis	O
and	O
properties	O
of	O
carminomycinone	I-TRIVIAL
derivatives	B-MODIFIER
]	O
The	O
possibility	O
of	O
chemical	O
modification	O
of	O
carminomycinone	I-TRIVIAL
-	I-TRIVIAL
aglycone	I-TRIVIAL
(	O
II	O
)	O
of	O
carminomicin	I-TRIVIAL
,	O
a	O
side	O
product	O
in	O
the	O
antibiotic	O
production	O
was	O
studied	O
.	O

The	O
methyl	I-PARTIUPAC
group	B-MODIFIER
C	B-SUM
-	I-SUM
14	I-SUM
was	O
functionilized	O
by	O
introducing	O
the	O
bromine	I-TRIVIAL
atom	B-MODIFIER
and	O
performing	O
a	O
number	O
of	O
exchange	O
reactions	O
with	O
the	O
bromine	I-TRIVIAL
atom	B-MODIFIER
.	O

It	O
was	O
found	O
that	O
under	O
definite	O
conditions	O
(	O
1	O
.	O

1	O
equiv	O
.	O

Br2	I-SUM
in	O
dioxane	I-TRIVIAL
,	O
20	O
degrees	O
,	O
24	O
hours	O
)	O
carminomycinone	I-TRIVIAL
(	O
II	O
)	O
was	O
subjected	O
to	O
selective	O
bromination	O
into	O
the	O
side	O
acetyl	I-TRIVIAL
group	B-MODIFIER
with	O
formation	O
of	O
14	I-IUPAC
-	I-IUPAC
bromcarminomycinone	I-IUPAC
(	O
III	O
)	O
.	O

On	O
interaction	O
with	O
anhydrous	O
potassium	I-IUPAC
acetate	I-IUPAC
14	I-IUPAC
-	I-IUPAC
bromcarminomycinone	I-IUPAC
(	O
III	O
)	O
yield	O
14	I-IUPAC
-	I-IUPAC
acetoxycarminomycinone	I-IUPAC
(	O
IV	O
)	O
.	O

In	O
its	O
turn	O
the	O
latter	O
compound	O
(	O
IV	O
)	O
easily	O
hydrolized	O
to	O
14	I-IUPAC
-	I-IUPAC
oxycarminomycinone	I-IUPAC
(	O
V	O
)	O
in	O
treatment	O
with	O
aqueous	O
alkali	O
or	O
acid	O
.	O

14	I-IUPAC
-	I-IUPAC
oxycarminomycinone	I-IUPAC
(	O
V	O
)	O
was	O
also	O
prepared	O
with	O
a	O
high	O
yield	O
(	O
80	O
per	O
cent	O
)	O
by	O
direct	O
alkaline	O
hydrolysis	O
of	O
14	I-IUPAC
-	I-IUPAC
bromcarminomycinone	I-IUPAC
(	O
III	O
)	O
in	O
treatment	O
with	O
0.1	O
N	O
solution	O
of	O
sodium	I-IUPAC
carbonate	I-IUPAC
in	O
a	O
mixture	O
of	O
dioxane	I-TRIVIAL
and	O
water	O
.	O

The	O
structure	O
of	O
14	O
-	O
substituted	O
derivatives	I-MODIFIER
of	O
carminomycinone	I-TRIVIAL
was	O
proved	O
by	O
analytical	O
and	O
spectral	O
data	O
and	O
confirmed	O
by	O
their	O
transformation	O
.	O

Thus	O
,	O
according	O
to	O
the	O
data	O
of	O
mass	O
-	O
spectrometry	O
14	I-IUPAC
-	I-IUPAC
oxycarminomycinone	I-IUPAC
(	O
V	O
)	O
had	O
a	O
molecular	O
weight	O
of	O
400	O
c	O
.	O

u	O
.	O

In	O
treatment	O
with	O
an	O
excess	O
of	O
acetic	I-IUPAC
anhydride	I-IUPAC
in	O
pyridine	I-TRIVIAL
it	O
formed	O
a	O
hexa	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
derivative	I-MODIFIER
,	O
i.e.	O
4	I-IUPAC
,	I-IUPAC
6	I-IUPAC
,	I-IUPAC
7	I-IUPAC
,	I-IUPAC
9	I-IUPAC
,	I-IUPAC
11	I-IUPAC
,	I-IUPAC
14	I-IUPAC
-	I-IUPAC
hexa	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
oxycarminomycinone	I-IUPAC
(	O
VI	O
)	O
.	O

The	O
aglycones	I-FAMILY
(	O
III	O
-	O
V	O
)	O
prepared	O
by	O
us	O
may	O
serve	O
a	O
starting	O
material	O
in	O
chemical	O
synthesis	O
,	O
as	O
well	O
as	O
biosynthesis	O
of	O
semi	O
-	O
synthetic	O
preparations	O
of	O
the	O
carminomycin	I-TRIVIAL
series	B-MODIFIER
.	O

Adenosine	O
5'	O
-	O
triphosphate	O
(	O
ATP	I-ABBREVIATION
)	O
derivatives	I-MODIFIER
of	O
the	O
types	O
N6	I-ABBREVIATION
-	I-ABBREVIATION
R	I-ABBREVIATION
-	I-ABBREVIATION
ATP	I-ABBREVIATION
[	O
R	O
=	O
(	I-SUM
CH2	I-SUM
)	I-SUM
nNHCOCH2I	I-SUM
,	O
(	I-SUM
CH2	I-SUM
)	I-SUM
nNHCO	I-SUM
-	I-SUM
(	I-SUM
CH2	I-SUM
)	I-SUM
mNHCOCH2I	I-SUM
,	O
or	O
(	I-SUM
CH2	I-SUM
)	I-SUM
nCON	I-SUM
(	I-SUM
Me	I-SUM
)	I-SUM
(	I-SUM
CH2	I-SUM
)	I-SUM
mN	I-SUM
(	I-SUM
Me	I-SUM
)	I-SUM
CO	I-SUM
(	I-SUM
CH2	I-SUM
)	I-SUM
nNHCOCH2I	I-SUM
]	O
,	O
N6	I-ABBREVIATION
-	I-ABBREVIATION
Me	I-ABBREVIATION
-	I-ABBREVIATION
N6	I-ABBREVIATION
-	I-ABBREVIATION
R	I-ABBREVIATION
-	I-ABBREVIATION
ATP	I-ABBREVIATION
[	O
R	O
=	O
(	I-SUM
CH2	I-SUM
)	I-SUM
nN	I-SUM
-	I-SUM
(	I-SUM
Me	I-SUM
)	I-SUM
CO	I-SUM
(	I-SUM
CH2	I-SUM
)	I-SUM
mNHCOCH2I	I-SUM
]	O
,	O
and	O
8	I-ABBREVIATION
-	I-ABBREVIATION
R	I-ABBREVIATION
-	I-ABBREVIATION
ATP	I-ABBREVIATION
[	O
R	O
=	O
NM	I-SUM
(	I-SUM
CH2	I-SUM
)	I-SUM
nNHCOCH2I	I-SUM
]	O
with	O
5	O
-	O
-	O
19	O
spacer	O
atoms	O
between	O
N6	O
or	O
C	O
-	O
8	O
and	O
iodine	I-TRIVIAL
have	O
been	O
evaluated	O
as	O
potential	O
exo	O
-	O
ATP	I-ABBREVIATION
-	O
site	O
-	O
directed	O
reagents	O
for	O
phosphokinases	O
.	O

Substrate	O
and	O
inhibitor	O
properties	O
indicated	O
that	O
the	O
compounds	O
possessed	O
affinity	O
for	O
the	O
ATP	I-ABBREVIATION
sites	O
of	O
the	O
muscle	O
(	O
M	O
)	O
,	O
kidney	O
(	O
K	O
)	O
,	O
and	O
liver	O
(	O
L	O
)	O
isozymes	O
of	O
rat	O
pyruvate	O
kinase	O
(	O
PK	O
)	O
,	O
of	O
E	O
.	O

coli	O
thymidine	O
kinase	O
(	O
TK	O
)	O
,	O
and	O
of	O
yeast	O
hexokinase	O
(	O
HK	O
)	O
and	O
rat	O
KH	O
I	O
,	O
II	O
,	O
and	O
III	O
isozymes	O
.	O

Tests	O
for	O
time	O
-	O
dependent	O
loss	O
of	O
enzyme	O
activity	O
(	O
inactivation	O
)	O
were	O
performed	O
under	O
conditions	O
in	O
which	O
a	O
large	O
proportion	O
of	O
each	O
phosphokinase	O
was	O
present	O
as	O
an	O
enzyme	O
-	O
inhibitor	O
complex	O
.	O

No	O
ATP	I-ABBREVIATION
-	O
site	O
-	O
directed	O
inactivations	O
resulted	O
when	O
the	O
M	O
,	O
L	O
,	O
or	O
K	O
isozymes	O
of	O
PK	O
were	O
exposed	O
for	O
8	O
h	O
,	O
22	O
degrees	O
C	O
,	O
to	O
5	O
mM	O
levels	O
of	O
18	O
ATP	I-ABBREVIATION
derivatives	B-MODIFIER
or	O
6	O
analogous	O
ADP	I-ABBREVIATION
derivatives	B-MODIFIER
or	O
when	O
yeast	O
HK	O
or	O
rat	O
KH	O
I	O
,	O
II	O
,	O
or	O
III	O
was	O
exposed	O
for	O
6	O
h	O
,	O
22	O
degrees	O
C	O
,	O
to	O
5	O
mM	O
levels	O
of	O
28	O
ATP	I-ABBREVIATION
derivatives	B-MODIFIER
.	O

Escherichia	O
coli	O
TK	O
was	O
inactivated	O
by	O
6	O
of	O
25	O
ATP	O
derivatives	O
tested	O
at	O
10	O
mM	O
,	O
6	O
h	O
,	O
0	O
degrees	O
C	O
;	O
inactivation	O
was	O
slowed	O
by	O
MgATP	I-ABBREVIATION
in	O
the	O
case	O
of	O
N6	I-ABBREVIATION
-	I-ABBREVIATION
CH3	I-ABBREVIATION
-	I-ABBREVIATION
N6	I-ABBREVIATION
-	I-ABBREVIATION
R	I-ABBREVIATION
-	I-ABBREVIATION
ATP	I-ABBREVIATION
[	O
R	O
=	O
(	I-SUM
CH2	I-SUM
)	I-SUM
4N	I-SUM
(	I-SUM
CH3	I-SUM
)	I-SUM
CO	I-SUM
(	I-SUM
CH2	I-SUM
)	I-SUM
5NHCOCH2I	I-SUM
]	O
.	O

Only	O
1%	O
of	O
298	O
enzyme	O
-	O
inhibitor	O
combinations	O
exhibited	O
ATP	I-ABBREVIATION
-	O
site	O
-	O
directed	O
inactivation	O
,	O
signifying	O
that	O
few	O
suitably	O
positioned	O
and	O
sufficiently	O
reactive	O
nucleophilic	O
groups	O
were	O
present	O
near	O
the	O
enzymic	O
ATP	I-ABBREVIATION
sites	O
.	O

Studies	O
have	O
now	O
shown	O
that	O
exo	O
-	O
active	O
-	O
site	O
-	O
directed	O
reagents	O
can	O
act	O
as	O
isozyme	O
-	O
or	O
species	O
-	O
selective	O
enzyme	O
inhibitors	O
.	O

The	O
present	O
survey	O
indicates	O
that	O
in	O
many	O
cases	O
such	O
reagents	O
may	O
be	O
difficult	O
of	O
access	O
when	O
data	O
are	O
not	O
available	O
regarding	O
structural	O
or	O
physicochemical	O
features	O
of	O
the	O
target	O
enzyme	O
adjacent	O
to	O
its	O
catalytic	O
site	O
.	O

Effect	O
of	O
recombinant	O
human	O
fibroblast	O
interferon	O
and	O
mezerein	I-TRIVIAL
on	O
growth	O
,	O
differentiation	O
,	O
immune	O
interferon	O
binding	O
and	O
tumor	O
associated	O
antigen	O
expression	O
in	O
human	O
melanoma	O
cells	O
.	O

The	O
combination	O
of	O
recombinant	O
human	O
fibroblast	O
interferon	O
(	O
INF	O
-	O
delta	O
)	O
and	O
the	O
antileukemic	O
compound	O
mezerein	I-TRIVIAL
(	O
MEZ	I-ABBREVIATION
)	O
results	O
in	O
a	O
synergistic	O
suppression	O
in	O
the	O
growth	O
of	O
human	O
melanoma	O
cells	O
and	O
a	O
concomitant	O
increase	O
in	O
melanin	I-TRIVIAL
synthesis	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
further	O
analyzed	O
this	O
synergistic	O
interaction	O
and	O
have	O
also	O
evaluated	O
the	O
effect	O
of	O
IFN	O
-	O
delta	O
and	O
MEZ	I-ABBREVIATION
,	O
alone	O
and	O
in	O
combination	O
,	O
on	O
recombinant	O
human	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
binding	O
and	O
Class	O
I	O
HLA	O
and	O
melanoma	O
associated	O
antigen	O
(	O
MAA	O
)	O
expression	O
in	O
the	O
HO	O
-	O
1	O
human	O
melanoma	O
cell	O
line	O
.	O

Single	O
cell	O
clones	O
isolated	O
from	O
the	O
HO	O
-	O
1	O
cell	O
line	O
varied	O
in	O
their	O
sensitivity	O
to	O
the	O
antiproliferative	O
effects	O
of	O
IFN	O
-	O
delta	O
and	O
MEZ	I-ABBREVIATION
.	O

With	O
all	O
twelve	O
clones	O
,	O
however	O
,	O
the	O
combination	O
of	O
IFN	O
-	O
delta	O
plus	O
MEZ	I-ABBREVIATION
was	O
more	O
growth	O
inhibitory	O
than	O
either	O
agent	O
used	O
alone	O
,	O
even	O
in	O
HO	O
-	O
1	O
subclones	O
displaying	O
relative	O
resistance	O
to	O
IFN	O
-	O
delta	O
.	O

By	O
continuous	O
growth	O
in	O
gradually	O
increasing	O
concentrations	O
of	O
IFN	O
-	O
delta	O
,	O
a	O
variant	O
population	O
of	O
HO	O
-	O
1	O
cells	O
,	O
HO	O
-	O
1	O
delta	O
R	O
-	O
D	O
,	O
was	O
generated	O
which	O
was	O
more	O
resistant	O
to	O
the	O
antigrowth	O
effects	O
of	O
IFN	O
-	O
delta	O
than	O
the	O
original	O
HO	O
-	O
1	O
parental	O
cell	O
line	O
.	O

In	O
the	O
IFN	O
delta	O
R	O
-	O
D	O
cell	O
line	O
the	O
combination	O
of	O
IFN	O
-	O
delta	O
plus	O
MEZ	I-ABBREVIATION
synergistically	O
suppressed	O
growth	O
.	O

Exposure	O
of	O
HO	O
-	O
1	O
cells	O
to	O
2500	O
units	O
/	O
ml	O
IFN	O
-	O
delta	O
or	O
50	O
ng	O
/	O
ml	O
MEZ	I-ABBREVIATION
for	O
96	O
hr	O
resulted	O
in	O
no	O
change	O
or	O
an	O
increase	O
in	O
the	O
binding	O
of	O
labelled	O
IFN	O
-	O
gamma	O
to	O
surface	O
receptors	O
,	O
whereas	O
the	O
combination	O
of	O
IFN	O
-	O
delta	O
plus	O
MEZ	I-ABBREVIATION
increased	O
IFN	O
-	O
gamma	O
binding	O
2	O
-	O
to	O
-	O
4	O
-	O
fold	O
in	O
HO	O
-	O
1	O
cells	O
.	O

This	O
increase	O
was	O
the	O
result	O
of	O
an	O
increase	O
in	O
the	O
number	O
of	O
receptors	O
on	O
treated	O
cells	O
coupled	O
with	O
a	O
protection	O
against	O
a	O
decrease	O
in	O
receptors	O
observed	O
for	O
confluent	O
untreated	O
cells	O
.	O

Changes	O
in	O
IFN	O
-	O
gamma	O
binding	O
resulting	O
from	O
treatment	O
with	O
IFN	O
-	O
delta	O
plus	O
MEZ	I-ABBREVIATION
were	O
not	O
associated	O
with	O
alterations	O
in	O
the	O
binding	O
affinity	O
of	O
INF	O
-	O
gamma	O
to	O
its	O
receptor	O
.	O

Changes	O
were	O
also	O
observed	O
in	O
the	O
expression	O
of	O
HLA	O
Class	O
I	O
antigens	O
and	O
MAAs	O
following	O
treatment	O
of	O
HO	O
-	O
1	O
cells	O
with	O
IFN	O
-	O
delta	O
,	O
MEZ	I-ABBREVIATION
or	O
IFN	O
-	O
delta	O
plus	O
MEZ	I-ABBREVIATION
.	O

IFN	O
-	O
delta	O
and	O
MEZ	I-ABBREVIATION
increased	O
the	O
expression	O
of	O
HLA	O
Class	O
I	O
antigens	O
a	O
96	O
kd	O
MAA	O
defined	O
by	O
MoAb	O
CL203	O
,	O
a	O
100	O
kd	O
MAA	O
defined	O
by	O
MoAb	O
376.96	O
and	O
a	O
115	O
kd	O
MAA	O
defined	O
by	O
MoAb	O
345.134	O
but	O
decreased	O
the	O
expression	O
of	O
a	O
high	O
molecular	O
weight	O
-	O
melanoma	O
associated	O
antigen	O
(	O
HMW	O
-	O
MAA	O
)	O
defined	O
by	O
MoAb	O
325.28	O
S	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Degarelix	O
(	O
FE200486	I-TRIVIALVAR
,	O
Ac	O
-	O
d	O
-	O
2Nal	O
(	O
1	O
)	O
-	O
d	O
-	O
4Cpa	O
(	O
2	O
)	O
-	O
d	O
-	O
3Pal	O
(	O
3	O
)	O
-	O
Ser	O
(	O
4	O
)	O
-	O
4Aph	O
(	O
l	O
-	O
Hor	O
)	O
(	O
5	O
)	O
-	O
d	O
-	O
4Aph	O
(	O
Cbm	O
)	O
(	O
6	O
)	O
-	O
Leu	O
(	O
7	O
)	O
-	O
ILys	O
(	O
8	O
)	O
-	O
Pro	O
(	O
9	O
)	O
-	O
d	O
-	O
Ala	O
(	O
10	O
)	O
-	O
NH	O
(	O
2	O
)	O
)	O
is	O
a	O
potent	O
and	O
very	O
long	O
acting	O
antagonist	O
of	O
gonadotropin	O
-	O
releasing	O
hormone	O
(	O
GnRH	O
)	O
after	O
subcutaneous	O
administration	O
in	O
mammals	O
including	O
humans	O
.	O

Analogues	O
of	O
degarelix	I-TRIVIAL
were	O
synthesized	O
,	O
characterized	O
,	O
and	O
screened	O
for	O
the	O
antagonism	O
of	O
GnRH	O
-	O
induced	O
response	O
in	O
a	O
reporter	O
gene	O
assay	O
in	O
HEK	O
-	O
293	O
cells	O
expressing	O
the	O
human	O
GnRH	O
receptor	O
.	O

The	O
duration	O
of	O
action	O
was	O
also	O
determined	O
in	O
the	O
castrated	O
male	O
rat	O
assay	O
to	O
measure	O
the	O
extent	O
(	O
efficacy	O
and	O
duration	O
of	O
action	O
)	O
of	O
inhibition	O
of	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
release	O
.	O

Structurally	O
,	O
this	O
series	O
of	O
analogues	O
has	O
novel	O
substitutions	O
at	O
positions	O
3	O
,	O
7	O
,	O
and	O
8	O
and	O
N	O
(	O
alpha	O
)	O
-	O
methylation	O
at	O
positions	O
6	O
,	O
7	O
,	O
and	O
8	O
in	O
the	O
structure	O
of	O
degarelix	I-TRIVIAL
.	O

These	O
substitutions	O
were	O
designed	O
to	O
probe	O
the	O
spatial	O
limitations	O
of	O
the	O
receptor	O
's	O
cavity	O
and	O
to	O
map	O
the	O
steric	O
and	O
ionic	O
boundaries	O
.	O

Some	O
functional	O
groups	O
were	O
introduced	O
that	O
were	O
hypothesized	O
to	O
influence	O
the	O
phamacokinetic	O
properties	O
of	O
the	O
analogues	O
such	O
as	O
bioavailability	O
,	O
solubility	O
,	O
intra	O
-	O
or	O
intermolecular	O
hydrogen	O
bond	O
forming	O
capacity	O
,	O
and	O
ability	O
to	O
bind	O
carrier	O
proteins	O
.	O

Substitutions	O
at	O
positions	O
3	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
)	I-IUPAC
d	I-IUPAC
-	I-IUPAC
Dap	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
2.71	O
nM	O
)	O
(	O
5	O
)	O
,	O
7	O
(	O
[	I-TRIVIAL
Pra	I-TRIVIAL
(	I-TRIVIAL
7	I-TRIVIAL
)	I-TRIVIAL
]	I-TRIVIAL
degarelix	I-TRIVIAL
,	O
IC	O
(	O
50	O
)	O
=	O
2.11	O
nM	O
)	O
(	O
16	O
)	O
,	O
and	O
8	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
delta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
IGly	I-IUPAC
)	I-IUPAC
Orn	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.38	O
nM	O
)	O
(	O
20	O
)	O
and	O
N	O
-	O
methylation	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
alpha	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
Leu	I-IUPAC
(	I-IUPAC
7	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.47	O
nM	O
)	O
(	O
32	O
)	O
yielded	O
analogues	O
that	O
were	O
equipotent	O
to	O
degarelix	I-TRIVIAL
(	O
2	O
)	O
in	O
vitro	O
(	O
IC	O
(	O
50	O
)	O
=	O
1.64	O
nM	O
)	O
but	O
shorter	O
acting	O
in	O
vivo	O
.	O

Out	O
of	O
the	O
33	O
novel	O
analogues	O
tested	O
for	O
the	O
duration	O
of	O
action	O
in	O
this	O
series	O
,	O
two	O
analogues	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
epsilon	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclohexyl	I-IUPAC
-	I-IUPAC
Lys	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.50	O
nM	O
)	O
(	O
23	O
)	O
and	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
IbetaAla	I-IUPAC
)	I-IUPAC
Dap	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.98	O
nM	O
)	O
(	O
26	O
)	O
had	O
antagonist	O
potencies	O
and	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
azaline	I-TRIVIAL
B	I-TRIVIAL
{	O
inhibited	O
LH	O
(	O
&	O
gt	O
;	O
80%	O
)	O
release	O
for	O
&	O
gt	O
;	O
72	O
h	O
after	O
sc	O
injection	O
to	O
castrated	O
male	O
rats	O
at	O
a	O
standard	O
dose	O
of	O
50	O
mug	O
/	O
rat	O
in	O
5%	O
mannitol	O
}	O
.	O

Under	O
similar	O
conditions	O
analogues	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
gamma	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
IGly	I-IUPAC
)	I-IUPAC
Dab	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.56	O
nM	O
)	O
(	O
21	O
)	O
and	O
(	O
[	I-IUPAC
IOrn	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.72	O
nM	O
)	O
(	O
18	O
)	O
had	O
a	O
longer	O
duration	O
of	O
action	O
{	O
inhibited	O
LH	O
(	O
&	O
gt	O
;	O
96	O
h	O
)	O
release	O
}	O
than	O
azaline	I-TRIVIAL
B	I-TRIVIAL
;	O
however	O
they	O
were	O
shorter	O
acting	O
than	O
degarelix	I-TRIVIAL
.	O

Hydrophilicity	O
of	O
these	O
analogues	O
,	O
a	O
potential	O
measure	O
of	O
their	O
ability	O
to	O
be	O
formulated	O
for	O
sustained	O
release	O
,	O
was	O
determined	O
using	O
RP	O
-	O
HPLC	O
at	O
neutral	O
pH	O
yielding	O
analogues	O
with	O
shorter	O
as	O
well	O
as	O
longer	O
retention	O
times	O
.	O

No	O
correlation	O
was	O
found	O
between	O
retention	O
times	O
and	O
antagonist	O
potency	O
or	O
duration	O
of	O
action	O
.	O

[	O
Method	O
of	O
determination	O
of	O
biogenic	O
amines	I-FAMILY
in	O
wines	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
with	O
fluorescence	O
detector	O
and	O
ultraviolet	O
detector	O
]	O
OBJECTIVE	O
:	O
A	O
pre	O
-	O
column	O
derivation	O
reversed	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
method	O
was	O
developed	O
for	O
the	O
determination	O
of	O
biogenic	O
amines	O
(	O
tryptamine	I-TRIVIAL
,	O
phenylethyamine	I-TRIVIAL
,	O
putrescine	I-TRIVIAL
,	O
cadaverine	I-TRIVIAL
,	O
histamine	I-TRIVIAL
,	O
tyramine	I-TRIVIAL
,	O
spermidine	I-TRIVIAL
,	O
and	O
spermine	I-TRIVIAL
)	O
in	O
wines	O
with	O
fluorescecse	O
detector	O
(	O
FLD	O
)	O
and	O
ultraviolet	O
detector	O
(	O
UVD	O
)	O
.	O

METHODS	O
:	O
Liqiud	O
-	O
liqiud	O
extraction	O
(	O
LLE	O
)	O
was	O
used	O
to	O
clean	O
up	O
wine	O
samples	O
with	O
chloroform	I-TRIVIAL
/	O
butanol	I-TRIVIAL
prior	O
to	O
derivatization	O
with	O
dansyl	I-IUPAC
chloride	I-IUPAC
,	O
biogenic	O
amines	O
were	O
separated	O
using	O
gradient	O
elution	O
.	O

Mobile	O
phase	O
A	O
was	O
methanol	O
and	O
mobile	O
phase	O
B	O
was	O
water	O
with	O
the	O
flow	O
rate	O
1.5	O
ml	O
/	O
min	O
.	O

The	O
column	O
used	O
was	O
a	O
CAPCELL	O
PAK	O
C18	O
MG	O
(	O
4.6	O
mm	O
I	O
.	O

D	O
.	O

x	O
150	O
mm	O
,	O
5	O
microm	O
)	O
and	O
gradient	O
elution	O
at	O
constant	O
column	O
tempereture	O
with	O
30	O
degrees	O
C	O
under	O
fluorescence	O
detector	O
with	O
Ex	O
350nm	O
and	O
Em	O
520nm	O
,	O
The	O
method	O
and	O
ultraviolet	O
detector	O
with	O
254nm	O
.	O

1,7	I-IUPAC
-	I-IUPAC
Diaminoheptane	I-IUPAC
was	O
used	O
as	O
the	O
internal	O
standard	O
(	O
IS	O
)	O
.	O

RESULTS	O
:	O
was	O
linear	O
for	O
the	O
amines	O
studied	O
at	O
concentration	O
ranging	O
from	O
0.05	O
to	O
25	O
mg	O
/	O
L	O
,	O
except	O
for	O
spermidine	I-TRIVIAL
and	O
spermine	I-TRIVIAL
,	O
which	O
ranging	O
from	O
0.05	O
to	O
15	O
mg	O
/	O
L	O
.	O

The	O
average	O
recoveries	O
ranged	O
from	O
79.2%	O
to	O
127.5%	O
for	O
all	O
amines	O
,	O
The	O
RSDs	O
were	O
less	O
than	O
10%	O
.	O

With	O
this	O
method	O
,	O
5	O
wine	O
samples	O
were	O
determined	O
,	O
the	O
results	O
were	O
favorable	O
.	O

CONCLUTION	O
:	O
method	O
can	O
be	O
applied	O
for	O
determination	O
of	O
biogenic	O
amines	O
in	O
wines	O
.	O

The	O
isomeric	O
4	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
hydroxyphenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinolines	I-IUPAC
,	O
the	O
N	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
derivative	I-MODIFIER
of	O
the	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
isomer	I-MODIFIER
,	O
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
were	O
synthesized	O
and	O
evaluated	O
for	O
dopamine	O
D	O
-	O
1	O
antagonist	O
activity	O
.	O

The	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
and	O
the	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
isomer	I-MODIFIER
possessed	O
similar	O
potencies	O
as	O
D	O
-	O
1	O
antagonists	O
.	O

Introduction	O
of	O
the	O
N	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
group	I-MODIFIER
enhanced	O
potency	O
about	O
twofold	O
.	O

The	O
"	O
pharmacophore	O
"	O
for	O
selective	O
dopamine	O
D	O
-	O
1	O
antagonist	O
activity	O
appears	O
to	O
be	O
a	O
tertiary	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenethylamine	I-IUPAC
.	O

In	O
a	O
continuing	O
effort	O
to	O
design	O
small	O
-	O
molecule	O
inhibitors	O
of	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
that	O
combine	O
the	O
enzyme	O
-	O
binding	O
selectivity	O
of	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxybenzyl	I-IUPAC
)	I-IUPAC
pyrimidine	I-IUPAC
(	O
trimethoprim	I-TRIVIAL
,	O
TMP	I-ABBREVIATION
)	O
with	O
the	O
potency	O
of	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
)	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
piritrexim	I-TRIVIAL
,	O
PTX	I-ABBREVIATION
)	O
,	O
seven	O
previously	O
undescribed	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
substituted	I-IUPAC
benzyl	I-IUPAC
)	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
were	O
synthesized	O
in	O
which	O
the	O
substituent	O
at	O
the	O
5'	O
-	O
position	O
was	O
a	O
carboxyphenyl	I-PARTIUPAC
group	B-MODIFIER
linked	O
to	O
the	O
benzyl	I-PARTIUPAC
moiety	B-MODIFIER
by	O
a	O
bridge	O
of	O
two	O
or	O
four	O
atoms	O
in	O
length	O
.	O

The	O
new	O
analogues	O
were	O
all	O
obtained	O
from	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
)	I-IUPAC
pyrimidine	I-IUPAC
via	O
a	O
Sonogashira	O
reaction	O
,	O
followed	O
,	O
where	O
appropriate	O
,	O
by	O
catalytic	O
hydrogenation	O
.	O

The	O
new	O
analogues	O
were	O
tested	O
as	O
inhibitors	O
of	O
DHFR	O
from	O
Pneumocystis	O
carinii	O
(	O
Pc	O
)	O
,	O
Toxoplasma	O
gondii	O
(	O
Tg	O
)	O
,	O
and	O
Mycobacterium	O
avium	O
(	O
Ma	O
)	O
,	O
three	O
life	O
-	O
threatening	O
pathogens	O
often	O
found	O
in	O
AIDS	O
patients	O
and	O
individuals	O
whose	O
immune	O
system	O
is	O
impaired	O
as	O
a	O
result	O
of	O
treatment	O
with	O
immunosuppressive	O
chemotherapy	O
or	O
radiation	O
.	O

The	O
selectivity	O
index	O
(	O
SI	O
)	O
of	O
each	O
compound	O
was	O
obtained	O
by	O
dividing	O
its	O
50%	O
inhibitory	O
concentration	O
(	O
IC	O
(	O
50	O
)	O
)	O
against	O
Pc	O
,	O
Tg	O
,	O
or	O
Ma	O
DHFR	O
by	O
its	O
IC	O
(	O
50	O
)	O
against	O
rat	O
DHFR	O
.	O

2,4	I-IUPAC
-	I-IUPAC
Diamino	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxyphenyl	I-IUPAC
)	I-IUPAC
ethynylbenzyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
28	O
)	O
,	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
23	O
nM	O
and	O
an	O
SI	O
of	O
28	O
in	O
the	O
Pc	O
DHFR	O
assay	O
,	O
had	O
about	O
the	O
same	O
potency	O
as	O
PTX	I-ABBREVIATION
and	O
was	O
520	O
times	O
more	O
potent	O
than	O
TMP	I-ABBREVIATION
.	O

As	O
an	O
inhibitor	O
of	O
Tg	O
DHFR	O
,	O
28	O
had	O
an	O
IC	O
(	O
50	O
)	O
of	O
5.5	O
nM	O
(	O
510	O
-	O
fold	O
lower	O
than	O
that	O
of	O
TMP	I-ABBREVIATION
and	O
similar	O
to	O
that	O
of	O
PTX	I-ABBREVIATION
)	O
and	O
an	O
SI	O
value	O
of	O
120	O
(	O
2	O
-	O
fold	O
better	O
than	O
TMP	I-ABBREVIATION
and	O
vastly	O
superior	O
to	O
PTX	I-ABBREVIATION
)	O
.	O

Against	O
Ma	O
DHFR	O
,	O
28	O
had	O
IC	O
(	O
50	O
)	O
and	O
SI	O
values	O
of	O
1.5	O
nM	O
and	O
430	O
,	O
respectively	O
,	O
compared	O
with	O
300	O
nM	O
and	O
610	O
for	O
TMP	I-ABBREVIATION
.	O

Although	O
it	O
had	O
2.5	O
-	O
fold	O
lower	O
potency	O
than	O
28	O
against	O
Ma	O
DHFR	O
(	O
IC	O
(	O
50	O
)	O
=	O
3.7	O
nM	O
)	O
and	O
was	O
substantially	O
weaker	O
against	O
Pc	O
and	O
Tg	O
DHFR	O
,	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxyphenyl	I-IUPAC
)	I-IUPAC
ethynylbenzyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
29	O
)	O
,	O
with	O
the	O
carboxy	I-TRIVIAL
group	B-MODIFIER
at	O
the	O
para	O
rather	O
than	O
the	O
meta	O
position	O
,	O
displayed	O
2200	O
-	O
fold	O
selectivity	O
against	O
the	O
Ma	O
enzyme	O
and	O
was	O
the	O
most	O
selective	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
benzyl	I-IUPAC
)	I-IUPAC
pyrimidine	I-IUPAC
inhibitor	O
of	O
this	O
enzyme	O
we	O
have	O
encountered	O
to	O
date	O
.	O

Additional	O
bioassay	O
data	O
for	O
these	O
compounds	O
are	O
also	O
reported	O
.	O

Parenteral	O
hydroxypropyl	I-IUPAC
cyclodextrins	I-IUPAC
:	O
intravenous	O
and	O
intracerebral	O
administration	O
of	O
lipophiles	O
.	O

Hydroxypropyl	I-IUPAC
cyclodextrins	I-IUPAC
are	O
nontoxic	O
carbohydrate	I-FAMILY
derivatives	B-MODIFIER
of	O
moderate	O
molecular	O
weight	O
(	O
1030-1750	O
Da	O
)	O
which	O
form	O
water	O
-	O
soluble	O
complexes	O
with	O
many	O
lipophiles	O
.	O

The	O
fate	O
of	O
hydroxypropyl	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
cyclodextrin	I-IUPAC
alone	O
and	O
in	O
complex	O
with	O
testosterone	I-TRIVIAL
or	O
cholesterol	I-TRIVIAL
injected	O
intravenously	O
or	O
intracerebrally	O
into	O
rats	O
was	O
followed	O
.	O

More	O
than	O
90%	O
of	O
intravenously	O
administered	O
hydroxypropyl	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
cyclodextrin	I-IUPAC
was	O
cleared	O
into	O
urine	O
in	O
4	O
h	O
,	O
as	O
previously	O
described	O
(	O
Monbaliu	O
,	O
J	O
.	O

;	O
Van	O
Beijsterveld	O
,	O
L	O
.	O

;	O
Meuldermans	O
,	O
W	O
.	O

;	O
Szathmary	O
,	O
S	O
.	O

;	O
Haykants	O
,	O
J	O
.	O

Abstracts	O
,	O
5th	O
International	O
Symposium	O
on	O
Cyclodextrins	I-TRIVIAL
,	O
Paris	O
,	O
1990	O
;	O
Abstract	O
65	O
)	O
.	O

After	O
the	O
injection	O
of	O
steroids	O
in	O
complex	O
with	O
hydroxypropyl	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
cyclodextrin	I-IUPAC
into	O
the	O
tail	O
vein	O
of	O
rats	O
,	O
the	O
steroid	O
component	O
was	O
released	O
from	O
the	O
complex	O
,	O
before	O
it	O
reached	O
the	O
kidneys	O
;	O
the	O
release	O
occurred	O
mainly	O
into	O
the	O
proteins	O
and	O
lipoproteins	O
of	O
serum	O
.	O

Hydroxypropyl	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
cyclodextrins	I-IUPAC
injected	O
alone	O
into	O
the	O
brain	O
were	O
cleared	O
within	O
less	O
than	O
24	O
h	O
,	O
presumably	O
via	O
the	O
flow	O
of	O
interstitial	O
and	O
cerebrospinal	O
fluids	O
,	O
and	O
eventually	O
were	O
excreted	O
in	O
urine	O
.	O

Testosterone	I-TRIVIAL
,	O
incorporated	O
in	O
a	O
hydroxypropyl	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
cyclodextrin	I-IUPAC
complex	I-MODIFIER
,	O
after	O
intracerebral	O
injection	O
was	O
cleared	O
from	O
the	O
brain	O
even	O
more	O
rapidly	O
than	O
hydroxypropyl	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
cyclodextrin	I-IUPAC
,	O
presumably	O
by	O
crossing	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
later	O
removal	O
to	O
the	O
liver	O
by	O
the	O
specific	O
carrier	O
proteins	O
in	O
serum	O
.	O

Complexed	O
cholesterol	I-TRIVIAL
,	O
in	O
a	O
similar	O
experiment	O
,	O
was	O
largely	O
retained	O
in	O
the	O
brain	O
and	O
its	O
distribution	O
there	O
was	O
uneven	O
and	O
remained	O
that	O
way	O
for	O
at	O
least	O
3	O
days	O
.	O

It	O
is	O
clear	O
that	O
lipophilic	O
agents	O
,	O
after	O
their	O
incorporation	O
into	O
hydroxypropyl	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
cyclodextrin	I-IUPAC
complexes	I-MODIFIER
and	O
subsequent	O
in	O
vivo	O
administration	O
,	O
are	O
rapidly	O
released	O
and	O
exchanged	O
into	O
the	O
plasma	O
.	O

In	O
absence	O
of	O
plasma	O
they	O
enter	O
tissues	O
surrounding	O
the	O
injection	O
site	O
and	O
thus	O
are	O
also	O
promptly	O
transferred	O
into	O
the	O
organism	O
's	O
lipid	I-FAMILY
systems	O
.	O

The	O
manner	O
in	O
which	O
different	O
lipophilic	O
agents	O
are	O
transported	O
in	O
vivo	O
appears	O
not	O
to	O
be	O
greatly	O
affected	O
by	O
their	O
previous	O
complexation	O
;	O
rather	O
hydroxypropyl	I-IUPAC
cyclodextrins	I-IUPAC
just	O
enable	O
their	O
entry	O
in	O
a	O
larger	O
amount	O
and	O
in	O
an	O
exchangeable	O
,	O
nonaggregated	O
form	O
.	O

Inhibition	O
of	O
renin	O
secretion	O
by	O
intrarenal	O
alpha	O
-	O
adrenoceptor	O
blockade	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
renal	O
alpha	O
-	O
adrenoceptors	O
can	O
mediate	O
tonic	O
neural	O
stimulation	O
of	O
renin	O
secretion	O
.	O

The	O
effect	O
of	O
alpha	O
-	O
adrenoceptor	O
blockade	O
by	O
phenoxybenzamine	I-TRIVIAL
(	O
POB	I-ABBREVIATION
)	O
or	O
prazosin	I-TRIVIAL
on	O
renin	O
secretion	O
rate	O
(	O
RSR	O
)	O
was	O
studied	O
in	O
pentobarbital	I-TRIVIAL
-	O
anesthetized	O
dogs	O
in	O
which	O
renal	O
perfusion	O
pressure	O
was	O
held	O
constant	O
with	O
an	O
adjustable	O
aortic	O
clamp	O
.	O

POB	I-ABBREVIATION
alone	O
(	O
100	O
micrograms	O
.	O

kg	O
-	O
1	O
.	O

min	O
-	O
1	O
iv	O
)	O
did	O
not	O
change	O
arterial	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
.	O

However	O
,	O
when	O
beta	O
-	O
adrenoceptors	O
were	O
blocked	O
by	O
intravenous	O
propranolol	I-TRIVIAL
,	O
intravenous	O
POB	I-ABBREVIATION
infusion	O
(	O
100	O
micrograms	O
.	O

kg	O
-	O
1	O
.	O

min	O
-	O
1	O
)	O
decreased	O
PRA	O
and	O
RSR	O
to	O
48	O
+	O
/	O
-	O
8	O
and	O
21	O
+	O
/	O
-	O
9%	O
of	O
previous	O
levels	O
within	O
30	O
min	O
.	O

This	O
effect	O
was	O
abolished	O
by	O
acute	O
bilateral	O
renal	O
denervation	O
.	O

Direct	O
intrarenal	O
POB	I-ABBREVIATION
infusion	O
(	O
10	O
or	O
3.3	O
micrograms	O
.	O

kg	O
-	O
1	O
.	O

min	O
-	O
1	O
)	O
decreased	O
RSR	O
,	O
whereas	O
intravenous	O
POB	I-ABBREVIATION
(	O
3.3	O
micrograms	O
.	O

kg	O
-	O
1	O
.	O

min	O
-	O
1	O
)	O
had	O
no	O
effect	O
on	O
either	O
RSR	O
or	O
PRA	O
in	O
propranolol	I-TRIVIAL
-	O
pretreated	O
dogs	O
.	O

Prazosin	I-TRIVIAL
(	O
1	O
microgram	O
.	O

kg	O
-	O
1	O
.	O

min	O
-	O
1	O
iv	O
)	O
also	O
significantly	O
decreased	O
PRA	O
.	O

These	O
data	O
indicate	O
that	O
when	O
beta	O
-	O
adrenoceptors	O
are	O
blocked	O
by	O
propranolol	I-TRIVIAL
,	O
tonic	O
neural	O
stimulation	O
of	O
renin	O
secretion	O
is	O
mediated	O
by	O
renal	O
alpha	O
-	O
adrenoceptors	O
.	O

Metabolism	O
of	O
D	I-IUPAC
-	I-IUPAC
and	O
L	I-IUPAC
-	I-IUPAC
glyceraldehyde	I-IUPAC
in	O
adipose	O
tissue	O
:	O
a	O
stereochemical	O
probe	O
for	O
glycerokinase	O
activity	O
.	O

Distributions	O
of	O
(	I-SUM
14	I-SUM
)	I-SUM
C	I-SUM
have	O
been	O
determined	O
in	O
free	O
glycerol	I-TRIVIAL
,	O
in	O
glycerol	I-TRIVIAL
from	O
triglycerides	I-FAMILY
,	O
in	O
glucose	I-TRIVIAL
from	O
glycogen	I-TRIVIAL
,	O
and	O
in	O
lactate	O
after	O
incubation	O
of	O
d	I-IUPAC
-	I-IUPAC
glyceraldehyde	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
14	I-IUPAC
)	I-IUPAC
C	I-IUPAC
and	O
l	I-IUPAC
-	I-IUPAC
glyceraldehyde	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
14	I-IUPAC
)	I-IUPAC
C	I-IUPAC
with	O
rat	O
adipose	O
tissue	O
.	O

The	O
distributions	O
are	O
interpreted	O
in	O
terms	O
of	O
presently	O
accepted	O
possible	O
reactions	O
for	O
the	O
initial	O
metabolism	O
of	O
glyceraldehyde	I-TRIVIAL
.	O

Formation	O
of	O
glycerol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
14	I-IUPAC
)	I-IUPAC
C	I-IUPAC
from	O
d	I-IUPAC
-	I-IUPAC
glyceraldehyde	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
14	I-IUPAC
)	I-IUPAC
C	I-IUPAC
indicates	O
that	O
in	O
adipose	O
tissue	O
glyceraldehyde	I-TRIVIAL
is	O
reduced	O
to	O
glycerol	I-TRIVIAL
.	O

Incorporation	O
of	O
(	I-SUM
14	I-SUM
)	I-SUM
C	I-SUM
from	O
d	I-IUPAC
-	I-IUPAC
glyceraldehyde	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
14	I-IUPAC
)	I-IUPAC
C	I-IUPAC
into	O
carbon	I-TRIVIAL
3	O
of	O
the	O
glycerol	I-TRIVIAL
of	O
triglyceride	I-FAMILY
indicates	O
that	O
d	I-IUPAC
-	I-IUPAC
glyceraldehyde	I-IUPAC
is	O
either	O
phosphorylated	O
or	O
oxidized	O
to	O
d	I-IUPAC
-	I-IUPAC
glyceric	I-IUPAC
acid	I-IUPAC
,	O
or	O
both	O
,	O
in	O
its	O
initial	O
metabolism	O
.	O

Incorporation	O
of	O
(	I-SUM
14	I-SUM
)	I-SUM
C	I-SUM
from	O
l	I-IUPAC
-	I-IUPAC
glyceraldehyde	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
14	I-IUPAC
)	I-IUPAC
C	I-IUPAC
into	O
carbon	I-TRIVIAL
3	O
of	O
glycerol	I-TRIVIAL
indicates	O
that	O
l	I-IUPAC
-	I-IUPAC
glyceraldehyde	I-IUPAC
is	O
reduced	O
to	O
glycerol	I-TRIVIAL
,	O
which	O
is	O
phosphorylated	O
and	O
(	O
or	O
)	O
converted	O
to	O
d	I-IUPAC
-	I-IUPAC
glyceric	I-IUPAC
acid	I-IUPAC
via	O
l	I-IUPAC
-	I-IUPAC
glyceric	I-IUPAC
acid	I-IUPAC
.	O

Some	O
(	I-SUM
14	I-SUM
)	I-SUM
C	I-SUM
from	O
l	I-IUPAC
-	I-IUPAC
glyceraldehyde	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
14	I-IUPAC
)	I-IUPAC
C	I-IUPAC
is	O
incorporated	O
into	O
carbon	I-TRIVIAL
1	O
of	O
glycerol	I-TRIVIAL
of	O
triglycerides	I-FAMILY
and	O
carbon	I-TRIVIAL
4	O
of	O
glycogen	I-TRIVIAL
;	O
the	O
explanation	O
for	O
this	O
incorporation	O
is	O
uncertain	O
.	O

Attenuation	O
of	O
glucocorticoid	I-FAMILY
functions	O
in	O
an	O
Anx	O
-	O
A1	O
-	O
/	O
-	O
cell	O
line	O
.	O

The	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
phospholipid	O
-	O
binding	O
protein	O
Anx	O
-	O
A1	O
(	O
annexin	O
1	O
;	O
lipocortin	O
1	O
)	O
has	O
been	O
described	O
both	O
as	O
an	O
inhibitor	O
of	O
phospholipase	O
A	O
(	O
2	O
)	O
(	O
PLA	O
(	O
2	O
)	O
)	O
activity	O
and	O
as	O
a	O
mediator	O
of	O
glucocorticoid	I-FAMILY
-	O
regulated	O
cell	O
growth	O
and	O
eicosanoid	I-TRIVIAL
generation	O
.	O

Here	O
we	O
show	O
that	O
,	O
when	O
compared	O
with	O
Anx	O
-	O
A1	O
(	O
+	O
/	O
+	O
)	O
cells	O
,	O
lung	O
fibroblast	O
cell	O
lines	O
derived	O
from	O
the	O
Anx	O
-	O
A1	O
(	O
-	O
/	O
-	O
)	O
mouse	O
exhibit	O
an	O
altered	O
morphology	O
characterized	O
by	O
a	O
spindle	O
-	O
shaped	O
appearance	O
and	O
an	O
accumulation	O
of	O
intracellular	O
organelles	O
.	O

Unlike	O
their	O
wild	O
-	O
type	O
counterparts	O
,	O
Anx	O
-	O
A1	O
(	O
-	O
/	O
-	O
)	O
cells	O
also	O
overexpress	O
cyclo	O
-	O
oxygenase	O
2	O
(	O
COX	O
2	O
)	O
,	O
cytosolic	O
PLA	O
(	O
2	O
)	O
and	O
secretory	O
PLA	O
(	O
2	O
)	O
and	O
in	O
response	O
to	O
fetal	O
calf	O
serum	O
,	O
exhibit	O
an	O
exaggerated	O
release	O
of	O
eicosanoids	I-TRIVIAL
,	O
which	O
is	O
insensitive	O
to	O
dexamethasone	I-TRIVIAL
(	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
inhibition	O
.	O

Proliferation	O
and	O
serum	O
-	O
induced	O
progression	O
of	O
Anx	O
-	O
A1	O
(	O
+	O
/	O
+	O
)	O
cells	O
from	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
into	O
S	O
phase	O
,	O
and	O
the	O
associated	O
expression	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
2	O
(	O
ERK2	O
)	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
4	O
(	O
cdk4	O
)	O
and	O
COX	O
2	O
,	O
is	O
strongly	O
inhibited	O
by	O
dexamethasone	O
,	O
whereas	O
Anx	O
-	O
A1	O
(	O
-	O
/	O
-	O
)	O
cells	O
are	O
refractory	O
to	O
the	O
drug	O
.	O

Loss	O
of	O
the	O
response	O
to	O
dexamethasone	I-TRIVIAL
in	O
Anx	O
-	O
A1	O
(	O
-	O
/	O
-	O
)	O
cells	O
occurs	O
against	O
a	O
background	O
of	O
no	O
apparent	O
change	O
in	O
glucocorticoid	O
receptor	O
expression	O
or	O
sensitivity	O
to	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
strongly	O
that	O
Anx	O
-	O
A1	O
functions	O
as	O
an	O
inhibitor	O
of	O
signal	O
-	O
transduction	O
pathways	O
that	O
lead	O
to	O
cell	O
proliferation	O
and	O
may	O
help	O
to	O
explain	O
how	O
glucocorticoids	I-FAMILY
regulate	O
these	O
processes	O
.	O

Cognitive	O
assessment	O
of	O
geriatric	O
schizophrenic	O
patients	O
with	O
severe	O
impairment	O
.	O

There	O
is	O
evidence	O
that	O
some	O
elderly	O
patients	O
with	O
chronic	O
schizophrenia	O
experience	O
marked	O
impairments	O
in	O
cognitive	O
functioning	O
.	O

Assessment	O
of	O
these	O
patients	O
may	O
be	O
difficult	O
with	O
traditional	O
neuropsychological	O
measures	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
cognitive	O
functioning	O
could	O
be	O
validly	O
assessed	O
with	O
the	O
Alzheimer	O
's	O
Disease	O
Assessment	O
Scale	O
-	O
Late	O
Version	O
Cognitive	O
factor	O
score	O
(	O
ADAS	O
-	O
L	O
Cog	O
)	O
in	O
patients	O
whose	O
scores	O
on	O
the	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
reflect	O
profound	O
cognitive	O
impairment	O
.	O

Patients	O
with	O
MMSE	O
scores	O
from	O
0	O
to	O
10	O
were	O
selected	O
from	O
a	O
larger	O
database	O
.	O

Neuropsychological	O
instruments	O
designed	O
for	O
the	O
assessment	O
of	O
mild	O
to	O
moderate	O
dementia	O
were	O
found	O
to	O
be	O
inadequate	O
in	O
this	O
profoundly	O
impaired	O
population	O
,	O
due	O
to	O
floor	O
effects	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
significant	O
relationship	O
between	O
ADAS	O
-	O
L	O
scores	O
and	O
several	O
criterion	O
measures	O
,	O
including	O
the	O
MMSE	O
(	O
R	O
=	O
-	O
.71	O
,	O
P	O
<	O
.001	O
)	O
,	O
the	O
Social	O
Adaptive	O
Functions	O
Evaluation	O
(	O
SAFE	O
)	O
social	O
functions	O
scale	O
(	O
R	O
=	O
.47	O
,	O
P	O
<	O
.001	O
)	O
,	O
and	O
the	O
negative	O
symptom	O
total	O
score	O
of	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
(	O
R	O
=	O
.412	O
,	O
P	O
<	O
.001	O
)	O
.	O

The	O
MMSE	O
was	O
somewhat	O
less	O
strongly	O
correlated	O
with	O
both	O
social	O
functions	O
(	O
R	O
=	O
-	O
.401	O
,	O
P	O
<	O
.001	O
)	O
and	O
the	O
negative	O
symptom	O
total	O
score	O
of	O
the	O
PANSS	O
(	O
R	O
=	O
-	O
.366	O
,	O
P	O
<	O
.001	O
)	O
.	O

These	O
results	O
suggest	O
that	O
cognition	O
can	O
be	O
reliably	O
and	O
validly	O
assessed	O
with	O
instruments	O
such	O
as	O
the	O
ADAS	O
-	O
L	O
that	O
are	O
designed	O
for	O
the	O
assessment	O
of	O
severely	O
impaired	O
patients	O
.	O

Evidence	O
for	O
messenger	O
ribonucleic	O
acid	O
of	O
an	O
ammonium	O
-	O
inducible	O
glutamate	O
dehydrogenase	O
and	O
synthesis	O
,	O
covalent	O
modification	O
,	O
and	O
degradation	O
of	O
enzyme	O
subunits	O
in	O
uninduced	O
Chlorella	O
sorokiniana	O
cells	O
.	O

The	O
cells	O
of	O
Chlorella	O
sorokiniana	O
cultured	O
in	O
nitrate	I-TRIVIAL
medium	O
contain	O
no	O
detectable	O
catalytic	O
activity	O
of	O
an	O
ammonium	O
-	O
inducible	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
-	O
specific	O
glutamate	O
dehydrogenase	O
(	O
NADP	O
-	O
GDH	O
)	O
.	O

However	O
,	O
several	O
lines	O
of	O
experimental	O
evidence	O
indicated	O
that	O
the	O
NADP	O
-	O
GDH	O
messenger	O
ribonucleic	O
acid	O
was	O
present	O
at	O
high	O
levels	O
and	O
was	O
being	O
translated	O
in	O
uninduced	O
cells	O
.	O

First	O
,	O
binding	O
studies	O
with	O
125I	O
-	O
labeled	O
anti	O
-	O
NADP	O
-	O
GDH	O
immunoglobulin	O
G	O
and	O
total	O
polysomes	O
isolated	O
from	O
uninduced	O
and	O
induced	O
cells	O
showed	O
that	O
NADP	O
-	O
GDH	O
subunits	O
were	O
being	O
synthesized	O
on	O
polysomes	O
from	O
both	O
types	O
of	O
cells	O
.	O

Second	O
,	O
when	O
polyadenylic	I-IUPAC
acid	I-IUPAC
-	O
containing	O
ribonucleic	O
acid	O
was	O
extracted	O
from	O
polysomes	O
from	O
uninduced	O
and	O
induced	O
cells	O
and	O
placed	O
into	O
a	O
messenger	O
ribonucleic	O
acid	O
-	O
dependent	O
in	O
vitro	O
translation	O
system	O
,	O
NADP	O
-	O
GDH	O
subunits	O
were	O
synthesized	O
from	O
the	O
ribonucleic	O
acid	O
from	O
both	O
sources	O
.	O

Third	O
,	O
when	O
ammonia	I-FAMILY
was	O
added	O
to	O
uninduced	O
cells	O
,	O
NADP	O
-	O
GDH	O
antigen	O
accumulated	O
without	O
an	O
apparent	O
induction	O
lag	O
.	O

Fourth	O
,	O
by	O
use	O
of	O
a	O
specific	O
immunoprecipitation	O
procedure	O
coupled	O
to	O
pulse	O
-	O
chase	O
studies	O
with	O
[	I-IUPAC
35S	I-IUPAC
]	I-IUPAC
sulfate	I-IUPAC
,	O
it	O
was	O
shown	O
that	O
the	O
NADP	O
-	O
GDH	O
subunits	O
are	O
rapidly	O
synthesized	O
,	O
covalently	O
modified	O
,	O
and	O
then	O
degraded	O
in	O
uninduced	O
cells	O
.	O

Nucleotide	I-FAMILY
regulation	O
of	O
heat	O
-	O
stable	O
enterotoxin	O
receptor	O
binding	O
and	O
of	O
guanylate	O
cyclase	O
activation	O
.	O

Certain	O
nucleotides	I-FAMILY
were	O
found	O
to	O
regulate	O
the	O
binding	O
of	O
the	O
Escherichia	O
coli	O
heat	O
-	O
stable	O
enterotoxin	O
(	O
STa	O
)	O
to	O
its	O
receptor	O
in	O
pig	O
intestinal	O
brush	O
border	O
membranes	O
.	O

ATP	I-ABBREVIATION
and	O
adenine	I-TRIVIAL
nucleotide	B-FAMILY
analogues	B-MODIFIER
inhibited	O
125I	O
-	O
STa	O
binding	O
,	O
while	O
guanine	I-TRIVIAL
nucleotide	B-FAMILY
analogues	B-MODIFIER
stimulated	O
binding	O
,	O
with	O
maximal	O
effects	O
at	O
0.5-1.0	O
mM	O
.	O

The	O
strongest	O
inhibitors	O
were	O
adenosine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
beta	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
imido	I-IUPAC
]	I-IUPAC
triphosphate	I-IUPAC
(	O
App	I-ABBREVIATION
[	I-ABBREVIATION
NH	I-ABBREVIATION
]	I-ABBREVIATION
p	I-ABBREVIATION
)	O
(	O
36%	O
)	O
and	O
adenosine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
thio	I-IUPAC
]	I-IUPAC
diphosphate	I-IUPAC
(	O
ADP	I-ABBREVIATION
[	I-ABBREVIATION
S	I-ABBREVIATION
]	I-ABBREVIATION
)	O
(	O
41%	O
)	O
.	O

Inhibition	O
did	O
not	O
require	O
Mg2+	I-SUM
,	O
and	O
was	O
blocked	O
by	O
p	I-IUPAC
-	I-IUPAC
chloromercuribenzenesulphonate	I-IUPAC
(	O
PCMBS	I-ABBREVIATION
)	O
.	O

Stimulation	O
of	O
binding	O
required	O
Mg2+	I-SUM
,	O
was	O
not	O
prevented	O
by	O
PCMBS	I-ABBREVIATION
and	O
was	O
maximal	O
with	O
GDP	I-ABBREVIATION
[	I-ABBREVIATION
S	I-ABBREVIATION
]	I-ABBREVIATION
(	O
41%	O
)	O
.	O

While	O
App	I-ABBREVIATION
[	I-ABBREVIATION
NH	I-ABBREVIATION
]	I-ABBREVIATION
p	I-ABBREVIATION
and	O
MgGDP	I-ABBREVIATION
[	I-ABBREVIATION
S	I-ABBREVIATION
]	I-ABBREVIATION
appeared	O
to	O
be	O
acting	O
at	O
different	O
sites	O
,	O
they	O
also	O
interfered	O
with	O
each	O
other	O
.	O

These	O
nucleotides	I-FAMILY
exerted	O
only	O
inhibitory	O
effects	O
on	O
STa	O
-	O
stimulated	O
guanylate	O
cyclase	O
activity	O
,	O
in	O
contrast	O
with	O
the	O
stimulatory	O
effects	O
of	O
adenine	I-TRIVIAL
nucleotides	O
on	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
-	O
stimulated	O
guanylate	O
cyclase	O
.	O

Inhibition	O
by	O
low	O
concentrations	O
of	O
MgApp	I-ABBREVIATION
[	I-ABBREVIATION
NH	I-ABBREVIATION
]	I-ABBREVIATION
p	I-ABBREVIATION
and	O
MgATP	I-ABBREVIATION
was	O
weaker	O
above	O
0.1	O
mM	O
,	O
while	O
MgGDP	I-ABBREVIATION
[	I-ABBREVIATION
S	I-ABBREVIATION
]	I-ABBREVIATION
and	O
magnesium	I-IUPAC
guanosine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
thio	I-IUPAC
]	I-IUPAC
triphosphate	I-IUPAC
(	O
MgGTP	I-ABBREVIATION
[	I-ABBREVIATION
S	I-ABBREVIATION
]	I-ABBREVIATION
)	O
inhibited	O
in	O
a	O
single	O
phase	O
.	O

Inhibition	O
by	O
MgApp	I-ABBREVIATION
[	I-ABBREVIATION
NH	I-ABBREVIATION
]	I-ABBREVIATION
p	I-ABBREVIATION
,	O
at	O
all	O
concentrations	O
,	O
was	O
competitive	O
with	O
the	O
substrate	O
(	O
MgGTP	I-ABBREVIATION
)	O
,	O
as	O
was	O
that	O
by	O
MgGDP	I-ABBREVIATION
[	I-ABBREVIATION
S	I-ABBREVIATION
]	I-ABBREVIATION
and	O
MgGTP	I-ABBREVIATION
[	I-ABBREVIATION
S	I-ABBREVIATION
]	I-ABBREVIATION
.	O

Whereas	O
membrane	O
guanylate	O
cyclases	O
usually	O
show	O
positively	O
co	O
-	O
operative	O
kinetics	O
with	O
respect	O
to	O
the	O
substrate	O
,	O
STa	O
-	O
stimulated	O
activity	O
exhibited	O
Michaelis	O
-	O
Menten	O
kinetics	O
with	O
respect	O
to	O
MgGTP	I-ABBREVIATION
.	O

This	O
changed	O
to	O
positive	O
co	O
-	O
operativity	O
when	O
Lubrol	I-TRIVIAL
PX	I-TRIVIAL
was	O
the	O
activator	O
,	O
or	O
when	O
the	O
substrate	O
was	O
MnGTP	I-ABBREVIATION
.	O

These	O
results	O
suggest	O
the	O
presence	O
of	O
both	O
a	O
regulatory	O
and	O
a	O
catalytic	O
nucleotide	O
-	O
binding	O
site	O
,	O
which	O
do	O
not	O
interact	O
co	O
-	O
operatively	O
with	O
STa	O
activation	O
.	O

The	O
syntheses	O
of	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
4	O
)	O
,	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
5SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
20	O
)	O
,	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
acetamidopiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
10	O
)	O
,	O
and	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
5SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
acetamidopiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
18	O
)	O
,	O
related	O
to	O
the	O
specific	O
gamma	I-IUPAC
-	I-IUPAC
aminobutyric	I-IUPAC
acid	I-IUPAC
(	O
GABA	I-ABBREVIATION
)	O
uptake	O
inhibitors	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
nipecotic	I-IUPAC
acid	I-IUPAC
)	O
and	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
21	O
)	O
,	O
are	O
described	O
.	O

Furthermore	O
,	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
14	O
)	O
,	O
related	O
to	O
the	O
specific	O
GABA	I-ABBREVIATION
agonist	O
piperidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
isonipecotic	I-IUPAC
acid	I-IUPAC
)	O
,	O
has	O
been	O
synthesized	O
.	O

The	O
structures	O
of	O
4	O
,	O
10	O
,	O
14	O
,	O
18	O
,	O
and	O
20	O
have	O
been	O
established	O
by	O
270	O
-	O
MHz	O
1H	O
NMR	O
spectroscopic	O
analyses	O
.	O

The	O
affinity	O
of	O
the	O
compounds	O
for	O
the	O
GABA	O
receptors	O
and	O
for	O
the	O
neuronal	O
(	O
synaptosomal	O
)	O
GABA	I-ABBREVIATION
uptake	O
system	O
in	O
vitro	O
has	O
been	O
measured	O
.	O

Compound	O
14	O
interacts	O
selectively	O
with	O
the	O
GABA	O
receptors	O
but	O
less	O
effectively	O
than	O
isonipecotic	I-IUPAC
acid	I-IUPAC
and	O
the	O
cis	O
-	O
isomer	O
22	O
.	O

Compounds	O
4	O
,	O
18	O
,	O
and	O
20	O
are	O
inhibitors	O
of	O
the	O
GABA	I-ABBREVIATION
uptake	O
system	O
,	O
although	O
much	O
weaker	O
than	O
nipecotic	I-IUPAC
acid	I-IUPAC
and	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
21	O
)	O
.	O

Compound	O
10	O
is	O
inactive	O
in	O
both	O
test	O
systems	O
.	O

Novel	O
genetic	O
variations	O
and	O
haplotypes	O
of	O
hepatocyte	O
nuclear	O
factor	O
4alpha	O
(	O
HNF4A	O
)	O
found	O
in	O
Japanese	O
type	O
II	O
diabetic	O
patients	O
.	O

Thirty	O
-	O
nine	O
single	O
nucleotide	O
variations	O
,	O
including	O
16	O
novel	O
ones	O
,	O
were	O
found	O
in	O
the	O
5'	O
promoter	O
region	O
,	O
all	O
of	O
the	O
exons	O
and	O
their	O
surrounding	O
introns	O
of	O
HNF4A	O
in	O
74	O
Japanese	O
type	O
II	O
diabetic	O
patients	O
.	O

The	O
following	O
novel	O
variations	O
were	O
identified	O
(	O
based	O
on	O
the	O
amino	O
acid	O
numbering	O
of	O
splicing	O
variant	O
2	O
)	O
:	O
-	O
208G	O
>	O
C	O
in	O
the	O
5'	O
promoter	O
region	O
;	O
1154C	O
>	O
T	O
(	O
A385V	O
)	O
and	O
1193T	O
>	O
C	O
(	O
M398T	O
)	O
in	O
the	O
coding	O
exons	O
;	O
1580G	O
>	O
A	O
,	O
1852G	O
>	O
T	O
,	O
2180C	O
>	O
T	O
,	O
2190G	O
>	O
A	O
,	O
and	O
2362	O
_2380	O
delAAGAATGGTGTGGGAGAGG	O
in	O
the	O
3'	O
-	O
untranslated	O
region	O
,	O
and	O
IVS1+	O
231G	O
>	O
A	O
,	O
IVS2	O
-	O
83C	O
>	O
T	O
,	O
IVS3+	O
50C	O
>	O
T	O
,	O
IVS3	O
-	O
54delC	O
,	O
IVS5+	O
173	O
_176	O
delTTAG	O
,	O
IVS5	O
-	O
181	O
_	O
-	O
180delAT	O
,	O
IVS8	O
-	O
106A	O
>	O
G	O
,	O
and	O
IVS9	O
-	O
151A	O
>	O
C	O
in	O
the	O
introns	O
.	O

The	O
allele	O
frequencies	O
were	O
0.311	O
for	O
2362	O
_2380	O
delAAGAATGGTGTGGGAGAGG	O
,	O
0.054	O
for	O
1580G	O
>	O
A	O
,	O
0.047	O
for	O
1852G	O
>	O
T	O
,	O
0.020	O
for	O
IVS1+	O
231G	O
>	O
A	O
,	O
0.014	O
for	O
IVS9	O
-	O
151A	O
>	O
C	O
,	O
and	O
0.007	O
for	O
the	O
other	O
11	O
variations	O
.	O

In	O
addition	O
,	O
one	O
known	O
nonsynonymous	O
single	O
nucleotide	O
polymorphism	O
,	O
416C	O
>	O
T	O
(	O
T139I	O
)	O
,	O
was	O
detected	O
at	O
a	O
0.007	O
frequency	O
.	O

Based	O
on	O
the	O
linkage	O
disequilibrium	O
profiles	O
,	O
the	O
region	O
analyzed	O
was	O
divided	O
into	O
three	O
blocks	O
.	O

Haplotype	O
analysis	O
determined	O
/	O
inferred	O
10	O
,	O
16	O
,	O
and	O
12	O
haplotypes	O
for	O
block	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
respectively	O
.	O

Our	O
results	O
on	O
HNF4A	O
variations	O
and	O
haplotypes	O
would	O
be	O
useful	O
for	O
pharmacogenetic	O
studies	O
in	O
Japanese	O
.	O

Predictive	O
clinical	O
parameters	O
for	O
therapeutic	O
efficacy	O
of	O
rosiglitazone	I-TRIVIAL
in	O
Korean	O
type	O
2	O
diabetes	O
mellitus	O
.	O

This	O
study	O
evaluated	O
the	O
efficacy	O
of	O
rosiglitazone	I-TRIVIAL
in	O
non	O
-	O
obese	O
and	O
obese	O
Korean	O
type	O
2	O
diabetic	O
patients	O
of	O
long	O
duration	O
.	O

A	O
total	O
of	O
125	O
patients	O
(	O
M	O
:	O
F	O
=	O
44	O
:	O
81	O
,	O
mean	O
age	O
:	O
58.4	O
+	O
/	O
-	O
9.1	O
years	O
,	O
BMI	O
:	O
24.2	O
+	O
/	O
-	O
2.7	O
kg	O
/	O
m2	O
,	O
duration	O
of	O
diabetes	O
:	O
11.0	O
+	O
/	O
-	O
6.4	O
years	O
)	O
were	O
randomly	O
allocated	O
to	O
12	O
weeks	O
of	O
rosiglitazone	I-TRIVIAL
treatment	O
(	O
4	O
mg	O
per	O
day	O
)	O
or	O
a	O
control	O
group	O
.	O

Responders	O
were	O
defined	O
as	O
patients	O
who	O
experienced	O
fasting	O
plasma	O
glucose	I-TRIVIAL
(	O
FPG	O
)	O
reduction	O
of	O
>	O
20%	O
or	O
HbA1c	O
reduction	O
of	O
>	O
1	O
(	O
%	O
)	O
.	O

Rosiglitazone	I-TRIVIAL
significantly	O
improved	O
glycemic	O
control	O
by	O
reducing	O
FPG	O
and	O
HbA1c	O
(	O
-	O
3.4	O
mmol	O
/	O
l	O
and	O
-	O
1.1%	O
,	O
P	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

It	O
also	O
significantly	O
increased	O
HOMA	O
(	O
beta	O
-	O
cell	O
function	O
)	O
(	O
+	O
9.7	O
,	O
P	O
<	O
0.01	O
)	O
and	O
QUICKI	O
(	O
+	O
0.029	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
decreased	O
HOMA	O
(	O
IR	O
)	O
(	O
-	O
1.73	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Females	O
and	O
those	O
with	O
higher	O
waist	O
-	O
hip	O
ratio	O
made	O
up	O
a	O
greater	O
portion	O
of	O
rosiglitazone	O
-	O
responders	O
.	O

Responders	O
(	O
45	O
patients	O
,	O
75%	O
)	O
also	O
showed	O
significantly	O
higher	O
FPG	O
,	O
HbA1c	O
,	O
systolic	O
blood	O
pressures	O
,	O
fasting	O
insulin	O
levels	O
and	O
HOMA	O
(	O
IR	O
)	O
,	O
and	O
lower	O
QUICKI	O
than	O
nonresponders	O
.	O

Among	O
these	O
parameters	O
of	O
responders	O
,	O
waist	O
-	O
hip	O
ratio	O
of	O
non	O
-	O
obese	O
subgroup	O
,	O
initial	O
glycemic	O
control	O
of	O
obese	O
subgroup	O
,	O
and	O
systolic	O
blood	O
pressure	O
of	O
both	O
subgroups	O
lost	O
their	O
significance	O
after	O
subdivision	O
analysis	O
.	O

However	O
,	O
the	O
baseline	O
HOMA	O
(	O
IR	O
)	O
and	O
QUICKI	O
were	O
significantly	O
correlated	O
with	O
the	O
response	O
rate	O
to	O
rosiglitazone	I-TRIVIAL
.	O

Moreover	O
,	O
in	O
multiple	O
logistic	O
regression	O
analysis	O
,	O
HOMA	O
(	O
IR	O
)	O
and	O
QUICKI	O
retained	O
their	O
significance	O
as	O
the	O
independent	O
predictors	O
.	O

Even	O
in	O
Korean	O
type	O
2	O
diabetic	O
patients	O
of	O
long	O
duration	O
but	O
with	O
relatively	O
preserved	O
beta	O
-	O
cell	O
function	O
,	O
rosiglitazone	O
improved	O
glycemic	O
control	O
,	O
insulin	O
sensitivity	O
,	O
and	O
beta	O
-	O
cell	O
function	O
.	O

In	O
this	O
ethnic	O
group	O
,	O
female	O
gender	O
,	O
central	O
obesity	O
,	O
and	O
especially	O
severe	O
insulin	O
resistance	O
were	O
identified	O
as	O
predictive	O
clinical	O
parameters	O
of	O
rosiglitazone	I-TRIVIAL
-	O
responders	O
.	O

The	O
synthesis	O
of	O
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideazafolic	I-IUPAC
acid	I-IUPAC
and	O
its	O
2	I-PARTIUPAC
-	I-PARTIUPAC
desamino	I-PARTIUPAC
,	O
2	I-PARTIUPAC
-	I-PARTIUPAC
desamino	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
hydroxymethyl	I-PARTIUPAC
,	O
and	O
2	I-PARTIUPAC
-	I-PARTIUPAC
desamino	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
methoxy	I-PARTIUPAC
analogues	I-MODIFIER
is	O
described	O
.	O

In	O
general	O
the	O
synthetic	O
route	O
involved	O
the	O
coupling	O
of	O
diethyl	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
prop	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ynylamino	I-IUPAC
)	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
with	O
the	O
appropriate	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
quinazoline	I-IUPAC
followed	O
by	O
deprotection	O
with	O
mild	O
alkali	O
.	O

These	O
four	O
compounds	O
together	O
with	O
the	O
2	I-PARTIUPAC
-	I-PARTIUPAC
desamino	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
analogue	I-MODIFIER
were	O
tested	O
for	O
their	O
activity	O
against	O
L1210	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
.	O

They	O
were	O
also	O
examined	O
for	O
their	O
inhibition	O
of	O
the	O
growth	O
of	O
the	O
L1210	O
cell	O
line	O
and	O
of	O
two	O
mutant	O
L1210	O
cell	O
lines	O
,	O
the	O
L1210	O
:	O
R7A	O
that	O
overproduces	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
and	O
the	O
L1210	O
:	O
1565	O
that	O
has	O
impaired	O
uptake	O
of	O
reduced	O
folates	O
.	O

Compared	O
with	O
their	O
non	O
-	O
fluorinated	O
parent	O
compounds	O
,	O
the	O
2'	I-PARTIUPAC
-	I-PARTIUPAC
fluoro	I-PARTIUPAC
analogues	I-MODIFIER
were	O
all	O
approximately	O
2	O
-	O
fold	O
more	O
potent	O
as	O
TS	O
inhibitors	O
.	O

Similarly	O
,	O
they	O
also	O
showed	O
improved	O
inhibition	O
of	O
L1210	O
cell	O
growth	O
(	O
1.5-5	O
-	O
fold	O
)	O
,	O
and	O
this	O
activity	O
was	O
prevented	O
by	O
co	O
-	O
incubation	O
with	O
thymidine	O
.	O

All	O
had	O
retained	O
or	O
improved	O
activity	O
against	O
both	O
the	O
L1210	O
:	O
R7A	O
and	O
L1210	O
:	O
1565	O
cell	O
lines	O
.	O

A	O
novel	O
class	O
of	O
5	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
acyclic	I-IUPAC
pyrimidine	I-IUPAC
nucleosides	I-IUPAC
,	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azidovinyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
9a	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azidovinyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
9b	O
)	O
,	O
and	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azidovinyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
9c	O
)	O
,	O
were	O
synthesized	O
by	O
regiospecific	O
addition	O
of	O
bromine	I-IUPAC
azide	I-IUPAC
to	O
the	O
5	I-PARTIUPAC
-	I-PARTIUPAC
vinyl	I-PARTIUPAC
substituent	I-MODIFIER
of	O
the	O
respective	O
5	I-IUPAC
-	I-IUPAC
vinyluracils	I-IUPAC
(	O
2a	O
-	O
c	O
)	O
followed	O
by	O
treatment	O
of	O
the	O
obtained	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromoethyl	I-IUPAC
)	I-IUPAC
compounds	I-MODIFIER
(	O
3a	O
-	O
c	O
)	O
with	O
t	I-TRIVIAL
-	I-TRIVIAL
BuOK	I-TRIVIAL
,	O
to	O
affect	O
the	O
base	O
-	O
catalyzed	O
elimination	O
of	O
HBr	I-SUM
.	O

Thermal	O
decomposition	O
of	O
9b	O
and	O
9c	O
at	O
110	O
degrees	O
C	O
in	O
dioxane	I-TRIVIAL
yielded	O
corresponding	O
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azirinyl	I-IUPAC
)	I-IUPAC
]	I-IUPAC
uracil	I-IUPAC
analogues	I-MODIFIER
(	O
10b	O
,	O
c	O
)	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azidovinyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
derivatives	I-MODIFIER
9a	O
-	O
c	O
were	O
found	O
to	O
exhibit	O
potent	O
and	O
selective	O
in	O
vitro	O
anti	O
-	O
HBV	O
activity	O
against	O
duck	O
hepatitis	O
B	O
virus	O
(	O
DHBV	O
)	O
infected	O
primary	O
duck	O
hepatocytes	O
at	O
low	O
concentrations	O
(	O
EC	O
(	O
50	O
)	O
=	O
0.01-0.1	O
microg	O
/	O
mL	O
range	O
)	O
.	O

The	O
most	O
active	O
anti	O
-	O
DHBV	O
agent	O
(	O
9c	O
)	O
,	O
possessing	O
a	O
[	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
hydroxymethyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
butyl	I-PARTIUPAC
]	I-PARTIUPAC
substituent	I-MODIFIER
at	O
N	O
-	O
1	O
,	O
exhibited	O
an	O
activity	O
(	O
EC	O
(	O
50	O
)	O
of	O
0.01-0.05	O
microg	O
/	O
mL	O
)	O
comparable	O
to	O
that	O
of	O
reference	O
compound	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
thiacytidine	I-IUPAC
(	O
3	O
-	O
TC	O
)	O
(	O
EC	O
(	O
50	O
)	O
=	O
0.01-0.05	O
microg	O
/	O
mL	O
)	O
.	O

In	O
contrast	O
,	O
related	O
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azirinyl	I-IUPAC
)	I-IUPAC
]	I-IUPAC
uracil	I-IUPAC
analogues	I-MODIFIER
(	O
10b	O
,	O
c	O
)	O
were	O
devoid	O
of	O
anti	O
-	O
DHBV	O
activity	O
,	O
indicating	O
that	O
an	O
acyclic	O
side	O
chain	O
at	O
C	O
-	O
5	O
position	O
of	O
the	O
pyrimidine	I-FAMILY
ring	O
is	O
essential	O
for	O
anti	O
-	O
HBV	O
activity	O
.	O

The	O
pyrimidine	I-FAMILY
nucleosides	B-MODIFIER
(	O
9a	O
-	O
c	O
,	O
10b	O
,	O
c	O
)	O
exhibited	O
no	O
cytotoxic	O
activity	O
against	O
a	O
panel	O
of	O
60	O
human	O
cancer	O
cell	O
lines	O
.	O

All	O
of	O
the	O
compounds	O
investigated	O
did	O
not	O
show	O
any	O
detectable	O
toxicity	O
to	O
several	O
stationary	O
and	O
proliferating	O
host	O
cell	O
lines	O
or	O
to	O
mitogen	O
stimulated	O
proliferating	O
human	O
T	O
lymphocytes	O
,	O
up	O
to	O
the	O
highest	O
concentration	O
tested	O
.	O

Antiestrogens	O
reduce	O
plasma	O
levels	O
of	O
endothelin	O
-	O
1	O
without	O
affecting	O
nitrate	I-IUPAC
levels	O
in	O
breast	O
cancer	O
patients	O
.	O

Tamoxifen	I-TRIVIAL
protects	O
against	O
myocardial	O
infarction	O
through	O
mechanisms	O
that	O
are	O
poorly	O
understood	O
.	O

We	O
studied	O
the	O
effects	O
of	O
tamoxifen	I-TRIVIAL
and	O
another	O
antiestrogen	O
,	O
toremifene	I-TRIVIAL
,	O
on	O
the	O
production	O
of	O
vasoconstrictive	O
endothelin	O
-	O
1	O
and	O
of	O
vasodilatory	O
nitric	I-IUPAC
oxide	I-IUPAC
in	O
44	O
postmenopausal	O
patients	O
with	O
breast	O
cancer	O
.	O

These	O
started	O
treatment	O
,	O
in	O
randomized	O
order	O
,	O
with	O
either	O
tamoxifen	I-TRIVIAL
(	O
20	O
mg	O
/	O
day	O
;	O
n	O
=	O
25	O
)	O
or	O
toremifene	O
(	O
40	O
mg	O
/	O
day	O
;	O
n	O
=	O
19	O
)	O
.	O

Plasma	O
samples	O
collected	O
before	O
treatment	O
and	O
after	O
6	O
and	O
12	O
months	O
of	O
both	O
regimens	O
were	O
assayed	O
for	O
endothelin	O
-	O
1	O
with	O
a	O
specific	O
radioimmunoassay	O
and	O
for	O
nitrite	I-TRIVIAL
/	O
nitrate	I-TRIVIAL
with	O
a	O
method	O
based	O
on	O
the	O
Griess	O
reaction	O
.	O

The	O
antiestrogen	O
group	O
as	O
a	O
whole	O
showed	O
a	O
fall	O
in	O
endothelin	O
-	O
1	O
at	O
6	O
months	O
(	O
5.9	O
+	O
/	O
-	O
3.3%	O
;	O
p	O
=	O
0.06	O
)	O
(	O
mean	O
+	O
/	O
-	O
SE	O
)	O
and	O
at	O
12	O
months	O
(	O
7.1	O
+	O
/	O
-	O
5.5%	O
;	O
p	O
=	O
0.03	O
)	O
.	O

This	O
fall	O
was	O
solely	O
due	O
to	O
toremifene	I-TRIVIAL
,	O
the	O
use	O
of	O
which	O
was	O
associated	O
with	O
falls	O
in	O
endothelin	O
-	O
1	O
at	O
6	O
months	O
(	O
12.9	O
+	O
/	O
-	O
4.7%	O
;	O
p	O
=	O
0.01	O
)	O
and	O
12	O
months	O
(	O
9.2	O
+	O
/	O
-	O
6.2%	O
;	O
p	O
=	O
0.06	O
)	O
.	O

The	O
antiestrogen	O
regimen	O
failed	O
to	O
affect	O
plasma	O
nitric	I-IUPAC
oxide	I-IUPAC
significantly	O
but	O
nevertheless	O
the	O
ratio	O
between	O
nitric	I-IUPAC
oxide	I-IUPAC
and	O
endothelin	O
-	O
1	O
rose	O
by	O
31.6	O
+	O
/	O
-	O
13.3%	O
at	O
6	O
months	O
and	O
by	O
35.6	O
+	O
/	O
-	O
15.3%	O
at	O
12	O
months	O
in	O
the	O
antiestrogen	O
users	O
,	O
an	O
effect	O
similar	O
in	O
the	O
tamoxifen	I-TRIVIAL
and	O
toremifene	I-TRIVIAL
groups	O
.	O

We	O
conclude	O
that	O
antiestrogens	O
may	O
protect	O
against	O
myocardial	O
infarction	O
by	O
preventing	O
the	O
release	O
of	O
endothelin	O
-	O
1	O
and	O
by	O
shifting	O
the	O
balance	O
between	O
nitric	I-IUPAC
oxide	I-IUPAC
and	O
endothelin	O
-	O
1	O
to	O
the	O
dominance	O
of	O
the	O
former	O
.	O

Our	O
data	O
predict	O
that	O
toremifene	I-TRIVIAL
and	O
tamoxifen	I-TRIVIAL
at	O
the	O
doses	O
studied	O
here	O
will	O
provide	O
similar	O
cardiovascular	O
protection	O
.	O

A	O
series	O
of	O
new	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
and	O
uridine	I-TRIVIAL
compounds	B-MODIFIER
(	O
11	O
,	O
16	O
)	O
was	O
synthesized	O
by	O
the	O
regiospecific	O
addition	O
of	O
HOI	I-SUM
to	O
the	O
vinyl	I-TRIVIAL
substituent	B-MODIFIER
of	O
5	I-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
10a	O
)	O
,	O
5	I-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
10b	O
)	O
,	O
5	I-IUPAC
-	I-IUPAC
vinyluridine	I-IUPAC
(	O
10c	O
)	O
,	O
and	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodovinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
4b	O
)	O
.	O

Treatment	O
of	O
the	O
iodohydrins	I-FAMILY
11a	O
-	O
c	O
with	O
methanolic	I-IUPAC
sulfuric	I-IUPAC
acid	I-IUPAC
afforded	O
the	O
corresponding	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
(	O
12a	O
-	O
c	O
)	O
.	O

In	O
contrast	O
,	O
reaction	O
of	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
11a	O
)	O
with	O
sodium	I-IUPAC
carbonate	I-IUPAC
in	O
methanol	I-TRIVIAL
afforded	O
a	O
mixture	O
of	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxyethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
13	O
)	O
and	O
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
furano	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
(	I-IUPAC
5H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
14	O
)	O
.	O

The	O
most	O
active	O
compound	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
12a	O
,	O
ID50	O
=	O
0.1	O
micrograms	O
/	O
mL	O
)	O
,	O
which	O
exhibited	O
antiviral	O
activity	O
(	O
HSV	O
-	O
1	O
)	O
100	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
analogue	I-MODIFIER
(	O
11a	O
)	O
,	O
was	O
less	O
active	O
than	O
IVDU	I-ABBREVIATION
or	O
acyclovir	I-TRIVIAL
(	O
ID50	O
=	O
0.01-0.1	O
micrograms	O
/	O
mL	O
range	O
)	O
.	O

The	O
C	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
substituent	I-MODIFIER
in	O
the	O
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
series	I-MODIFIER
was	O
a	O
determinant	O
of	O
cytotoxic	O
activity	O
,	O
as	O
determined	O
in	O
the	O
in	O
vitro	O
L1210	O
screen	O
,	O
where	O
the	O
relative	O
activity	O
order	O
was	O
CH	I-SUM
(	I-SUM
OH	I-SUM
)	I-SUM
CHI2	I-SUM
(	O
16	O
)	O
greater	O
than	O
CH	I-SUM
(	I-SUM
OMe	I-SUM
)	I-SUM
CH2I	I-SUM
(	O
12a	O
)	O
greater	O
than	O
CH	I-SUM
(	I-SUM
OH	I-SUM
)	I-SUM
CH2I	I-SUM
(	O
11a	O
)	O
congruent	O
to	O
CH	I-SUM
(	I-SUM
OH	I-SUM
)	I-SUM
CH2OMe	I-SUM
(	O
13	O
)	O
.	O

The	O
2'	I-PARTIUPAC
-	I-PARTIUPAC
substituent	O
was	O
also	O
a	O
determinant	O
of	O
cytotoxic	O
activity	O
in	O
the	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
(	O
11a	O
-	O
c	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
series	I-MODIFIER
of	O
compounds	O
,	O
where	O
the	O
relative	O
activity	O
profile	O
was	O
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
greater	O
than	O
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
greater	O
than	O
uridine	I-TRIVIAL
(	O
11a	O
greater	O
than	O
11b	O
greater	O
than	O
or	O
equal	O
to	O
11c	O
;	O
12a	O
greater	O
than	O
12b	O
greater	O
than	O
12c	O
)	O
.	O

The	O
most	O
active	O
cytotoxic	O
agent	O
(	O
16	O
)	O
,	O
possessing	O
a	O
5	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
-	I-PARTIUPAC
2,2	I-PARTIUPAC
-	I-PARTIUPAC
diiodoethyl	I-PARTIUPAC
)	I-PARTIUPAC
substituent	I-MODIFIER
(	O
ED50	O
=	O
0.77	O
micrograms	O
/	O
mL	O
)	O
,	O
exhibited	O
an	O
activity	O
approaching	O
that	O
of	O
melphalan	I-TRIVIAL
(	O
ED50	O
=	O
0.15	O
micrograms	O
/	O
mL	O
)	O
.	O

All	O
compounds	O
tested	O
,	O
except	O
for	O
13	O
and	O
14	O
,	O
exhibited	O
high	O
affinity	O
(	O
Ki	O
=	O
0.035-0.22	O
mM	O
range	O
relative	O
to	O
deoxyuridine	I-TRIVIAL
,	O
Ki	O
=	O
0.125	O
)	O
for	O
the	O
murine	O
NBMPR	O
-	O
sensitive	O
erythrocyte	O
nucleoside	O
transport	O
system	O
,	O
suggesting	O
that	O
these	O
iodohydrins	I-FAMILY
are	O
good	O
permeants	O
of	O
cell	O
membranes	O
.	O

N	O
-	O
Methylacetazolamide	O
was	O
shown	O
to	O
be	O
active	O
topically	O
in	O
reducing	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
to	O
a	O
small	O
but	O
statistically	O
significant	O
level	O
in	O
the	O
normotensive	O
rabbit	O
eye	O
.	O

In	O
vivo	O
experiments	O
with	O
N	I-IUPAC
-	I-IUPAC
methylacetazolamide	I-IUPAC
suggest	O
that	O
ocular	O
metabolism	O
to	O
acetazolamide	I-TRIVIAL
was	O
responsible	O
for	O
the	O
observed	O
topical	O
activity	O
.	O

Examination	O
of	O
initial	O
rate	O
kinetics	O
of	O
carbonic	O
anhydrase	O
catalyzed	O
p	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
acetate	I-IUPAC
hydrolysis	O
showed	O
that	O
N	I-IUPAC
-	I-IUPAC
methylacetazolamide	I-IUPAC
was	O
a	O
competitive	O
inhibitor	O
,	O
in	O
contrast	O
to	O
noncompetitive	O
inhibition	O
seen	O
with	O
acetazolamide	I-TRIVIAL
and	O
other	O
primary	O
sulfonamide	I-TRIVIAL
inhibitors	O
.	O

N	I-PARTIUPAC
-	I-PARTIUPAC
Substituted	I-PARTIUPAC
and	O
unsubstituted	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
chlorobenzene	I-PARTIUPAC
-	I-PARTIUPAC
and	O
4	I-IUPAC
-	I-IUPAC
nitrobenzenesulfonamides	I-IUPAC
were	O
also	O
synthesized	O
,	O
and	O
their	O
biochemical	O
characteristics	O
and	O
in	O
vivo	O
ability	O
to	O
lower	O
IOP	O
when	O
applied	O
topically	O
were	O
determined	O
.	O

The	O
primary	O
sulfonamides	I-FAMILY
were	O
reversible	O
noncompetitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
with	O
no	O
effect	O
on	O
IOP	O
after	O
topical	O
administration	O
.	O

4	I-PARTIUPAC
-	I-PARTIUPAC
Nitrobenzene	I-PARTIUPAC
-	I-PARTIUPAC
and	O
4	I-IUPAC
-	I-IUPAC
chlorobenzenesulfonamides	I-IUPAC
containing	O
both	O
N	I-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
and	O
N	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
substituents	I-MODIFIER
were	O
model	O
irreversible	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
and	O
exhibited	O
a	O
trend	O
toward	O
topical	O
activity	O
in	O
reducing	O
IOP	O
in	O
normotensive	O
rabbit	O
eyes	O
.	O

Therefore	O
,	O
this	O
paper	O
describes	O
the	O
synthesis	O
and	O
characterization	O
of	O
two	O
types	O
of	O
carbonic	O
anhydrase	O
inhibitors	O
;	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
sulfonamides	I-IUPAC
are	O
reversible	O
competitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
while	O
the	O
N	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
sulfonamides	I-IUPAC
are	O
irreversible	O
inhibitors	O
.	O

Condensation	O
of	O
14	I-IUPAC
-	I-IUPAC
bromodaunorubicin	I-IUPAC
with	O
thiols	I-FAMILY
in	O
methanol	I-TRIVIAL
,	O
in	O
the	O
presence	O
of	O
potassium	I-TRIVIAL
carbonate	I-TRIVIAL
,	O
resulted	O
in	O
the	O
formation	O
of	O
14	I-PARTIUPAC
-	I-PARTIUPAC
thia	I-PARTIUPAC
analogues	I-MODIFIER
of	O
the	O
antitumor	O
antibiotic	O
adriamycin	I-TRIVIAL
.	O

However	O
,	O
similar	O
condensation	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
iododaunorubicin	I-IUPAC
with	O
thiols	O
invariably	O
led	O
to	O
a	O
redox	O
reaction	O
,	O
with	O
the	O
formation	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
daunorubicin	I-IUPAC
and	O
disulfides	I-FAMILY
.	O

Accordingly	O
,	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
bromodaunorubicin	I-IUPAC
was	O
used	O
for	O
reaction	O
with	O
thiols	I-FAMILY
to	O
yield	O
thia	O
analogues	O
of	O
the	O
clinically	O
active	O
but	O
non	O
-	O
DNA	O
-	O
binding	O
adriamycin	I-TRIVIAL
analogue	B-MODIFIER
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
adriamycin	I-IUPAC
14	I-IUPAC
-	I-IUPAC
valerate	I-IUPAC
(	O
AD	O
32	O
)	O
.	O

Reaction	O
of	O
14	I-IUPAC
-	I-IUPAC
bromoadunorubicin	I-IUPAC
with	O
alpha	I-IUPAC
,	I-IUPAC
omega	I-IUPAC
-	I-IUPAC
alkanedithiols	I-IUPAC
gave	O
bis	I-TRIVIAL
(	I-TRIVIAL
thiaadriamycin	I-TRIVIAL
)	I-TRIVIAL
analogues	I-MODIFIER
as	O
potential	O
difunctional	O
intercalating	O
agents	O
.	O

The	O
aforementioned	O
products	O
,	O
plus	O
two	O
related	O
phenylselena	I-TRIVIAL
derivatives	B-MODIFIER
,	O
were	O
examined	O
for	O
in	O
vitro	O
growth	O
inhibition	O
,	O
in	O
vivo	O
antitumor	O
activity	O
,	O
and	O
,	O
where	O
appropriate	O
,	O
DNA	O
binding	O
.	O

A	O
number	O
of	O
agents	O
,	O
most	O
notably	O
14	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carbethoxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
thiaadriamycin	I-IUPAC
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
selenaadriamycin	I-IUPAC
,	O
were	O
active	O
against	O
murine	O
L1210	O
leukemia	O
in	O
vivo	O
.	O

Several	O
of	O
the	O
amino	I-IUPAC
glycoside	I-IUPAC
unsubstituted	I-IUPAC
14	I-IUPAC
-	I-IUPAC
thiaadriamycin	I-IUPAC
analogues	I-MODIFIER
exhibited	O
DNA	O
-	O
binding	O
properties	O
equivalent	O
to	O
those	O
of	O
adriamycin	I-TRIVIAL
.	O

Enalapril	I-TRIVIAL
in	O
subantihypertensive	O
dosage	O
attenuates	O
kidney	O
proliferation	O
and	O
functional	O
recovery	O
in	O
normotensive	O
ablation	O
nephropathy	O
of	O
the	O
rat	O
.	O

Most	O
studies	O
on	O
the	O
antiproliferative	O
action	O
of	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
(	O
ACEI	O
)	O
were	O
performed	O
in	O
a	O
rat	O
hypertensive	O
remnant	O
kidney	O
model	O
with	O
5/6	O
kidney	O
ablation	O
which	O
raised	O
objections	O
about	O
the	O
antihypertensive	O
effect	O
of	O
ACEI	O
and	O
the	O
influence	O
of	O
other	O
antihypertensive	O
drugs	O
administered	O
to	O
remnant	O
kidney	O
control	O
rats	O
.	O

To	O
prevent	O
these	O
objections	O
,	O
a	O
normotensive	O
4/6	O
remnant	O
kidney	O
model	O
was	O
elaborated	O
and	O
a	O
subantihypertensive	O
dosage	O
of	O
enalapril	I-TRIVIAL
was	O
used	O
to	O
evaluate	O
its	O
antiproliferative	O
action	O
.	O

Subtotally	O
nephrectomized	O
rats	O
(	O
Nx	O
)	O
markedly	O
increased	O
the	O
remnant	O
kidney	O
weight	O
during	O
a	O
4	O
-	O
week	O
period	O
and	O
this	O
rise	O
was	O
prevented	O
by	O
the	O
treatment	O
with	O
enalapril	I-TRIVIAL
(	O
NxE	O
)	O
(	O
Nx	O
+	O
297	O
+	O
/	O
-	O
35	O
mg	O
vs.	O
sham	O
-	O
operated	O
+	O
145	O
+	O
/	O
-	O
32	O
mg	O
,	O
p	O
<	O
0.001	O
;	O
NxE	O
+	O
154	O
+	O
/	O
-	O
35	O
mg	O
vs.	O
Nx	O
p	O
<	O
0.001	O
)	O
.	O

While	O
collagen	O
concentration	O
in	O
the	O
kidney	O
cortex	O
was	O
not	O
increased	O
in	O
sham	O
-	O
operated	O
rats	O
(	O
Sham	O
)	O
in	O
comparison	O
with	O
the	O
control	O
group	O
(	O
Ctrl	O
)	O
at	O
the	O
beginning	O
of	O
the	O
study	O
,	O
the	O
subsequent	O
increase	O
was	O
significant	O
in	O
the	O
Nx	O
group	O
and	O
enalapril	I-TRIVIAL
did	O
not	O
attenuate	O
this	O
increase	O
(	O
Sham	O
148	O
+	O
/	O
-	O
5	O
mg	O
/	O
100	O
g	O
w	O
.	O

w	O
.	O

vs.	O
Nx	O
164	O
+	O
/	O
-	O
2	O
mg	O
/	O
100	O
g	O
w	O
.	O

w	O
.	O

,	O
p	O
<	O
0.01	O
;	O
NxE	O
161	O
+	O
/	O
-	O
4	O
mg	O
/	O
100	O
g	O
w	O
.	O

w	O
.	O

vs.	O
Sham	O
p	O
<	O
0.05	O
)	O
.	O

The	O
tubular	O
protein	O
/	O
DNA	O
ratio	O
increase	O
,	O
which	O
was	O
significant	O
in	O
the	O
Nx	O
group	O
,	O
was	O
inhibited	O
by	O
enalapril	I-TRIVIAL
(	O
Nx	O
26.2	O
+	O
/	O
-	O
10.5	O
vs.	O
NxE	O
15.3	O
+	O
/	O
-	O
2.6	O
,	O
p	O
<	O
0.05	O
)	O
.	O

The	O
protein	O
/	O
DNA	O
ratio	O
was	O
much	O
lower	O
in	O
glomeruli	O
,	O
with	O
no	O
significant	O
changes	O
in	O
either	O
the	O
Nx	O
or	O
NxE	O
groups	O
.	O

Serum	O
urea	I-TRIVIAL
concentrations	O
were	O
slightly	O
higher	O
in	O
the	O
Nx	O
group	O
than	O
in	O
the	O
sham	O
-	O
operated	O
group	O
,	O
but	O
markedly	O
elevated	O
in	O
the	O
NxE	O
group	O
(	O
Nx	O
10.71	O
+	O
/	O
-	O
0.76	O
mmol	O
/	O
l	O
vs.	O
Sham	O
6.10	O
+	O
/	O
-	O
0.33	O
mmol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
;	O
NxE	O
28.9	O
+	O
/	O
-	O
2.6	O
mmol	O
/	O
l	O
vs.	O
Sham	O
p	O
<	O
0.001	O
)	O
.	O

Creatinine	I-TRIVIAL
concentrations	O
in	O
the	O
Nx	O
group	O
were	O
increased	O
in	O
comparison	O
with	O
the	O
sham	O
-	O
operated	O
group	O
and	O
markedly	O
increased	O
in	O
the	O
NxE	O
group	O
(	O
Nx	O
63.7	O
+	O
/	O
-	O
3.56	O
micromol	O
/	O
l	O
vs.	O
Sham	O
37.2	O
+	O
/	O
-	O
2.84	O
micromol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
;	O
NxE	O
107.0	O
+	O
/	O
-	O
5.2	O
micromol	O
/	O
l	O
vs.	O
Sham	O
p	O
<	O
0.001	O
)	O
.	O

The	O
clearance	O
of	O
creatinine	I-TRIVIAL
was	O
lower	O
in	O
the	O
Nx	O
group	O
than	O
in	O
the	O
sham	O
-	O
operated	O
group	O
and	O
was	O
markedly	O
reduced	O
in	O
the	O
NxE	O
group	O
(	O
Nx	O
0.89	O
+	O
/	O
-	O
0.06	O
ml	O
/	O
min	O
.	O

g	O
kidney	O
wt	O
.	O

vs.	O
Sham	O
1.05	O
+	O
/	O
-	O
0.16	O
ml	O
/	O
min	O
x	O
g	O
kidney	O
wt	O
.	O

,	O
p	O
<	O
0.01	O
;	O
NxE	O
0.58	O
+	O
/	O
-	O
0.029	O
ml	O
/	O
min	O
x	O
g	O
kidney	O
wt	O
.	O

vs.	O
Sham	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Enalapril	I-TRIVIAL
improved	O
proteinuria	O
in	O
comparison	O
with	O
the	O
Nx	O
group	O
(	O
NxE	O
5.6	O
+	O
/	O
-	O
0.6	O
mg	O
/	O
24	O
h	O
vs.	O
Nx	O
16.1	O
+	O
/	O
-	O
3.4	O
mg	O
/	O
24	O
h	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Thus	O
remnant	O
kidney	O
proliferation	O
is	O
substantial	O
even	O
in	O
normotensive	O
rats	O
.	O

It	O
includes	O
both	O
proliferation	O
and	O
collagen	O
accumulation	O
with	O
partial	O
recovery	O
of	O
kidney	O
weight	O
and	O
function	O
,	O
but	O
is	O
accompanied	O
by	O
enhanced	O
proteinuria	O
.	O

Enalapril	I-TRIVIAL
attenuates	O
the	O
proliferation	O
and	O
decreases	O
proteinuria	O
but	O
prolongs	O
kidney	O
function	O
recovery	O
.	O

Replacing	O
dietary	O
palmitic	I-IUPAC
acid	I-IUPAC
with	O
elaidic	I-IUPAC
acid	I-IUPAC
(	O
t	O
-	O
C18	O
:	O
1	O
delta9	O
)	O
depresses	O
HDL	O
and	O
increases	O
CETP	O
activity	O
in	O
cebus	O
monkeys	O
.	O

The	O
question	O
whether	O
dietary	O
trans	O
fatty	O
acids	O
affect	O
lipoprotein	O
metabolism	O
similarly	O
to	O
specific	O
saturated	I-FAMILY
fatty	I-FAMILY
acids	I-FAMILY
was	O
investigated	O
in	O
11	O
normolipemic	O
cebus	O
monkeys	O
by	O
exchanging	O
5%	O
dietary	O
energy	O
(	O
%	O
en	O
)	O
between	O
elaidic	I-PARTIUPAC
(	O
t	O
-	O
C18	O
:	O
1	O
delta9	O
)	O
and	O
palmitic	I-IUPAC
acid	I-IUPAC
(	O
16	O
:	O
0	O
)	O
in	O
two	O
test	O
diets	O
(	O
30%	O
en	O
fat	O
+	O
100	O
mg	O
cholesterol	I-TRIVIAL
/	O
1000	O
kcal	O
diet	O
)	O
conforming	O
to	O
the	O
American	O
Heart	O
Association	O
(	O
AHA	O
)	O
Step	O
1	O
guidelines	O
.	O

These	O
were	O
compared	O
with	O
a	O
normal	O
control	O
diet	O
rich	O
in	O
saturated	O
fat	O
and	O
cholesterol	I-TRIVIAL
(	O
38%	O
en	O
fat	O
+	O
180	O
mg	O
cholesterol	I-TRIVIAL
/	O
1000	O
kcal	O
diet	O
)	O
.	O

The	O
control	O
diet	O
was	O
fed	O
initially	O
for	O
14	O
wk	O
,	O
followed	O
by	O
each	O
of	O
the	O
the	O
two	O
test	O
diets	O
in	O
a	O
crossover	O
design	O
.	O

Plasma	O
lipid	I-FAMILY
concentrations	O
were	O
determined	O
four	O
times	O
between	O
the	O
6th	O
and	O
14th	O
wk	O
.	O

Turnover	O
studies	O
(	O
using	O
125I	O
-	O
HDL	O
and	O
131I	O
-	O
LDL	O
)	O
were	O
conducted	O
after	O
9	O
wk	O
in	O
each	O
dietary	O
period	O
.	O

Relative	O
to	O
the	O
control	O
diet	O
,	O
both	O
test	O
diets	O
significantly	O
reduced	O
plasma	O
total	O
cholesterol	I-TRIVIAL
(	O
TC	O
)	O
,	O
HDL	O
cholesterol	I-TRIVIAL
(	O
HDL	O
-	O
C	O
)	O
and	O
VLDL	O
plus	O
LDL	O
cholesterol	I-TRIVIAL
(	O
LDL	O
-	O
C	O
)	O
concentrations	O
;	O
triglyceride	I-FAMILY
(	O
TG	I-ABBREVIATION
)	O
concentrations	O
tended	O
to	O
be	O
lower	O
.	O

However	O
,	O
the	O
trans	O
diet	O
resulted	O
in	O
a	O
significantly	O
greater	O
reduction	O
in	O
HDL	O
-	O
C	O
than	O
the	O
palmitate	O
diet	O
(	O
124	O
+	O
/	O
-	O
17	O
,	O
117	O
+	O
/	O
-	O
18	O
and	O
106	O
+	O
/	O
-	O
13	O
mg	O
/	O
dL	O
for	O
the	O
control	O
,	O
palmitate	O
and	O
trans	O
diets	O
,	O
respectively	O
)	O
.	O

The	O
palmitate	I-TRIVIAL
diet	O
significantly	O
decreased	O
the	O
TC	O
/	O
HDL	O
-	O
C	O
ratio	O
by	O
11%	O
when	O
compared	O
with	O
the	O
control	O
diet	O
(	O
1.68	O
+	O
/	O
-	O
0.17	O
vs.	O
1.89	O
+	O
/	O
-	O
0.30	O
)	O
,	O
whereas	O
the	O
trans	O
diet	O
had	O
no	O
effect	O
(	O
1.81	O
+	O
/	O
-	O
0.20	O
vs.	O
1.89	O
+	O
/	O
-	O
0.30	O
)	O
.	O

Kinetic	O
studies	O
revealed	O
that	O
,	O
relative	O
to	O
the	O
control	O
diet	O
,	O
both	O
test	O
diets	O
significantly	O
lowered	O
the	O
LDL	O
apolipoprotein	O
B	O
(	O
apoB	O
)	O
pool	O
size	O
,	O
principally	O
reflecting	O
an	O
increase	O
in	O
the	O
LDL	O
apoB	O
fractional	O
catabolic	O
rate	O
(	O
FCR	O
)	O
related	O
to	O
the	O
reduced	O
cholesterol	O
intake	O
.	O

Between	O
the	O
two	O
test	O
diets	O
,	O
no	O
significant	O
differences	O
in	O
LDL	O
kinetic	O
parameters	O
were	O
observed	O
.	O

Both	O
test	O
diets	O
significantly	O
decreased	O
HDL	O
apoA1	O
concentrations	O
in	O
comparison	O
with	O
the	O
control	O
diet	O
,	O
which	O
was	O
partly	O
explained	O
by	O
an	O
increase	O
in	O
the	O
fractional	O
catabolic	O
rate	O
of	O
HDL	O
.	O

Of	O
the	O
two	O
test	O
diets	O
,	O
the	O
trans	O
diet	O
was	O
associated	O
with	O
a	O
9.5%	O
greater	O
HDL	O
FCR	O
than	O
the	O
palmitate	I-TRIVIAL
diet	O
(	O
P	O
<	O
0.08	O
)	O
and	O
a	O
significant	O
increase	O
in	O
plasma	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
activity	O
(	O
%	O
transfer	O
114	O
+	O
/	O
-	O
7	O
vs.	O
91	O
+	O
/	O
-	O
7	O
;	O
P	O
<	O
0.03	O
)	O
.	O

Thus	O
,	O
palmitic	I-IUPAC
acid	I-IUPAC
-	O
and	O
elaidic	I-IUPAC
acid	I-IUPAC
-	O
rich	O
diets	O
produced	O
identical	O
effects	O
on	O
LDL	O
metabolism	O
in	O
normocholesterolemic	O
cebus	O
monkeys	O
fed	O
diets	O
with	O
low	O
levels	O
of	O
cholesterol	I-TRIVIAL
,	O
whereas	O
elaidic	I-IUPAC
acid	I-IUPAC
depressed	O
HDL	O
-	O
C	O
,	O
attributable	O
to	O
both	O
increased	O
CETP	O
activity	O
and	O
HDL	O
clearance	O
.	O

Radiolabeled	O
m	I-IUPAC
-	I-IUPAC
iodobenzylguanidine	I-IUPAC
(	O
MIBG	I-ABBREVIATION
)	O
is	O
a	O
tumor	O
-	O
seeking	O
radioactive	O
drug	O
used	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
pheochromocytomas	O
and	O
neuroblastomas	O
.	O

It	O
is	O
transported	O
into	O
the	O
tumor	O
cells	O
by	O
the	O
neuronal	O
norepinephrine	I-TRIVIAL
(	O
NE	I-ABBREVIATION
)	O
transporter	O
(	O
NET	O
)	O
which	O
is	O
expressed	O
in	O
almost	O
all	O
neuroblastoma	O
cells	O
.	O

Here	O
,	O
we	O
describe	O
the	O
synthesis	O
and	O
some	O
pharmacological	O
properties	O
of	O
a	O
series	O
of	O
fluorescent	O
compounds	O
structurally	O
related	O
to	O
the	O
NET	O
substrate	O
,	O
MIBG	I-ABBREVIATION
,	O
or	O
to	O
the	O
NET	O
inhibitors	O
,	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2R	I-IUPAC
,	I-IUPAC
3S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cocaine	I-IUPAC
and	O
nisoxetine	I-TRIVIAL
.	O

Three	O
of	O
10	O
synthesized	O
fluorescent	O
compounds	O
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthylmethyl	I-IUPAC
)	I-IUPAC
guanidinium	I-IUPAC
sulfate	I-IUPAC
(	O
1	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dibenz	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
f	I-IUPAC
]	I-IUPAC
azepin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
guanidinium	I-IUPAC
sulfate	I-IUPAC
(	O
2	O
)	O
,	O
and	O
(	I-IUPAC
2R	I-IUPAC
,	I-IUPAC
3S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2beta	I-IUPAC
-	I-IUPAC
ethoxycarbonyl	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
tropanyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
naphthalene	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
sulfonate	I-IUPAC
(	O
6	O
)	O
,	O
exhibited	O
high	O
affinity	O
(	O
IC	O
(	O
50	O
)	O
about	O
50	O
nM	O
)	O
for	O
the	O
NET	O
.	O

The	O
nisoxetine	I-TRIVIAL
derivatives	B-MODIFIER
8	O
(	O
rac	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthale	I-IUPAC
nesulfonamide	I-IUPAC
)	O
and	O
9	O
(	O
rac	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2,1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzoxadiazole	I-IUPAC
)	O
and	O
especially	O
the	O
guanidine	I-TRIVIAL
derivative	B-MODIFIER
4	O
(	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
butadienyl	I-IUPAC
)	I-IUPAC
benzyl	I-IUPAC
]	I-IUPAC
guanidinium	I-IUPAC
sulfate	I-IUPAC
)	O
which	O
are	O
characterized	O
by	O
intermediate	O
affinity	O
for	O
the	O
NET	O
(	O
IC	O
(	O
50	O
)	O
370-850	O
nM	O
)	O
caused	O
significant	O
and	O
nisoxetine	I-TRIVIAL
-	O
sensitive	O
cell	O
fluorescence	O
.	O

At	O
least	O
the	O
guanidine	I-TRIVIAL
derivative	B-MODIFIER
4	O
might	O
represent	O
a	O
potentially	O
useful	O
agent	O
for	O
imaging	O
of	O
neuroblastoma	O
cells	O
.	O

Influence	O
of	O
estrogens	I-FAMILY
on	O
the	O
androgen	I-FAMILY
metabolism	O
in	O
different	O
subunits	O
of	O
human	O
hair	O
follicles	O
.	O

The	O
molecular	O
pathways	O
involved	O
in	O
estrogen	I-FAMILY
-	O
mediated	O
induction	O
of	O
hair	O
growth	O
in	O
androgenetic	O
alopecia	O
are	O
unknown	O
.	O

Some	O
authors	O
found	O
that	O
estradiol	I-TRIVIAL
(	O
E	I-ABBREVIATION
)	O
inhibited	O
5alpha	O
-	O
reductase	O
(	O
5alpha	O
-	O
R	O
)	O
activity	O
and	O
therefore	O
we	O
addressed	O
the	O
question	O
whether	O
17alpha	I-PARTIUPAC
-	I-PARTIUPAC
or	O
17beta	I-IUPAC
-	I-IUPAC
E	I-IUPAC
are	O
able	O
to	O
modulate	O
the	O
activity	O
of	O
5alpha	O
-	O
R	O
,	O
3beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
(	O
3beta	O
-	O
HSD	O
)	O
or	O
17beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
(	O
17beta	O
-	O
HSD	O
)	O
in	O
isolated	O
compartments	O
of	O
human	O
hair	O
follicles	O
.	O

For	O
this	O
purpose	O
,	O
scalp	O
biopsies	O
from	O
volunteers	O
were	O
taken	O
and	O
from	O
each	O
biopsy	O
root	O
sheaths	O
,	O
connective	O
tissue	O
sheaths	O
and	O
dermal	O
papillae	O
(	O
DP	O
)	O
were	O
dissected	O
and	O
incubated	O
in	O
the	O
presence	O
of	O
3H	I-IUPAC
-	I-IUPAC
testosterone	I-IUPAC
(	O
T	I-ABBREVIATION
)	O
and	O
,	O
in	O
addition	O
,	O
either	O
17alpha	I-IUPAC
-	I-IUPAC
E	I-IUPAC
,	O
17beta	I-IUPAC
-	I-IUPAC
E	I-IUPAC
,	O
progesterone	I-TRIVIAL
or	O
finasteride	I-TRIVIAL
for	O
up	O
to	O
48	O
hrs	O
.	O

Thereafter	O
high	O
-	O
performance	O
liquid	O
chromatography	O
analysis	O
of	O
culture	O
supernatants	O
was	O
performed	O
to	O
detect	O
T	O
-	O
metabolites	O
.	O

At	O
the	O
tested	O
concentrations	O
,	O
finasteride	I-TRIVIAL
was	O
found	O
to	O
be	O
a	O
major	O
inhibitor	O
of	O
dihydrotestosterone	I-TRIVIAL
(	O
DHT	I-ABBREVIATION
)	O
formation	O
.	O

Even	O
1	O
nM	O
finasteride	I-TRIVIAL
inhibited	O
DHT	I-ABBREVIATION
synthesis	O
in	O
DP	O
by	O
86%	O
and	O
1	O
nM	O
progesterone	O
by	O
75%	O
.	O

Estrogens	I-FAMILY
were	O
less	O
able	O
to	O
inhibit	O
the	O
synthesis	O
of	O
DHT	I-ABBREVIATION
in	O
DP	O
(	O
e.g.	O
100	O
nM	O
17alpha	I-IUPAC
-	I-IUPAC
E	I-IUPAC
:	O
20%	O
;	O
100	O
nM	O
17beta	I-IUPAC
-	I-IUPAC
E	I-IUPAC
:	O
60%	O
)	O
.	O

Whether	O
E	I-ABBREVIATION
directly	O
inhibits	O
5alpha	O
-	O
R	O
in	O
DP	O
's	O
or	O
whether	O
the	O
effect	O
of	O
estrogens	I-FAMILY
might	O
be	O
explained	O
by	O
an	O
increased	O
conversion	O
of	O
T	I-ABBREVIATION
to	O
the	O
weaker	O
androgens	I-FAMILY
such	O
as	O
androstendione	I-TRIVIAL
(	O
via	O
17beta	O
-	O
HSD	O
)	O
,	O
androstenediol	I-TRIVIAL
(	O
via	O
3beta	O
-	O
HSD	O
)	O
or	O
17beta	I-IUPAC
-	I-IUPAC
E	I-IUPAC
(	O
via	O
aromatase	O
)	O
,	O
thereby	O
diminishing	O
the	O
amount	O
of	O
T	I-ABBREVIATION
available	O
for	O
the	O
conversion	O
to	O
DHT	I-ABBREVIATION
,	O
remains	O
to	O
be	O
shown	O
.	O

Involvement	O
of	O
phospholipase	O
D2	O
in	O
lysophosphatidate	I-TRIVIAL
-	O
induced	O
transactivation	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
-	O
beta	O
in	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

Lysophosphatidate	I-TRIVIAL
(	O
LPA	I-ABBREVIATION
)	O
mediates	O
multiple	O
cellular	O
responses	O
via	O
heterotrimeric	O
G	O
protein	O
coupled	O
LPA	O
-	O
1	O
,	O
LPA	O
-	O
2	O
,	O
and	O
LPA	O
-	O
3	O
receptors	O
.	O

Many	O
G	O
protein	O
-	O
coupled	O
receptors	O
stimulate	O
ERK	O
following	O
tyrosine	I-TRIVIAL
phosphorylation	O
of	O
growth	O
factor	O
receptors	O
;	O
however	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
transactivation	O
of	O
receptor	O
tyrosine	O
kinases	O
are	O
not	O
well	O
defined	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
involvement	O
of	O
phospholipase	O
D	O
(	O
PLD	O
)	O
in	O
LPA	I-ABBREVIATION
-	O
mediated	O
transactivation	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
-	O
beta	O
(	O
PDGF	O
-	O
R	O
beta	O
)	O
.	O

In	O
primary	O
cultures	O
of	O
human	O
bronchial	O
epithelial	O
cells	O
(	O
HBEpCs	O
)	O
,	O
LPA	I-ABBREVIATION
stimulated	O
tyrosine	I-TRIVIAL
phosphorylation	O
of	O
PDGF	O
-	O
R	O
beta	O
and	O
threonine	I-TRIVIAL
/	O
tyrosine	I-TRIVIAL
phosphorylation	O
of	O
ERK1/2	O
.	O

The	O
LPA	I-ABBREVIATION
-	O
mediated	O
activation	O
of	O
ERK	O
and	O
tyrosine	I-TRIVIAL
phosphorylation	O
of	O
PDGF	O
-	O
R	O
beta	O
was	O
attenuated	O
by	O
tyrphostin	I-TRIVIAL
AG	B-TRIVIALVAR
1296	I-TRIVIALVAR
,	O
an	O
inhibitor	O
of	O
PDGF	O
-	O
R	O
kinase	O
,	O
suggesting	O
transactivation	O
of	O
PDGF	O
-	O
R	O
by	O
LPA	I-ABBREVIATION
.	O

Furthermore	O
,	O
LPA	I-ABBREVIATION
-	O
,	O
but	O
not	O
PDGF	O
beta	O
-	O
chain	O
homodimer	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
PDGF	O
-	O
R	O
beta	O
was	O
partially	O
blocked	O
by	O
pertussis	O
toxin	O
,	O
indicating	O
coupling	O
of	O
LPA	I-ABBREVIATION
-	O
R	O
(	O
s	O
)	O
to	O
Gi	O
.	O

Exposure	O
of	O
HBEpCs	O
to	O
LPA	O
activated	O
PLD	O
.	O

Butan	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
,	O
which	O
acts	O
as	O
an	O
acceptor	O
of	O
phosphatidate	I-TRIVIAL
generated	O
by	O
the	O
PLD	O
pathway	O
,	O
blocked	O
LPA	I-ABBREVIATION
-	O
mediated	O
transactivation	O
of	O
PDGF	O
-	O
R	O
beta	O
.	O

This	O
effect	O
was	O
not	O
seen	O
with	O
butan	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
,	O
suggesting	O
PLD	O
involvement	O
.	O

The	O
role	O
of	O
PLD1	O
and	O
PLD2	O
in	O
the	O
PDGF	O
-	O
R	O
beta	O
transactivation	O
by	O
LPA	I-ABBREVIATION
was	O
investigated	O
by	O
infection	O
of	O
cells	O
with	O
adenoviral	O
constructs	O
of	O
wild	O
type	O
and	O
catalytically	O
inactive	O
mutants	O
of	O
PLD	O
.	O

LPA	I-ABBREVIATION
activated	O
both	O
PLD1	O
and	O
PLD2	O
in	O
HBEpCs	O
;	O
however	O
,	O
infection	O
of	O
cells	O
with	O
cDNA	O
for	O
wild	O
type	O
PLD2	O
,	O
but	O
not	O
PLD1	O
,	O
increased	O
the	O
tyrosine	O
phosphorylation	O
of	O
PDGF	O
-	O
R	O
beta	O
in	O
response	O
to	O
LPA	I-ABBREVIATION
.	O

Also	O
,	O
the	O
LPA	I-ABBREVIATION
-	O
mediated	O
tyrosine	I-TRIVIAL
phosphorylation	O
of	O
PDGF	O
-	O
R	O
beta	O
was	O
attenuated	O
by	O
the	O
catalytically	O
inactive	O
mutant	O
mPLD2	O
-	O
K758R	O
.	O

Infection	O
of	O
HBEpCs	O
with	O
adenoviral	O
constructs	O
of	O
wild	O
type	O
hPLD1	O
,	O
mPLD2	O
,	O
and	O
the	O
inactive	O
mutants	O
of	O
hPLD1	O
and	O
mPLD2	O
resulted	O
in	O
association	O
of	O
PLD2	O
wild	O
type	O
and	O
inactive	O
mutant	O
proteins	O
with	O
the	O
PDGF	O
-	O
R	O
beta	O
compared	O
with	O
PLD1	O
.	O

These	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
transactivation	O
of	O
PDGF	O
-	O
R	O
beta	O
by	O
LPA	I-ABBREVIATION
in	O
HBEpCs	O
is	O
regulated	O
by	O
PLD2	O
.	O

Thyrotropin	O
modulates	O
low	O
density	O
lipoprotein	O
binding	O
activity	O
in	O
FRTL	O
-	O
5	O
thyroid	O
cells	O
.	O

FRTL	O
-	O
5	O
cells	O
possess	O
high	O
affinity	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
receptors	O
which	O
bind	O
,	O
internalize	O
,	O
and	O
degrade	O
LDL	O
.	O

When	O
FRTL	O
-	O
5	O
cells	O
are	O
deprived	O
of	O
thyrotropin	O
(	O
TSH	O
)	O
the	O
binding	O
of	O
LDL	O
increases	O
more	O
than	O
2	O
-	O
fold	O
.	O

Upon	O
addition	O
of	O
TSH	O
,	O
at	O
a	O
concentration	O
of	O
1	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
or	O
greater	O
,	O
LDL	O
binding	O
decreases	O
rapidly	O
and	O
within	O
24	O
h	O
reaches	O
the	O
level	O
which	O
is	O
typical	O
of	O
FRTL	O
-	O
5	O
cells	O
chronically	O
stimulated	O
by	O
TSH	O
.	O

The	O
data	O
available	O
suggest	O
that	O
TSH	O
-	O
dependent	O
down	O
-	O
regulation	O
of	O
LDL	O
receptor	O
activity	O
is	O
exerted	O
through	O
a	O
reduction	O
of	O
the	O
number	O
of	O
active	O
LDL	O
receptors	O
,	O
with	O
no	O
change	O
in	O
affinity	O
.	O

It	O
is	O
unlikely	O
that	O
the	O
synthesis	O
of	O
LDL	O
receptors	O
is	O
impaired	O
,	O
since	O
LDL	O
receptor	O
messenger	O
RNA	O
is	O
not	O
decreased	O
by	O
TSH	O
.	O

The	O
effect	O
of	O
the	O
hormone	O
on	O
LDL	O
receptor	O
activity	O
can	O
be	O
mimicked	O
by	O
8	I-IUPAC
-	I-IUPAC
Br	I-IUPAC
-	I-IUPAC
cAMP	I-IUPAC
and	O
is	O
completely	O
abolished	O
by	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	I-TRIVIAL
but	O
not	O
by	O
actinomycin	I-TRIVIAL
D	I-TRIVIAL
.	O

TSH	O
regulation	O
of	O
LDL	O
receptor	O
activity	O
is	O
lost	O
in	O
v	O
-	O
ras	O
Ki	O
-	O
transformed	O
FRTL	O
-	O
5	O
cells	O
(	O
Ki	O
Mol	O
)	O
which	O
also	O
have	O
lost	O
TSH	O
dependence	O
for	O
adenylate	O
cyclase	O
activation	O
and	O
growth	O
.	O

However	O
,	O
8	I-IUPAC
-	I-IUPAC
Br	I-IUPAC
-	I-IUPAC
cAMP	I-IUPAC
decreases	O
LDL	O
binding	O
in	O
Ki	O
Mol	O
FRTL	O
-	O
5	O
cells	O
.	O

The	O
reduced	O
availability	O
of	O
LDL	O
receptor	O
in	O
TSH	O
-	O
stimulated	O
FRTL	O
-	O
5	O
cells	O
may	O
be	O
related	O
to	O
the	O
increased	O
membrane	O
fluidity	O
(	O
Beguinot	O
,	O
F	O
.	O

,	O
Beguinot	O
,	O
L	O
.	O

,	O
Tramontano	O
,	O
D	O
.	O

,	O
Duilio	O
,	O
C	O
.	O

,	O
Formisano	O
,	O
S	O
.	O

,	O
Bifulco	O
,	O
M	O
.	O

,	O
Ambesi	O
-	O
Impiombato	O
,	O
F	O
.	O

S	O
.	O

,	O
and	O
Aloj	O
,	O
S	O
.	O

M	O
.	O

(	O
1987	O
)	O
J	O
.	O

Biol.	O
Chem.	O
262	O
,	O
1575-1582	O
)	O
or	O
may	O
reflect	O
increased	O
degradation	O
of	O
LDL	O
receptors	O
.	O

We	O
propose	O
that	O
a	O
lower	O
cholesterol	O
uptake	O
is	O
needed	O
in	O
an	O
actively	O
proliferating	O
cell	O
population	O
,	O
to	O
increase	O
the	O
production	O
of	O
isoprenoids	I-FAMILY
whether	O
it	O
be	O
for	O
cholesterol	I-TRIVIAL
biosynthesis	O
or	O
for	O
the	O
synthesis	O
of	O
other	O
compounds	O
requiring	O
isoprenoid	O
precursors	O
.	O

In	O
order	O
to	O
develop	O
tracers	O
with	O
higher	O
specific	O
activity	O
to	O
supplant	O
the	O
currently	O
used	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
OH	I-IUPAC
-	I-IUPAC
DPAT	I-IUPAC
[	O
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylamino	I-IUPAC
)	I-IUPAC
tetralin	I-IUPAC
]	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
of	O
5	O
-	O
HT1A	O
receptors	O
,	O
a	O
new	O
radioiodinated	O
ligand	O
was	O
prepared	O
.	O

(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
Hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
tetralin	I-IUPAC
(	O
trans	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
OH	I-IUPAC
-	I-IUPAC
PIPAT	I-IUPAC
)	O
,	O
8	O
,	O
was	O
synthesized	O
by	O
a	O
10	O
-	O
step	O
reaction	O
.	O

Binding	O
studies	O
with	O
rat	O
hippocampal	O
membrane	O
homogenates	O
showed	O
that	O
8	O
exhibited	O
a	O
Ki	O
value	O
of	O
0.92	O
nM	O
against	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
OH	I-IUPAC
-	I-IUPAC
DPAT	I-IUPAC
.	O

Radiolabeled	O
[	I-PARTIUPAC
125I	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
8	O
was	O
prepared	O
from	O
the	O
corresponding	O
tri	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butyltin	I-IUPAC
precursor	O
via	O
an	O
oxidative	O
iododestannylation	O
reaction	O
with	O
sodium	O
[	I-IUPAC
125I	I-IUPAC
]	I-IUPAC
iodide	I-IUPAC
.	O

Binding	O
studies	O
in	O
the	O
hippocampal	O
homogenates	O
revealed	O
that	O
[	I-PARTIUPAC
125I	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
8	O
bound	O
to	O
a	O
single	O
high	O
-	O
affinity	O
site	O
(	O
Kd	O
=	O
0.38	O
+	O
/	O
-	O
0.03	O
nM	O
,	O
Bmax	O
=	O
310	O
+	O
/	O
-	O
20	O
fmol	O
/	O
mg	O
of	O
protein	O
)	O
.	O

Competition	O
binding	O
experiments	O
clearly	O
indicated	O
that	O
the	O
new	O
ligand	O
displayed	O
the	O
expected	O
5	O
-	O
HT1A	O
receptor	O
binding	O
profile	O
.	O

The	O
rank	O
order	O
of	O
potency	O
was	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
OH	I-IUPAC
-	I-IUPAC
PIPAT	I-IUPAC
&	O
gt	O
;	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
OH	I-IUPAC
-	I-IUPAC
DPAT	I-IUPAC
&	O
gt	O
;	O
WB4101	I-TRIVIAL
&	O
gt	O
;	O
5	O
-	O
HT	O
&	O
gt	O
;	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
OH	I-IUPAC
-	I-IUPAC
PIPAT	I-IUPAC
&	O
gt	O
;	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
OH	I-IUPAC
-	I-IUPAC
DPAT	I-IUPAC
&	O
gt	O
;	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
propranolol	I-IUPAC
&	O
gt	O
;	O
spiperone	I-TRIVIAL
&	O
gt	O
;	O
&	O
gt	O
;	O
ketanserin	I-TRIVIAL
&	O
gt	O
;	O
&	O
gt	O
;	O
dopamine	I-TRIVIAL
&	O
gt	O
;	O
atropine	I-TRIVIAL
.	O

This	O
new	O
ligand	O
offers	O
several	O
unique	O
advantages	O
,	O
including	O
high	O
specific	O
activity	O
,	O
high	O
binding	O
affinity	O
,	O
and	O
low	O
nonspecific	O
binding	O
,	O
all	O
of	O
which	O
make	O
it	O
an	O
excellent	O
probe	O
for	O
the	O
investigation	O
and	O
characterization	O
of	O
5	O
-	O
HT1A	O
receptors	O
.	O

The	O
synthesis	O
and	O
pharmacological	O
profile	O
of	O
a	O
series	O
of	O
neuroprotective	O
adenosine	O
agonists	O
are	O
described	O
.	O

Novel	O
A	O
(	O
1	O
)	O
agonists	O
with	O
potent	O
central	O
nervous	O
system	O
effects	O
and	O
diminished	O
influence	O
on	O
the	O
cardiovascular	O
system	O
are	O
reported	O
and	O
compared	O
to	O
selected	O
reference	O
adenosine	O
agonists	O
.	O

The	O
novel	O
compounds	O
featured	O
are	O
derived	O
structurally	O
from	O
two	O
key	O
lead	O
structures	O
:	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
(	O
NNC	I-TRIVIALVAR
21-0041	I-TRIVIALVAR
,	O
9	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
(	O
NNC	I-TRIVIALVAR
90-1515	I-TRIVIALVAR
,	O
4	O
)	O
.	O

The	O
agonists	O
are	O
characterized	O
in	O
terms	O
of	O
their	O
in	O
vitro	O
profiles	O
,	O
both	O
binding	O
and	O
functional	O
,	O
and	O
in	O
vivo	O
activity	O
in	O
relevant	O
animal	O
models	O
.	O

Neuroprotective	O
properties	O
assessed	O
after	O
postischemic	O
dosing	O
in	O
a	O
Mongolian	O
gerbil	O
severe	O
temporary	O
forebrain	O
ischemia	O
paradigm	O
,	O
using	O
hippocampal	O
CA1	O
damage	O
endpoints	O
,	O
and	O
the	O
efficacy	O
of	O
these	O
agonists	O
in	O
an	O
A	O
(	O
1	O
)	O
functional	O
assay	O
show	O
similarities	O
to	O
some	O
reference	O
adenosine	O
agonists	O
.	O

However	O
,	O
the	O
new	O
compounds	O
we	O
describe	O
exhibit	O
diminished	O
cardiovascular	O
effects	O
in	O
both	O
anesthetized	O
and	O
awake	O
rats	O
when	O
compared	O
to	O
reference	O
A	O
(	O
1	O
)	O
agonists	O
such	O
as	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
phenylisopropyladenosine	I-IUPAC
(	O
R	I-ABBREVIATION
-	I-ABBREVIATION
PIA	I-ABBREVIATION
,	O
5	O
)	O
,	O
N	I-IUPAC
-	I-IUPAC
cyclopentyladenosine	I-IUPAC
(	O
CPA	I-ABBREVIATION
,	O
2	O
)	O
,	O
4	O
,	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
trans	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxycyclopentyl	I-IUPAC
]	I-IUPAC
adenosine	I-IUPAC
(	O
GR	I-TRIVIALVAR
79236	I-TRIVIALVAR
,	O
26	O
)	O
,	O
N	I-IUPAC
-	I-IUPAC
cyclohexyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyladenosine	I-IUPAC
(	O
SDZ	I-TRIVIALVAR
WAG	I-TRIVIALVAR
994	I-TRIVIALVAR
,	O
27	O
)	O
,	O
and	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
adenosine	I-IUPAC
(	O
Metrifudil	I-TRIVIAL
,	O
28	O
)	O
.	O

In	O
mouse	O
permanent	O
middle	O
cerebral	O
artery	O
occlusion	O
focal	O
ischemia	O
,	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzothiazolyl	I-IUPAC
)	I-IUPAC
thio	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
adenosine	I-IUPAC
(	O
NNC	I-TRIVIALVAR
21-0136	I-TRIVIALVAR
,	O
12	O
)	O
exhibited	O
significant	O
neuroprotection	O
at	O
the	O
remarkably	O
low	O
total	O
intraperitoneal	O
dose	O
of	O
0.1	O
mg	O
/	O
kg	O
,	O
a	O
dose	O
at	O
which	O
no	O
cardiovascular	O
effects	O
are	O
observed	O
in	O
conscious	O
rats	O
.	O

The	O
novel	O
agonists	O
described	O
inhibit	O
6	I-IUPAC
,	I-IUPAC
7	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
carboline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
-	O
induced	O
seizures	O
,	O
and	O
in	O
mouse	O
locomotor	O
activity	O
higher	O
doses	O
are	O
required	O
to	O
reach	O
ED	O
(	O
50	O
)	O
values	O
than	O
for	O
reference	O
A	O
(	O
1	O
)	O
agonists	O
.	O

We	O
conclude	O
that	O
two	O
of	O
the	O
novel	O
adenosine	O
derivatives	O
revealed	O
herein	O
,	O
12	O
and	O
5'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
]	I-IUPAC
adenosine	I-IUPAC
(	O
NNC	I-TRIVIALVAR
21-0147	I-TRIVIALVAR
,	O
13	O
)	O
,	O
representatives	O
of	O
a	O
new	O
series	O
of	O
P	O
(	O
1	O
)	O
ligands	O
,	O
reinforce	O
the	O
fact	O
that	O
novel	O
selective	O
adenosine	O
A	O
(	O
1	O
)	O
agonists	O
have	O
potential	O
in	O
the	O
treatment	O
of	O
cerebral	O
ischemia	O
in	O
humans	O
.	O

A	O
series	O
of	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
quinolones	I-IUPAC
has	O
been	O
prepared	O
and	O
evaluated	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
antibacterial	O
activity	O
,	O
and	O
phototolerance	O
in	O
a	O
mouse	O
phototolerance	O
assay	O
.	O

These	O
analogues	O
were	O
compared	O
to	O
the	O
corresponding	O
series	O
of	O
6,8	I-PARTIUPAC
-	I-PARTIUPAC
difluoro	I-PARTIUPAC
-	I-PARTIUPAC
and	O
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
8H	I-IUPAC
-	I-IUPAC
quinolones	I-IUPAC
(	O
ciprofloxacin	I-TRIVIAL
type	O
)	O
.	O

Although	O
their	O
in	O
vitro	O
antibacterial	O
activities	O
are	O
less	O
than	O
the	O
6,8	I-PARTIUPAC
-	I-PARTIUPAC
difluoro	I-PARTIUPAC
analogues	I-MODIFIER
,	O
the	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
quinolones	I-IUPAC
are	O
generally	O
equivalent	O
to	O
their	O
8H	I-PARTIUPAC
analogues	B-MODIFIER
.	O

In	O
vivo	O
,	O
they	O
are	O
comparable	O
to	O
the	O
6,8	I-PARTIUPAC
-	I-PARTIUPAC
difluoro	I-PARTIUPAC
series	I-MODIFIER
and	O
show	O
up	O
to	O
10	O
-	O
fold	O
improvement	O
in	O
efficacy	O
when	O
compared	O
to	O
their	O
ciprofloxacin	I-TRIVIAL
counterparts	O
vs	O
Streptococcus	O
pyogenes	O
and	O
Streptococcus	O
pneumonia	O
.	O

In	O
the	O
phototolerance	O
model	O
,	O
the	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
quinolones	I-IUPAC
are	O
comparable	O
to	O
the	O
8H	I-IUPAC
-	I-IUPAC
quinolones	I-IUPAC
.	O

Both	O
of	O
these	O
series	O
display	O
much	O
higher	O
no	O
effect	O
doses	O
(	O
greater	O
tolerance	O
)	O
than	O
the	O
corresponding	O
6,8	I-IUPAC
-	I-IUPAC
difluoroquinolones	I-IUPAC
.	O

This	O
study	O
emphasizes	O
the	O
importance	O
of	O
the	O
metabolic	O
conversion	O
of	O
the	O
enantiomers	O
of	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylpiperidine	I-IUPAC
(	O
3	I-ABBREVIATION
-	I-ABBREVIATION
PPP	I-ABBREVIATION
)	O
into	O
their	O
catechol	I-TRIVIAL
analogues	B-MODIFIER
,	O
the	O
enantiomers	O
of	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylpiperidine	I-IUPAC
.	O

These	O
isomers	O
are	O
both	O
shown	O
to	O
be	O
excellent	O
substrates	O
for	O
COMT	O
,	O
with	O
a	O
slight	O
preference	O
for	O
the	O
S	O
-	O
(	O
-	O
)	O
enantiomer	O
.	O

Assessment	O
of	O
the	O
dopaminergic	O
activity	O
of	O
these	O
catechols	O
and	O
the	O
results	O
from	O
the	O
determination	O
of	O
brain	O
levels	O
of	O
the	O
enantiomers	O
of	O
3	I-ABBREVIATION
-	I-ABBREVIATION
PPP	I-ABBREVIATION
and	O
their	O
metabolites	O
indicate	O
that	O
the	O
metabolites	O
probably	O
do	O
not	O
alter	O
the	O
pharmacological	O
profiles	O
established	O
for	O
(	I-PARTIUPAC
R	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
+	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
PPP	I-IUPAC
.	O

The	O
conversion	O
of	O
the	O
monophenols	I-FAMILY
into	O
catecholic	O
metabolites	O
is	O
only	O
1-5%	O
,	O
and	O
the	O
further	O
conversion	O
of	O
these	O
catecholic	O
metabolites	O
into	O
methoxylated	O
analogues	O
is	O
very	O
rapid	O
.	O

However	O
,	O
the	O
very	O
interesting	O
observation	O
was	O
made	O
that	O
,	O
when	O
inhibiting	O
COMT	O
by	O
means	O
of	O
tropolone	I-TRIVIAL
and	O
subsequently	O
treating	O
the	O
rats	O
with	O
high	O
doses	O
of	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
PPP	I-IUPAC
(	O
ip	O
)	O
,	O
postsynaptic	O
dopaminergic	O
activity	O
was	O
elicited	O
.	O

This	O
has	O
never	O
been	O
seen	O
for	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
PPP	I-IUPAC
without	O
tropolone	I-TRIVIAL
pretreatment	O
and	O
might	O
indicate	O
that	O
,	O
in	O
this	O
special	O
case	O
,	O
the	O
catecholic	O
metabolite	O
affects	O
the	O
in	O
vivo	O
pharmacological	O
profile	O
of	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
PPP	I-IUPAC
.	O

Genetic	O
absence	O
epilepsy	O
in	O
rats	O
from	O
Strasbourg	O
-	O
-	O
a	O
review	O
.	O

We	O
have	O
selected	O
a	O
strain	O
of	O
rats	O
and	O
designated	O
it	O
the	O
Genetic	O
Absence	O
Epilepsy	O
Rat	O
from	O
Strasbourg	O
(	O
GAERS	O
)	O
.	O

In	O
this	O
strain	O
,	O
100%	O
of	O
the	O
animals	O
present	O
recurrent	O
generalized	O
non	O
-	O
convulsive	O
seizures	O
characterized	O
by	O
bilateral	O
and	O
synchronous	O
spike	O
-	O
and	O
-	O
wave	O
discharges	O
accompanied	O
with	O
behavioural	O
arrest	O
,	O
staring	O
and	O
sometimes	O
twitching	O
of	O
the	O
vibrissae	O
.	O

Spontaneous	O
SWD	O
(	O
7-11	O
cps	O
,	O
300-1,000	O
microV	O
,	O
0.5-75	O
sec	O
)	O
start	O
and	O
end	O
abruptly	O
on	O
a	O
normal	O
background	O
EEG	O
.	O

They	O
usually	O
occur	O
at	O
a	O
mean	O
frequency	O
of	O
1.5	O
per	O
min	O
when	O
the	O
animals	O
are	O
in	O
a	O
state	O
of	O
quiet	O
wakefulness	O
.	O

Drugs	O
effective	O
against	O
absence	O
seizures	O
in	O
humans	O
(	O
ethosuccimide	I-TRIVIAL
,	O
trimethadione	I-TRIVIAL
,	O
valproate	I-TRIVIAL
,	O
benzodiazepines	I-TRIVIAL
)	O
suppress	O
the	O
SWD	O
dose	O
-	O
dependently	O
,	O
whereas	O
drugs	O
specific	O
for	O
convulsive	O
or	O
focal	O
seizures	O
(	O
carbamazepine	I-TRIVIAL
,	O
phenytoin	I-TRIVIAL
)	O
are	O
ineffective	O
.	O

SWD	O
are	O
increased	O
by	O
epileptogenic	O
drugs	O
inducing	O
petit	O
mal	O
-	O
like	O
seizures	O
,	O
such	O
as	O
pentylenetetrazol	I-TRIVIAL
,	O
gamma	I-IUPAC
-	I-IUPAC
hydroxybutyrate	I-IUPAC
,	O
THIP	I-ABBREVIATION
and	O
penicillin	I-TRIVIAL
.	O

Depth	O
EEG	O
recordings	O
and	O
lesion	O
experiments	O
show	O
that	O
SWD	O
in	O
GAERs	O
depend	O
on	O
cortical	O
and	O
thalamic	O
structures	O
with	O
a	O
possible	O
rhythmic	O
triggering	O
by	O
the	O
lateral	O
thalamus	O
.	O

Most	O
neurotransmitters	O
are	O
involved	O
in	O
the	O
control	O
of	O
SWD	O
(	O
dopamine	I-TRIVIAL
,	O
noradrenaline	I-TRIVIAL
,	O
NMDA	I-ABBREVIATION
,	O
acetylcholine	I-TRIVIAL
)	O
,	O
but	O
GABA	I-ABBREVIATION
and	O
gamma	I-IUPAC
-	I-IUPAC
hydroxybutyrate	I-IUPAC
(	O
GHB	I-ABBREVIATION
)	O
seem	O
to	O
play	O
a	O
critical	O
role	O
.	O

SWD	O
are	O
genetically	O
determined	O
with	O
an	O
autosomal	O
dominant	O
inheritance	O
.	O

The	O
variable	O
expression	O
of	O
SWD	O
in	O
offsprings	O
from	O
GAERS	O
x	O
control	O
reciprocal	O
crosses	O
may	O
be	O
due	O
to	O
the	O
existence	O
of	O
multiple	O
genes	O
.	O

Neurophysiological	O
,	O
behavioural	O
,	O
pharmacological	O
and	O
genetic	O
studies	O
demonstrate	O
that	O
spontaneous	O
SWD	O
in	O
GAERS	O
fulfill	O
all	O
the	O
requirements	O
for	O
an	O
experimental	O
model	O
of	O
absence	O
epilepsy	O
.	O

As	O
the	O
mechanisms	O
underlying	O
absence	O
epilepsy	O
in	O
humans	O
are	O
still	O
unknown	O
,	O
the	O
analysis	O
of	O
the	O
genetic	O
thalamocortical	O
dysfunction	O
in	O
GAERS	O
may	O
be	O
fruitful	O
in	O
investigations	O
of	O
the	O
pathogenesis	O
of	O
generalized	O
non	O
-	O
convulsive	O
seizures	O
.	O

Diphenol	I-FAMILY
activation	O
of	O
the	O
monophenolase	O
and	O
diphenolase	O
activities	O
of	O
field	O
bean	O
(	O
Dolichos	O
lablab	O
)	O
polyphenol	O
oxidase	O
.	O

This	O
paper	O
reports	O
a	O
study	O
on	O
the	O
hydroxylation	O
of	O
ferulic	I-IUPAC
acid	I-IUPAC
and	O
tyrosine	I-TRIVIAL
by	O
field	O
bean	O
(	O
Dolichos	O
lablab	O
)	O
polyphenol	O
oxidase	O
,	O
a	O
reaction	O
that	O
does	O
not	O
take	O
place	O
without	O
the	O
addition	O
of	O
catechol	I-TRIVIAL
.	O

A	O
lag	O
period	O
similar	O
to	O
the	O
characteristic	O
lag	O
of	O
tyrosinase	O
activity	O
was	O
observed	O
,	O
the	O
length	O
of	O
which	O
decreased	O
with	O
increasing	O
catechol	I-TRIVIAL
concentration	O
and	O
increased	O
with	O
increasing	O
ferulic	I-IUPAC
acid	I-IUPAC
concentration	O
.	O

The	O
activation	O
constant	O
K	O
(	O
a	O
)	O
of	O
catechol	I-TRIVIAL
for	O
ferulic	I-IUPAC
acid	I-IUPAC
hydroxylation	O
reaction	O
was	O
5	O
mM	O
.	O

The	O
kinetic	O
parameters	O
of	O
field	O
bean	O
polyphenol	O
oxidase	O
toward	O
ferulic	I-IUPAC
acid	I-IUPAC
and	O
tyrosine	I-TRIVIAL
were	O
evaluated	O
in	O
the	O
presence	O
of	O
catechol	I-TRIVIAL
.	O

4	I-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
catechol	I-IUPAC
,	O
L	I-IUPAC
-	I-IUPAC
dihydroxyphenylalanine	I-IUPAC
,	O
pyrogallol	I-TRIVIAL
,	O
and	O
2,3,4	I-IUPAC
-	I-IUPAC
trihydroxybenzoic	I-IUPAC
acid	I-IUPAC
,	O
substrates	O
with	O
high	O
binding	O
affinity	O
to	O
field	O
bean	O
polyphenol	O
oxidase	O
,	O
could	O
stimulate	O
this	O
hydroxylation	O
reaction	O
.	O

In	O
contrast	O
,	O
diphenols	I-FAMILY
such	O
as	O
protocatechuic	I-IUPAC
acid	I-IUPAC
,	O
gallic	I-IUPAC
acid	I-IUPAC
,	O
chlorogenic	I-IUPAC
acid	I-IUPAC
,	O
and	O
caffeic	I-IUPAC
acid	I-IUPAC
,	O
which	O
were	O
not	O
substrates	O
for	O
the	O
oxidation	O
reaction	O
,	O
were	O
unable	O
to	O
bring	O
about	O
this	O
activation	O
.	O

It	O
is	O
most	O
likely	O
that	O
only	O
o	I-FAMILY
-	I-FAMILY
diphenols	I-FAMILY
that	O
are	O
substrates	O
for	O
the	O
diphenolase	O
serve	O
as	O
cosubstrates	O
by	O
donating	O
electrons	O
at	O
the	O
active	O
site	O
for	O
the	O
monophenolase	O
activity	O
.	O

The	O
reaction	O
mechanism	O
for	O
this	O
activation	O
is	O
consistent	O
with	O
that	O
proposed	O
for	O
tyrosinase	O
(	O
Sanchez	O
-	O
Ferrer	O
,	O
A	O
.	O

;	O
Rodriguez	O
-	O
Lopez	O
,	O
J	O
.	O

N	O
.	O

;	O
Garcia	O
-	O
Canovas	O
,	O
F	O
.	O

;	O
Garcia	O
-	O
Carmona	O
,	O
F	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
1995	O
,	O
1247	O
,	O
1-11	O
)	O
.	O

The	O
presence	O
of	O
o	I-FAMILY
-	I-FAMILY
diphenols	I-FAMILY
,	O
viz	O
.	O

catechol	I-TRIVIAL
,	O
L	I-IUPAC
-	I-IUPAC
dihydroxyphenylalanine	I-IUPAC
,	O
and	O
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
catechol	I-IUPAC
,	O
is	O
also	O
necessary	O
for	O
the	O
oxidation	O
of	O
the	O
diphenols	I-FAMILY
,	O
caffeic	I-TRIVIAL
acid	I-TRIVIAL
,	O
and	O
catechin	I-TRIVIAL
to	O
their	O
quinones	I-FAMILY
by	O
the	O
field	O
bean	O
polyphenol	O
oxidase	O
.	O

This	O
oxidation	O
reaction	O
occurs	O
immediately	O
with	O
no	O
lag	O
period	O
and	O
does	O
not	O
occur	O
without	O
the	O
addition	O
of	O
diphenol	I-FAMILY
.	O

The	O
kinetic	O
parameters	O
for	O
caffeic	I-TRIVIAL
acid	I-TRIVIAL
(	O
K	O
(	O
m	O
)	O
=	O
0.08	O
mM	O
,	O
V	O
(	O
max	O
)	O
=	O
32440	O
u	O
/	O
mg	O
)	O
in	O
the	O
presence	O
of	O
catechol	I-TRIVIAL
and	O
the	O
activation	O
constant	O
K	O
(	O
a	O
)	O
of	O
catechol	I-TRIVIAL
(	O
4.6	O
mM	O
)	O
for	O
this	O
reaction	O
were	O
enumerated	O
.	O

The	O
absence	O
of	O
a	O
lag	O
period	O
for	O
this	O
reaction	O
indicates	O
that	O
the	O
diphenol	I-FAMILY
mechanism	O
of	O
diphenolase	O
activation	O
differs	O
from	O
the	O
way	O
in	O
which	O
the	O
same	O
o	I-FAMILY
-	I-FAMILY
diphenols	I-FAMILY
activate	O
the	O
monophenolase	O
activity	O
.	O

In	O
the	O
present	O
investigation	O
,	O
the	O
last	O
two	O
possible	O
modes	O
of	O
generating	O
conformationally	O
semirigid	O
diacylglycerol	I-TRIVIAL
(	O
DAG	I-ABBREVIATION
)	O
analogues	I-MODIFIER
embedded	O
into	O
five	O
-	O
membered	O
ring	O
lactones	I-FAMILY
as	O
templates	O
III	O
and	O
IV	O
are	O
investigated	O
.	O

The	O
first	O
two	O
templates	O
studied	O
in	O
previous	O
investigations	O
corresponded	O
to	O
2	I-IUPAC
-	I-IUPAC
deoxyribonolactone	I-IUPAC
(	O
template	O
I	O
)	O
and	O
4,4	I-IUPAC
-	I-IUPAC
disubstituted	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
butyrolactone	I-IUPAC
(	O
template	O
II	O
)	O
,	O
with	O
the	O
latter	O
producing	O
potent	O
protein	O
kinase	O
C	O
(	O
PK	O
-	O
C	O
)	O
ligands	O
with	O
low	O
nanomolar	O
binding	O
affinities	O
.	O

The	O
templates	O
reported	O
in	O
this	O
work	O
correspond	O
to	O
2,3	I-PARTIUPAC
-	I-PARTIUPAC
dideoxy	I-PARTIUPAC
-	I-PARTIUPAC
L	I-PARTIUPAC
-	I-PARTIUPAC
erythro	I-PARTIUPAC
-	I-PARTIUPAC
or	O
-	I-IUPAC
threo	I-IUPAC
-	I-IUPAC
hexono	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
lactone	I-IUPAC
(	O
template	O
III	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
deoxyapiolactone	I-IUPAC
(	O
template	O
IV	O
)	O
.	O

Compounds	O
constructed	O
with	O
the	O
dideoxy	I-PARTIUPAC
-	I-PARTIUPAC
L	I-PARTIUPAC
-	I-PARTIUPAC
erythro	I-PARTIUPAC
-	I-PARTIUPAC
or	O
-	I-IUPAC
threo	I-IUPAC
-	I-IUPAC
hexono	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
lactone	I-IUPAC
template	O
were	O
synthesized	O
stereospecifically	O
from	O
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glucal	I-IUPAC
and	O
L	I-IUPAC
-	I-IUPAC
galactono	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
lactone	I-IUPAC
,	O
respectively	O
.	O

Compounds	O
constructed	O
with	O
the	O
2	I-IUPAC
-	I-IUPAC
deoxyapiolactone	I-IUPAC
template	O
were	O
synthesized	O
stereoselectively	O
from	O
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
isopropylidene	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
apiose	I-IUPAC
.	O

Inhibition	O
of	O
the	O
binding	O
of	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
phorbol	I-IUPAC
-	I-IUPAC
12,13	I-IUPAC
-	I-IUPAC
dibutyrate	I-IUPAC
to	O
PK	O
-	O
C	O
alpha	O
showed	O
that	O
only	O
the	O
threo	I-FAMILY
-	I-FAMILY
isomer	I-FAMILY
,	O
5	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
tetradecanoyl	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
threo	I-IUPAC
-	I-IUPAC
hexono	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
lactone	I-IUPAC
(	O
2	O
)	O
was	O
a	O
good	O
PK	O
-	O
C	O
ligand	O
(	O
Ki	O
=	O
1	O
microM	O
)	O
.	O

The	O
rest	O
of	O
the	O
ligands	O
had	O
poorer	O
affinities	O
with	O
Ki	O
values	O
between	O
10	O
and	O
28	O
microM	O
.	O

With	O
these	O
results	O
,	O
the	O
order	O
of	O
importance	O
of	O
five	O
-	O
membered	O
ring	O
lactones	I-FAMILY
as	O
competent	O
templates	O
for	O
the	O
construction	O
of	O
semirigid	O
DAG	I-ABBREVIATION
surrogates	O
with	O
effective	O
PK	O
-	O
C	O
binding	O
affinity	O
can	O
be	O
established	O
as	O
II	O
&	O
gt	O
;	O
&	O
gt	O
;	O
I	O
approximately	O
III	O
&	O
gt	O
;	O
IV	O
.	O

Hypoxic	O
cells	O
are	O
an	O
important	O
target	O
for	O
antitumor	O
therapy	O
because	O
tumors	O
are	O
typically	O
characterized	O
by	O
such	O
cells	O
.	O

Virtually	O
all	O
tumors	O
which	O
are	O
present	O
as	O
solid	O
masses	O
contain	O
hypoxic	O
cells	O
,	O
while	O
normal	O
cells	O
generally	O
have	O
an	O
adequate	O
supply	O
of	O
oxygen	O
.	O

Accordingly	O
,	O
antitumor	O
agents	O
can	O
be	O
made	O
selective	O
for	O
tumors	O
by	O
virtue	O
of	O
high	O
activity	O
under	O
hypoxic	O
conditions	O
.	O

The	O
initial	O
purpose	O
of	O
this	O
work	O
was	O
to	O
determine	O
the	O
influence	O
of	O
different	O
groups	O
in	O
position	O
3	O
.	O

Thus	O
,	O
the	O
synthesis	O
of	O
some	O
3	I-PARTIUPAC
-	I-PARTIUPAC
NH	I-PARTIUPAC
-	I-PARTIUPAC
substituted	I-PARTIUPAC
derivatives	I-MODIFIER
(	O
2a	O
,	O
3a	O
,	O
4a	O
)	O
starting	O
from	O
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
quinoxalinecarbonitrile	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
1a	O
)	O
is	O
described	O
.	O

Reductive	O
deamination	O
of	O
compounds	O
1a	O
-	O
k	O
provides	O
the	O
2	I-IUPAC
-	I-IUPAC
quinoxalinecarbonitriles	I-IUPAC
5a	O
-	O
k	O
,	O
which	O
are	O
more	O
potent	O
,	O
while	O
selectivity	O
is	O
maintained	O
or	O
increased	O
in	O
some	O
derivatives	O
.	O

The	O
compound	O
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
quinoxalinecarbonitrile	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
5k	O
)	O
is	O
150	O
-	O
fold	O
more	O
potent	O
than	O
tirapazamine	I-TRIVIAL
(	O
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
benzotriazine	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
)	O
,	O
which	O
has	O
been	O
used	O
as	O
a	O
standard	O
.	O

Three	O
derivatives	O
(	O
5g	O
,	O
i	O
,	O
k	O
)	O
show	O
a	O
hypoxic	O
cytotoxicity	O
ratio	O
(	O
HCR	O
)	O
&	O
gt	O
;	O
or	O
=	O
200	O
,	O
better	O
than	O
that	O
of	O
tirapazamine	I-TRIVIAL
(	O
HCR	O
=	O
75	O
)	O
in	O
V79	O
cells	O
.	O

Replacement	O
of	O
the	O
3	I-PARTIUPAC
-	I-PARTIUPAC
amino	I-PARTIUPAC
group	I-MODIFIER
by	O
chlorine	I-TRIVIAL
affords	O
the	O
potent	O
but	O
nonselective	O
3	I-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
derivatives	I-MODIFIER
6a	O
-	O
k	O
showing	O
similar	O
toxicities	O
under	O
both	O
aerobic	O
and	O
hypoxic	O
conditions	O
.	O

These	O
compounds	O
were	O
used	O
as	O
intermediates	O
for	O
the	O
synthesis	O
of	O
a	O
new	O
series	O
of	O
water	O
-	O
soluble	O
compounds	O
derived	O
from	O
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
[	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
quinoxalinecarbonitrile	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxides	I-IUPAC
10a	O
-	O
i	O
and	O
11a	O
-	O
i	O
.	O

The	O
7	I-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
and	O
the	O
7	I-PARTIUPAC
-	I-PARTIUPAC
trifluoromethyl	I-PARTIUPAC
derivatives	I-MODIFIER
10b	O
,	O
f	O
have	O
demonstrated	O
high	O
potency	O
(	O
0.4	O
and	O
0.3	O
microM	O
)	O
and	O
excellent	O
selectivity	O
(	O
HCR	O
=	O
250	O
and	O
340	O
)	O
.	O

Several	O
7	I-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
analogues	I-MODIFIER
,	O
12b	O
,	O
13b	O
.1	O
,	O
b	O
.2	O
,	O
and	O
14b	O
,	O
and	O
the	O
dimer	O
16b	O
have	O
been	O
prepared	O
and	O
evaluated	O
in	O
order	O
to	O
determine	O
the	O
optimum	O
lateral	O
chain	O
in	O
position	O
3	O
,	O
which	O
appears	O
to	O
be	O
the	O
[	O
(	I-PARTIUPAC
N	I-PARTIUPAC
,	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
dimethylamino	I-PARTIUPAC
)	I-PARTIUPAC
propyl	I-PARTIUPAC
]	I-PARTIUPAC
amino	I-PARTIUPAC
moiety	I-MODIFIER
.	O

Activity	O
of	O
beta	O
-	O
lactamase	O
inhibitor	O
combinations	O
on	O
Escherichia	O
coli	O
isolates	O
exhibiting	O
various	O
patterns	O
of	O
resistance	O
to	O
beta	I-FAMILY
-	I-FAMILY
lactam	I-FAMILY
agents	O
.	O

The	O
efficacy	O
of	O
the	O
clinically	O
available	O
beta	O
-	O
lactam	O
/	O
beta	O
-	O
lactamase	O
inhibitor	O
combinations	O
(	O
amoxicillin	I-TRIVIAL
/	O
clavulanic	I-TRIVIAL
acid	I-TRIVIAL
(	O
CA	I-ABBREVIATION
)	O
,	O
ticarcillin	I-TRIVIAL
/	O
CA	I-ABBREVIATION
,	O
amoxicillin	I-TRIVIAL
/	O
sulbactam	I-TRIVIAL
,	O
and	O
piperacillin	I-TRIVIAL
/	O
tazobactam	I-TRIVIAL
)	O
was	O
evaluated	O
on	O
300	O
amoxicillin	I-TRIVIAL
-	O
resistant	O
Escherichia	O
coli	O
isolates	O
having	O
the	O
main	O
patterns	O
of	O
beta	I-FAMILY
-	I-FAMILY
lactam	I-FAMILY
resistance	O
.	O

The	O
patterns	O
,	O
which	O
reflect	O
the	O
production	O
of	O
various	O
beta	O
-	O
lactamase	O
enzymes	O
,	O
were	O
analyzed	O
by	O
a	O
principal	O
component	O
analysis	O
of	O
susceptibility	O
to	O
11	O
beta	I-FAMILY
-	I-FAMILY
lactam	I-FAMILY
antibiotics	O
or	O
beta	I-FAMILY
-	I-FAMILY
lactam	I-FAMILY
/	O
beta	O
-	O
lactamase	O
inhibitor	O
combinations	O
.	O

Sixty	O
-	O
two	O
percent	O
of	O
strains	O
were	O
not	O
very	O
susceptible	O
to	O
penicillins	I-TRIVIAL
,	O
cephalothin	I-TRIVIAL
,	O
or	O
any	O
beta	I-FAMILY
-	I-FAMILY
lactam	I-FAMILY
/	O
beta	O
-	O
lactamase	O
inhibitor	O
combinations	O
except	O
for	O
piperacillin	I-TRIVIAL
/	O
tazobactam	I-TRIVIAL
;	O
these	O
strains	O
may	O
represent	O
high	O
-	O
level	O
broad	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
(	O
so	O
-	O
called	O
penicillinase	O
)	O
production	O
phenotype	O
or	O
inhibitor	O
-	O
resistant	O
TEM	O
-	O
like	O
enzyme	O
production	O
phenotype	O
.	O

Of	O
the	O
strains	O
,	O
14.7%	O
were	O
resistant	O
to	O
amoxicillin	I-TRIVIAL
and	O
ticarcillin	I-TRIVIAL
compatible	O
with	O
low	O
-	O
level	O
broad	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
production	O
phenotype	O
;	O
5.7%	O
were	O
cefoxitin	I-TRIVIAL
resistant	O
and	O
were	O
postulated	O
to	O
present	O
a	O
high	O
-	O
level	O
cephalosporinase	O
production	O
phenotype	O
;	O
and	O
2.6%	O
were	O
resistant	O
to	O
cephalothin	I-TRIVIAL
only	O
,	O
attributable	O
to	O
a	O
low	O
-	O
level	O
cephalosporinase	O
production	O
phenotype	O
.	O

Three	O
percent	O
of	O
strains	O
were	O
intermediate	O
or	O
resistant	O
to	O
cefotaxime	I-TRIVIAL
and	O
may	O
produce	O
an	O
extended	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
,	O
and	O
the	O
remaining	O
strains	O
(	O
12	O
%	O
)	O
,	O
resistant	O
to	O
all	O
tested	O
antibiotics	O
except	O
for	O
cefotaxime	I-TRIVIAL
and	O
piperacillin	I-TRIVIAL
/	O
tazobactam	I-TRIVIAL
,	O
were	O
hypothesized	O
to	O
produce	O
both	O
broad	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
plus	O
cephalosporinase	O
.	O

The	O
minimal	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
for	O
these	O
phenotype	O
patterns	O
indicated	O
that	O
combinations	O
of	O
CA	I-ABBREVIATION
plus	O
amoxicillin	I-TRIVIAL
or	O
ticarcillin	I-TRIVIAL
,	O
or	O
sulbactam	I-TRIVIAL
plus	O
amoxicillin	I-TRIVIAL
,	O
restored	O
the	O
activity	O
of	O
penicillins	I-TRIVIAL
against	O
phenotype	O
1	O
strains	O
,	O
whereas	O
these	O
combinations	O
remained	O
inactive	O
against	O
the	O
other	O
phenotype	O
strains	O
.	O

Piperacillin	I-TRIVIAL
plus	O
tazobactam	I-TRIVIAL
showed	O
the	O
best	O
in	O
vitro	O
effect	O
against	O
the	O
strains	O
of	O
all	O
resistance	O
phenotypes	O
.	O

The	O
syntheses	O
and	O
anthelmintic	O
activities	O
of	O
31	O
3	I-PARTIUPAC
-	I-PARTIUPAC
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazoles	I-IUPAC
are	O
reported	O
.	O

In	O
the	O
primary	O
anthelmintic	O
screen	O
,	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
39	O
)	O
showed	O
100%	O
nematocidal	O
activity	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
63	O
)	O
,	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
64	O
)	O
,	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
66	O
)	O
showed	O
100%	O
taeniacidal	O
activity	O
when	O
administered	O
orally	O
to	O
mice	O
.	O

The	O
two	O
most	O
active	O
members	O
of	O
this	O
series	O
,	O
39	O
and	O
63	O
,	O
were	O
active	O
against	O
the	O
gastrointestinal	O
nematodes	O
of	O
sheep	O
at	O
100	O
mg	O
/	O
kg	O
.	O

In	O
addition	O
,	O
39	O
was	O
also	O
found	O
to	O
be	O
active	O
against	O
hookworms	O
in	O
dogs	O
at	O
a	O
single	O
,	O
oral	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
.	O

Allopurinol	I-TRIVIAL
induces	O
renal	O
toxicity	O
by	O
impairing	O
pyrimidine	I-FAMILY
metabolism	O
in	O
mice	O
.	O

We	O
investigated	O
the	O
relationship	O
between	O
the	O
toxic	O
effect	O
of	O
allopurinol	I-TRIVIAL
and	O
pyrimidine	I-FAMILY
metabolism	O
in	O
mice	O
.	O

Allopurinol	I-TRIVIAL
-	O
induced	O
increases	O
in	O
plasma	O
transaminase	O
levels	O
in	O
dinitrofluorobenzene	I-TRIVIAL
(	O
DNFB	I-ABBREVIATION
)	O
-	O
sensitized	O
mice	O
were	O
not	O
affected	O
by	O
uridine	I-TRIVIAL
.	O

In	O
contrast	O
,	O
plasma	O
creatinine	I-TRIVIAL
and	O
BUN	O
tended	O
to	O
decrease	O
18	O
hr	O
after	O
the	O
last	O
injection	O
of	O
uridine	I-TRIVIAL
.	O

Both	O
plasma	O
and	O
urinary	O
orotidine	I-TRIVIAL
(	O
OD	I-ABBREVIATION
)	O
were	O
detected	O
in	O
DNFB	O
-	O
sensitized	O
mice	O
after	O
administration	O
of	O
a	O
single	O
dose	O
of	O
allopurinol	I-TRIVIAL
.	O

In	O
contrast	O
,	O
TEI	I-TRIVIALVAR
-	I-TRIVIALVAR
6720	I-TRIVIALVAR
,	O
a	O
newly	O
synthesized	O
xanthine	O
oxidase	O
/	O
xanthine	O
dehydrogenase	O
inhibitor	O
,	O
caused	O
neither	O
pyrimidine	I-FAMILY
metabolism	O
abnormality	O
nor	O
renal	O
impairment	O
in	O
DNFB	I-ABBREVIATION
-	O
sensitized	O
mice	O
.	O

Also	O
,	O
normal	O
mice	O
administered	O
high	O
doses	O
of	O
allopurinol	I-TRIVIAL
showed	O
abnormal	O
pyrimidine	I-FAMILY
metabolism	O
together	O
with	O
renal	O
toxicity	O
which	O
could	O
be	O
ameliorated	O
by	O
uridine	I-TRIVIAL
,	O
indicating	O
that	O
allopurinol	I-TRIVIAL
essentially	O
causes	O
pyrimidine	I-FAMILY
metabolism	O
abnormality	O
leading	O
to	O
renal	O
impairment	O
.	O

In	O
DNFB	O
-	O
sensitized	O
mice	O
,	O
allopurinol	I-TRIVIAL
increased	O
urinary	O
OD	I-ABBREVIATION
excretion	O
to	O
an	O
extent	O
similar	O
to	O
that	O
in	O
normal	O
mice	O
administered	O
the	O
same	O
dose	O
of	O
allopurinol	I-TRIVIAL
.	O

However	O
,	O
renal	O
impairment	O
by	O
allopurinol	I-TRIVIAL
was	O
more	O
striking	O
in	O
DNFB	O
-	O
sensitized	O
mice	O
than	O
in	O
normal	O
mice	O
.	O

Histopathological	O
observations	O
showed	O
that	O
allopurinol	I-TRIVIAL
induced	O
calculus	O
formation	O
in	O
the	O
collecting	O
tubules	O
and	O
papillary	O
duct	O
.	O

Calculus	O
formation	O
was	O
increased	O
by	O
DNFB	I-ABBREVIATION
and	O
decreased	O
by	O
uridine	I-TRIVIAL
.	O

These	O
observations	O
indicate	O
that	O
the	O
enhancement	O
of	O
the	O
renal	O
toxicity	O
of	O
allopurinol	I-TRIVIAL
by	O
DNFB	O
-	O
sensitization	O
may	O
be	O
due	O
to	O
some	O
biological	O
interactions	O
between	O
DNFB	I-ABBREVIATION
and	O
allopurinol	I-TRIVIAL
.	O

In	O
humans	O
,	O
it	O
is	O
possible	O
that	O
there	O
are	O
some	O
biological	O
interactions	O
which	O
serve	O
to	O
enhance	O
the	O
toxicity	O
of	O
allopurinol	I-TRIVIAL
,	O
resulting	O
in	O
the	O
development	O
of	O
allopurinol	I-TRIVIAL
hypersensitivity	O
syndrome	O
(	O
AHS	O
)	O
.	O

In	O
contrast	O
,	O
TEI	I-TRIVIALVAR
-	I-TRIVIALVAR
6720	I-TRIVIALVAR
,	O
had	O
no	O
effect	O
on	O
pyrimidine	I-FAMILY
metabolism	O
and	O
showed	O
no	O
toxic	O
effect	O
.	O

The	O
determination	O
of	O
the	O
structure	O
and	O
function	O
of	O
the	O
sigma	O
receptor	O
subtypes	O
and	O
their	O
physiological	O
role	O
(	O
s	O
)	O
has	O
been	O
impeded	O
by	O
the	O
unavailability	O
of	O
selective	O
ligands	O
.	O

We	O
have	O
developed	O
a	O
new	O
class	O
of	O
sigma	O
subtype	O
selective	O
receptor	O
ligands	O
that	O
are	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
benzylidene	I-IUPAC
derivatives	I-MODIFIER
of	O
the	O
synthetic	O
opioid	O
(	I-PARTIUPAC
+	I-PARTIUPAC
/	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
,	O
(	I-PARTIUPAC
+	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
morphan	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
1	O
)	O
.	O

The	O
derivatives	O
can	O
be	O
prepared	O
by	O
reaction	O
of	O
1	O
,	O
(	O
+	O
)	O
-	O
1	O
,	O
and	O
(	O
-	O
)	O
-	O
1	O
with	O
the	O
appropriate	O
benzaldehyde	I-TRIVIAL
under	O
Claisen	O
-	O
Schmidt	O
conditions	O
.	O

Incorporation	O
of	O
substituted	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
benzylidene	I-IUPAC
moieties	I-MODIFIER
onto	O
the	O
7	O
-	O
keto	O
precursor	O
of	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
morphan	I-IUPAC
,	O
(	O
+	O
)	O
-	O
1	O
,	O
produces	O
compounds	O
(	O
-	O
)	O
-	O
2	O
through	O
(	O
-	O
)	O
-	O
7	O
(	O
5.8-32.0	O
nM	O
,	O
sigma	O
1	O
)	O
,	O
which	O
have	O
between	O
a	O
25	O
-	O
and	O
131	O
-	O
fold	O
increase	O
in	O
affinity	O
for	O
the	O
sigma	O
1	O
receptor	O
subtype	O
relative	O
to	O
the	O
keto	O
precursor	O
(	O
+	O
)	O
-	O
1	O
(	O
Ki	O
=	O
762	O
nM	O
,	O
sigma	O
1	O
)	O
.	O

Compound	O
(	O
-	O
)	O
-	O
2	O
is	O
the	O
most	O
selective	O
of	O
this	O
group	O
(	O
16	O
-	O
fold	O
)	O
for	O
the	O
sigma	O
1	O
subtype	O
versus	O
sigma	O
2	O
.	O

Substitution	O
of	O
an	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
benzylidene	I-IUPAC
moiety	O
onto	O
the	O
7	O
-	O
keto	O
precursor	O
of	O
(	O
-	O
)	O
-	O
2	O
-	O
methyl	O
-	O
5	O
-	O
(	O
3	O
-	O
hydroxyphenyl	O
)	O
morphan	O
,	O
(	O
-	O
)	O
-	O
1	O
,	O
produces	O
compounds	O
(	O
+	O
)	O
-	O
2	O
-	O
(	O
+	O
)	O
-	O
9	O
(	O
6.4-52.6	O
nM	O
,	O
sigma	O
2	O
)	O
,	O
which	O
have	O
at	O
least	O
a	O
475-3906	O
-	O
fold	O
increase	O
in	O
affinity	O
for	O
the	O
sigma	O
2	O
receptor	O
subtype	O
relative	O
to	O
the	O
keto	O
precursor	O
(	O
-	O
)	O
-	O
1	O
(	O
Ki	O
=	O
25	O
x	O
10	O
(	O
3	O
)	O
nM	O
)	O
.	O

This	O
enhancement	O
of	O
sigma	O
2	O
receptor	O
affinity	O
is	O
accompanied	O
by	O
substantial	O
selectivity	O
of	O
all	O
of	O
these	O
dextrorotatory	O
products	O
for	O
the	O
sigma	O
2	O
relative	O
to	O
the	O
sigma	O
1	O
subtype	O
(	O
32-238	O
-	O
fold	O
)	O
,	O
and	O
thus	O
,	O
they	O
are	O
among	O
the	O
most	O
sigma	O
2	O
selective	O
compounds	O
currently	O
known	O
.	O

Furthermore	O
,	O
the	O
sigma	O
1	O
subtype	O
is	O
highly	O
enantioselective	O
for	O
the	O
levorotatory	O
isomers	O
,	O
(	O
-	O
)	O
-	O
2	O
-	O
(	O
-	O
)	O
-	O
7	O
(	O
41-1034	O
-	O
fold	O
)	O
,	O
whereas	O
the	O
sigma	O
2	O
subtype	O
is	O
only	O
somewhat	O
enantioselective	O
for	O
the	O
dextrorotatory	O
isomers	O
,	O
(	O
+	O
)	O
-	O
2	O
-	O
(	O
+	O
)	O
-	O
7	O
(	O
2.6-9.3	O
-	O
fold	O
)	O
.	O

All	O
of	O
these	O
derivatives	O
retain	O
substantial	O
affinity	O
for	O
the	O
mu	O
opioid	O
receptor	O
.	O

Despite	O
the	O
high	O
affinity	O
of	O
the	O
dextrorotatory	O
derivatives	O
for	O
the	O
mu	O
opioid	O
receptor	O
,	O
the	O
high	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
2	O
over	O
sigma	O
1	O
sites	O
will	O
surely	O
prove	O
beneficial	O
as	O
tools	O
for	O
the	O
delineation	O
of	O
the	O
function	O
and	O
physiological	O
role	O
of	O
sigma	O
2	O
receptors	O
.	O

The	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
several	O
unsaturated	I-FAMILY
acyclonucleosides	I-FAMILY
related	O
to	O
augustmycin	I-TRIVIAL
A	I-TRIVIAL
are	O
described	O
.	O

The	O
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
acyclonucleoside	I-IUPAC
analogues	I-MODIFIER
of	O
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
,	O
adenine	I-TRIVIAL
,	O
6	I-IUPAC
-	I-IUPAC
methoxypurine	I-IUPAC
,	O
hypoxanthine	I-TRIVIAL
,	O
6	I-IUPAC
-	I-IUPAC
mercaptopurine	I-IUPAC
,	O
and	O
azathioprine	I-TRIVIAL
have	O
been	O
prepared	O
.	O

The	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
adenine	I-IUPAC
(	O
5	O
)	O
and	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
hypoxanthine	I-IUPAC
(	O
12	O
)	O
analogues	I-MODIFIER
were	O
converted	O
to	O
the	O
corresponding	O
5'	I-PARTIUPAC
-	I-PARTIUPAC
tributylstannyl	I-PARTIUPAC
intermediates	I-MODIFIER
(	O
9	O
and	O
13	O
)	O
,	O
respectively	O
,	O
which	O
gave	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
adenine	I-IUPAC
(	O
10	O
)	O
and	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
hypoxanthine	I-IUPAC
(	O
14	O
)	O
,	O
respectively	O
,	O
after	O
iododestannylation	O
.	O

The	O
[	O
125I	O
]	O
-	O
radiolabeled	O
congeners	O
of	O
10	O
and	O
14	O
were	O
prepared	O
as	O
potential	O
metabolic	O
markers	O
.	O

Among	O
the	O
unsaturated	I-FAMILY
acyclonucleosides	I-FAMILY
tested	O
,	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
(	O
3	O
)	O
,	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
mercaptopurine	I-IUPAC
(	O
15	O
)	O
,	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
azathioprine	I-IUPAC
(	O
17	O
)	O
,	O
and	O
angustmycin	I-TRIVIAL
A	I-TRIVIAL
analogue	O
10	O
showed	O
inhibition	O
of	O
cancer	O
cell	O
growth	O
,	O
but	O
only	O
at	O
a	O
minimal	O
level	O
,	O
and	O
17	O
also	O
showed	O
14%	O
cancer	O
cell	O
death	O
in	O
vitro	O
.	O

Compound	O
10	O
provided	O
approximately	O
50%	O
protection	O
against	O
HIV	O
at	O
10	O
(	O
-	O
4	O
)	O
M	O
concentrations	O
.	O

Biodistribution	O
results	O
of	O
[	O
125I	O
]	O
-	O
10	O
in	O
mice	O
indicate	O
that	O
compound	O
10	O
is	O
readily	O
metabolized	O
via	O
deiodination	O
in	O
vivo	O
,	O
possibly	O
by	O
serving	O
as	O
a	O
substrate	O
for	O
the	O
enzyme	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
homocysteine	O
hydrolase	O
.	O

In	O
an	O
attempt	O
to	O
increase	O
the	O
combined	O
toxicity	O
of	O
the	O
metabolic	O
end	O
-	O
products	O
[	O
acrolein	I-TRIVIAL
(	O
4	O
)	O
and	O
phosphoramide	O
mustard	O
(	O
3	O
)	O
]	O
from	O
cyclophosphamide	I-TRIVIAL
(	O
1	O
)	O
,	O
the	O
analog	I-MODIFIER
2	B-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
trifluoromethyl	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
oxazaphosphorine	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
2	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
trifluoromethylcyclophosphamide	I-IUPAC
)	O
was	O
synthesized	O
and	O
its	O
metabolism	O
and	O
antitumor	O
activity	O
studied	O
.	O

Following	O
metabolism	O
of	O
2	O
by	O
rat	O
liver	O
microsomes	O
the	O
predicted	O
formation	O
of	O
4,4,4	I-IUPAC
-	I-IUPAC
trifluorocrotonaldehyde	I-IUPAC
(	O
5	O
)	O
was	O
confirmed	O
by	O
isolation	O
and	O
identification	O
,	O
by	O
mass	O
spectrometry	O
,	O
of	O
its	O
dinitrophenylhydrazone	I-TRIVIAL
.	O

The	O
therapeutic	O
indices	O
(	O
LD50	O
-	O
/	O
ID90	O
)	O
for	O
2	O
against	O
the	O
ADJ	O
/	O
PC6	O
mouse	O
tumor	O
and	O
the	O
Walker	O
256	O
tumor	O
in	O
the	O
rat	O
were	O
28.6	O
and	O
7.7	O
,	O
respectively	O
,	O
and	O
were	O
lower	O
than	O
the	O
corresponding	O
values	O
for	O
1	O
(	O
91.8	O
and	O
33.2	O
,	O
respectively	O
)	O
although	O
the	O
toxicities	O
toward	O
Walker	O
cells	O
in	O
a	O
bioassay	O
system	O
of	O
1	O
and	O
2	O
following	O
microsomal	O
metabolism	O
were	O
similar	O
.	O

In	O
order	O
to	O
study	O
the	O
toxicities	O
of	O
4	O
and	O
5	O
released	O
under	O
drug	O
metabolizing	O
conditions	O
independently	O
of	O
the	O
production	O
of	O
a	O
toxic	O
mustard	I-FAMILY
the	O
analogs	I-MODIFIER
18	O
[	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
oxazaphosphorine	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
]	O
and	O
6	O
[	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
trifluoromethyl	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
oxazaphosphorine	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
]	O
were	O
also	O
synthesized	O
.	O

The	O
release	O
of	O
5	O
from	O
6	O
following	O
metabolism	O
was	O
confirmed	O
and	O
shown	O
by	O
use	O
of	O
the	O
bioassay	O
system	O
to	O
be	O
an	O
event	O
of	O
similar	O
toxicity	O
to	O
release	O
of	O
4	O
from	O
18	O
;	O
in	O
vivo	O
,	O
however	O
,	O
6	O
(	O
LD50	O
330	O
mg	O
/	O
kg	O
)	O
was	O
more	O
toxic	O
to	O
mice	O
than	O
18	O
(	O
LD50	O
greater	O
than	O
500	O
mg	O
/	O
kg	O
)	O
.	O

There	O
is	O
reported	O
the	O
first	O
four	O
members	O
of	O
heteroarotinoids	I-FAMILY
,	O
the	O
names	O
of	O
which	O
are	O
ethyl	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethylthiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
1b	O
)	O
,	O
ethyl	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethylchroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
1c	O
)	O
,	O
ethyl	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxothiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
1d	O
)	O
,	O
and	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethylchroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
1e	O
)	O
.	O

IR	O
,	O
1H	O
NMR	O
and	O
13C	O
NMR	O
data	O
have	O
been	O
recorded	O
for	O
each	O
compound	O
and	O
support	O
the	O
structural	O
assignments	O
.	O

To	O
provide	O
a	O
firm	O
basis	O
for	O
comparison	O
purposes	O
of	O
future	O
analogues	O
,	O
an	O
X	O
-	O
ray	O
analysis	O
was	O
performed	O
on	O
a	O
single	O
crystal	O
of	O
ethyl	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethylthiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
1b	O
)	O
and	O
a	O
precursor	O
4,4	I-IUPAC
-	I-IUPAC
dimethylthiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
methyl	I-IUPAC
ketone	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
(	O
18	O
)	O
.	O

These	O
data	O
for	O
the	O
heteroarotinoid	I-FAMILY
1b	O
revealed	O
that	O
the	O
two	O
aryl	O
ring	O
systems	O
were	O
nearly	O
perpendicular	O
in	O
each	O
of	O
the	O
two	O
molecules	O
present	O
in	O
the	O
unit	O
cell	O
(	O
86.37	O
degrees	O
and	O
84.17	O
degrees	O
,	O
respectively	O
)	O
.	O

The	O
space	O
group	O
for	O
both	O
molecules	O
was	O
P1	O
in	O
triclinic	O
systems	O
.	O

Unit	O
cell	O
dimensions	O
(	O
at	O
15	O
degrees	O
C	O
)	O
are	O
as	O
follows	O
:	O
for	O
1b	O
,	O
a	O
=	O
20.568	O
(	O
6	O
)	O
A	O
,	O
b	O
=	O
14.760	O
(	O
3	O
)	O
A	O
,	O
c	O
=	O
7.679	O
(	O
2	O
)	O
A	O
,	O
alpha	O
=	O
113.33	O
(	O
2	O
)	O
degrees	O
,	O
beta	O
=	O
79.45	O
(	O
2	O
)	O
degrees	O
,	O
gamma	O
=	O
79.98	O
(	O
2	O
)	O
degrees	O
,	O
Z	O
=	O
4	O
;	O
for	O
18	O
,	O
a	O
=	O
9.292	O
(	O
5	O
)	O
A	O
,	O
b	O
=	O
9.291	O
(	O
5	O
)	O
A	O
,	O
c	O
=	O
7.951	O
(	O
3	O
)	O
A	O
,	O
alpha	O
=	O
102.16	O
(	O
3	O
)	O
degrees	O
,	O
beta	O
=	O
77.49	O
(	O
3	O
)	O
degrees	O
,	O
gamma	O
=	O
79.60	O
(	O
4	O
)	O
degrees	O
,	O
Z	O
=	O
2	O
.	O

The	O
sulfur	I-TRIVIAL
-	O
containing	O
ring	O
is	O
in	O
a	O
distorted	O
half	O
-	O
chair	O
in	O
1b	O
and	O
the	O
methyl	I-PARTIUPAC
carbon	B-TRIVIAL
C	O
(	O
12	O
)	O
is	O
shown	O
to	O
be	O
trans	O
to	O
H	O
(	O
13	O
)	O
at	O
the	O
C	O
(	O
11	O
)	O
-	O
C	O
(	O
13	O
)	O
bond	O
.	O

The	O
biological	O
activity	O
of	O
these	O
arotinoids	I-FAMILY
was	O
determined	O
in	O
the	O
tracheal	O
organ	O
culture	O
assay	O
and	O
compared	O
with	O
trans	I-TRIVIAL
-	I-TRIVIAL
retinoic	I-TRIVIAL
acid	I-TRIVIAL
for	O
ability	O
to	O
reverse	O
keratinization	O
in	O
vitamin	I-TRIVIAL
A	I-TRIVIAL
deficient	O
hamsters	O
.	O

The	O
ester	O
1b	O
displayed	O
activity	O
about	O
one	O
-	O
half	O
log	O
unit	O
less	O
than	O
that	O
of	O
the	O
reference	O
while	O
1c	O
and	O
1e	O
had	O
activity	O
nearly	O
one	O
log	O
until	O
less	O
than	O
trans	I-TRIVIAL
-	I-TRIVIAL
retinoic	I-TRIVIAL
acid	I-TRIVIAL
.	O

The	O
sulfoxide	I-FAMILY
was	O
the	O
least	O
active	O
of	O
the	O
heteroretinoids	I-FAMILY
.	O

Identification	O
of	O
MAGI	O
-	O
3	O
as	O
a	O
transforming	O
growth	O
factor	O
-	O
alpha	O
tail	O
binding	O
protein	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
alpha	O
precursor	O
(	O
proTGFalpha	O
)	O
contains	O
a	O
C	O
-	O
terminal	O
PSD	O
-	O
95	O
/	O
SAP90	O
,	O
Discs	O
Large	O
,	O
and	O
Zona	O
Occludens	O
-	O
1	O
(	O
PDZ	O
)	O
recognition	O
motif	O
(	O
TVV	O
)	O
.	O

By	O
yeast	O
two	O
-	O
hybrid	O
screening	O
of	O
a	O
mouse	O
embryo	O
library	O
,	O
we	O
have	O
found	O
that	O
a	O
third	O
member	O
of	O
a	O
family	O
of	O
PDZ	O
-	O
containing	O
proteins	O
,	O
membrane	O
associated	O
guanylate	O
kinase	O
inverted	O
-	O
3	O
(	O
MAGI	O
-	O
3	O
)	O
,	O
binds	O
to	O
TGFalpha	O
's	O
TVV	O
.	O

MAGI	O
-	O
3	O
is	O
widely	O
expressed	O
in	O
multiple	O
mouse	O
tissues	O
,	O
including	O
brain	O
.	O

Immunolocalization	O
showed	O
that	O
MAGI	O
-	O
3	O
and	O
TGFalpha	O
were	O
colocalized	O
in	O
neurons	O
in	O
the	O
cortex	O
and	O
dentate	O
gyrus	O
,	O
as	O
well	O
as	O
in	O
ependymal	O
cells	O
and	O
some	O
astrocytes	O
.	O

In	O
vitro	O
,	O
proTGFalpha	O
bound	O
the	O
PDZ	O
-	O
1	O
domain	O
of	O
MAGI	O
-	O
3	O
and	O
MAGI	O
-	O
2	O
,	O
but	O
not	O
MAGI	O
-	O
1	O
.	O

MAGI	O
-	O
3	O
and	O
the	O
17	O
-	O
kDa	O
cell	O
surface	O
form	O
of	O
proTGFalpha	O
interact	O
transiently	O
in	O
MDCK	O
cells	O
stably	O
transfected	O
with	O
both	O
MAGI	O
-	O
3	O
and	O
human	O
proTGFalpha	O
cDNAs	O
.	O

MAGI	O
-	O
3	O
and	O
wild	O
-	O
type	O
proTGFalpha	O
colocalize	O
at	O
the	O
cell	O
surface	O
.	O

In	O
contrast	O
,	O
MAGI	O
-	O
3	O
forms	O
a	O
stable	O
complex	O
with	O
membrane	O
-	O
fixed	O
TGFalpha	O
early	O
in	O
the	O
secretory	O
pathway	O
and	O
interacts	O
with	O
immature	O
and	O
cell	O
surface	O
forms	O
of	O
membrane	O
-	O
fixed	O
TGFalpha	O
.	O

Overexpression	O
of	O
MAGI	O
-	O
3	O
resulted	O
in	O
increased	O
levels	O
of	O
TGFalpha	O
in	O
the	O
basolateral	O
medium	O
of	O
polarized	O
MDCK	O
cells	O
,	O
suggesting	O
that	O
MAGI	O
-	O
3	O
has	O
a	O
role	O
in	O
efficient	O
trafficking	O
of	O
TGFalpha	O
to	O
the	O
cell	O
surface	O
in	O
polarized	O
epithelial	O
cells	O
.	O

A	O
series	O
of	O
22	I-IUPAC
-	I-IUPAC
hydroxycholesterol	I-IUPAC
derivatives	I-MODIFIER
with	O
a	O
modified	O
side	O
chain	O
terminus	O
was	O
prepared	O
.	O

These	O
agents	O
were	O
evaluated	O
in	O
vitro	O
and	O
in	O
vivo	O
for	O
their	O
ability	O
to	O
suppress	O
HMG	O
CoA	O
reductase	O
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
of	O
cholesterol	I-TRIVIAL
biosynthesis	O
.	O

In	O
tissue	O
culture	O
assays	O
,	O
22	I-IUPAC
-	I-IUPAC
hydroxycholesterol	I-IUPAC
as	O
well	O
as	O
the	O
side	O
chain	O
modified	O
analogues	O
were	O
potent	O
inhibitors	O
of	O
HMG	O
CoA	O
reductase	O
.	O

However	O
,	O
only	O
those	O
sterols	O
with	O
a	O
modified	O
side	O
chain	O
terminus	O
were	O
effective	O
suppressors	O
of	O
liver	O
reductase	O
when	O
administered	O
ig	O
to	O
rats	O
.	O

22	I-IUPAC
-	I-IUPAC
Hydroxy	I-IUPAC
-	I-IUPAC
25	I-IUPAC
-	I-IUPAC
methylcholesterol	I-IUPAC
(	O
4a	O
)	O
and	O
25	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
22	I-IUPAC
-	I-IUPAC
hydroxycholesterol	I-IUPAC
(	O
15a	O
)	O
significantly	O
lowered	O
serum	O
cholesterol	O
levels	O
when	O
administered	O
ig	O
to	O
primates	O
;	O
25	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
22	I-IUPAC
-	I-IUPAC
hydroxycholesterol	I-IUPAC
(	O
15b	O
)	O
and	O
the	O
analogue	O
with	O
a	O
cyclopropyl	I-TRIVIAL
terminus	O
,	O
20b	O
,	O
were	O
ineffective	O
.	O

The	O
cholesterol	I-TRIVIAL
-	O
lowering	O
sterols	I-FAMILY
did	O
not	O
significantly	O
alter	O
lipoprotein	O
levels	O
;	O
however	O
,	O
the	O
two	O
compounds	O
have	O
been	O
shown	O
to	O
inhibit	O
acyl	O
-	O
coenzyme	O
A	O
:	O
cholesterol	O
acyl	O
-	O
transferase	O
(	O
ACAT	O
)	O
in	O
tissue	O
culture	O
studies	O
.	O

Synthesis	O
of	O
pyridino	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
f	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
4,9	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
and	O
6,7	I-IUPAC
-	I-IUPAC
disubstituted	I-IUPAC
quinoline	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
derivatives	I-MODIFIER
and	O
evaluation	O
on	O
their	O
cytotoxic	O
activity	O
.	O

We	O
report	O
upon	O
the	O
synthesis	O
of	O
the	O
following	O
derivatives	O
:	O
N	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
-	I-IUPAC
pyridino	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
f	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
4,9	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
,	O
and	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
diethoxycarbonyl	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
quinoline	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
,	O
which	O
contain	O
the	O
active	O
quinoline	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
(	O
VII	O
)	O
moiety	I-MODIFIER
.	O

The	O
cytotoxic	O
activities	O
of	O
these	O
compounds	O
have	O
been	O
tested	O
in	O
SRB	O
(	O
SulfoRhodamine	O
B	O
)	O
assays	O
against	O
the	O
cancer	O
cell	O
lines	O
of	O
A	O
-	O
549	O
(	O
human	O
lung	O
cancer	O
)	O
,	O
SK	O
-	O
MEL	O
-	O
2	O
(	O
human	O
melanoma	O
cancer	O
)	O
,	O
SK	O
-	O
OV	O
-	O
3	O
(	O
human	O
ovarian	O
cancer	O
)	O
,	O
XF	O
-	O
498	O
(	O
human	O
brain	O
cancer	O
)	O
and	O
HCT	O
15	O
(	O
human	O
colon	O
cancer	O
)	O
.	O

The	O
compound	O
,	O
N	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethoxycarbonyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
pyridino	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
f	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
4,9	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
(	O
A	O
-	O
9	O
)	O
,	O
also	O
showed	O
higher	O
activity	O
than	O
cis	I-TRIVIAL
-	I-TRIVIAL
platin	I-TRIVIAL
.	O

The	O
highest	O
level	O
of	O
cytotoxic	O
activity	O
in	O
these	O
human	O
tumor	O
cell	O
lines	O
was	O
observed	O
in	O
the	O
compound	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
diethoxycarbonyl	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
quinoline	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
(	O
B	O
-	O
3	O
)	O
.	O

Two	O
2,3	I-IUPAC
-	I-IUPAC
dihydrobenzofuran	I-IUPAC
analogues	I-MODIFIER
of	O
hallucinogenic	O
amphetamines	I-FAMILY
were	O
prepared	O
and	O
evaluated	O
for	O
activity	O
in	O
the	O
two	O
-	O
lever	O
drug	O
-	O
discrimination	O
paradigm	O
in	O
rats	O
trained	O
to	O
discriminate	O
saline	O
from	O
LSD	I-IUPAC
tartrate	I-IUPAC
(	O
0.08	O
mg	O
/	O
kg	O
)	O
and	O
for	O
the	O
ability	O
to	O
displace	O
[	I-IUPAC
125I	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
DOI	I-IUPAC
[	O
(	I-IUPAC
125I	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
iodophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopropane	I-IUPAC
)	I-IUPAC
from	O
rat	O
cortical	O
homogenate	O
5	O
-	O
HT2	O
receptors	O
.	O

The	O
compounds	O
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydrobenzofuran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopropane	I-IUPAC
(	O
6a	O
)	O
and	O
its	O
7	I-PARTIUPAC
-	I-PARTIUPAC
brominated	I-PARTIUPAC
analogue	I-MODIFIER
6b	O
,	O
possessed	O
activity	O
comparable	O
to	O
their	O
conformationally	O
flexible	O
counterparts	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
dimethoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopropane	I-IUPAC
(	O
3	O
)	O
and	O
its	O
4	I-PARTIUPAC
-	I-PARTIUPAC
bromo	I-PARTIUPAC
derivative	I-MODIFIER
DOB	B-ABBREVIATION
(	O
5	O
)	O
,	O
respectively	O
.	O

The	O
results	O
suggest	O
that	O
the	O
dihydrofuran	I-TRIVIAL
ring	O
in	O
6a	O
and	O
6b	O
models	O
the	O
active	O
conformation	O
of	O
the	O
5	I-PARTIUPAC
-	I-PARTIUPAC
methoxy	I-PARTIUPAC
groups	I-MODIFIER
in	O
3	O
and	O
5	O
.	O

Free	O
energy	O
of	O
binding	O
,	O
derived	O
from	O
radioligand	O
displacement	O
KA	O
values	O
,	O
indicated	O
that	O
addition	O
of	O
the	O
bromine	I-TRIVIAL
in	O
either	O
series	O
contributes	O
2.4-3.2	O
kcal	O
/	O
mol	O
of	O
binding	O
energy	O
.	O

On	O
the	O
basis	O
of	O
surface	O
area	O
of	O
the	O
bromine	I-TRIVIAL
atom	B-MODIFIER
,	O
this	O
value	O
is	O
2-3	O
times	O
higher	O
than	O
would	O
be	O
expected	O
on	O
the	O
basis	O
of	O
hydrophobic	O
binding	O
.	O

Thus	O
,	O
hydrophobicity	O
of	O
the	O
para	O
substituent	O
alone	O
cannot	O
account	O
for	O
the	O
dramatic	O
enhancement	O
of	O
hallucinogenic	O
activity	O
.	O

Although	O
this	O
substituent	O
may	O
play	O
a	O
minor	O
role	O
in	O
orienting	O
the	O
conformation	O
of	O
the	O
5	I-PARTIUPAC
-	I-PARTIUPAC
methoxy	I-PARTIUPAC
group	I-MODIFIER
in	O
derivatives	O
such	O
as	O
4	O
and	O
5	O
,	O
there	O
appears	O
to	O
be	O
some	O
other	O
,	O
as	O
yet	O
unknown	O
,	O
critical	O
receptor	O
interaction	O
.	O

Sulfur	O
-	O
bridged	O
pregnanes	O
6,19	I-IUPAC
-	I-IUPAC
epithioprogesterone	I-IUPAC
,	O
21	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
6,19	I-IUPAC
-	I-IUPAC
epithioprogesterone	I-IUPAC
,	O
and	O
the	O
corresponding	O
sulfoxides	I-FAMILY
and	O
sulfones	I-FAMILY
were	O
synthesized	O
and	O
tested	O
as	O
blockers	O
of	O
the	O
immunosuppresive	O
activity	O
of	O
dexamethasone	I-TRIVIAL
in	O
rat	O
thymocytes	O
.	O

A	O
new	O
one	O
-	O
pot	O
procedure	O
is	O
described	O
for	O
the	O
preparation	O
of	O
6,19	I-IUPAC
-	I-IUPAC
epithioprogesterone	I-IUPAC
and	O
related	O
compounds	O
by	O
iodocyclization	O
of	O
a	O
19	I-IUPAC
-	I-IUPAC
sulfanylpregn	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ene	I-IUPAC
.	O

Antiimmunosuppresive	O
activity	O
was	O
evaluated	O
by	O
the	O
ability	O
of	O
the	O
different	O
steroids	O
to	O
block	O
dexamethasone	I-TRIVIAL
-	O
mediated	O
apoptosis	O
in	O
thymocytes	O
and	O
dexamethasone	I-TRIVIAL
-	O
mediated	O
inhibition	O
of	O
the	O
NFkappa	O
-	O
B	O
transcription	O
factor	O
activity	O
.	O

DNA	O
fragmentation	O
and	O
annexin	O
V	O
-	O
FITC	O
positive	O
cells	O
were	O
taken	O
as	O
parameters	O
of	O
apoptosis	O
whereas	O
NFkappa	O
-	O
B	O
activity	O
was	O
tested	O
by	O
the	O
expression	O
of	O
the	O
reporter	O
vector	O
kappaB	O
-	O
luciferase	O
by	O
TNF	O
-	O
alpha	O
in	O
Hela	O
cells	O
.	O

21	I-IUPAC
-	I-IUPAC
Hydroxy	I-IUPAC
-	I-IUPAC
6,19	I-IUPAC
-	I-IUPAC
epithioprogesterone	I-IUPAC
S	I-IUPAC
,	I-IUPAC
S	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
had	O
improved	O
activity	O
in	O
both	O
parameters	O
,	O
while	O
21	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
6,19	I-IUPAC
-	I-IUPAC
epithioprogesterone	I-IUPAC
had	O
improved	O
activity	O
only	O
in	O
blocking	O
dexamethasone	I-TRIVIAL
-	O
induced	O
programmed	O
cell	O
death	O
.	O

A	O
number	O
of	O
derivatives	O
structurally	O
related	O
to	O
cirazoline	I-TRIVIAL
(	O
1	O
)	O
were	O
synthesized	O
and	O
studied	O
with	O
the	O
purpose	O
of	O
modulating	O
alpha2	O
-	O
adrenoreceptors	O
selectivity	O
versus	O
both	O
alpha1	O
-	O
adrenoreceptors	O
and	O
I2	O
imidazoline	I-TRIVIAL
binding	O
sites	O
.	O

The	O
most	O
potent	O
alpha2	O
-	O
agonist	O
was	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yloxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazole	I-IUPAC
(	O
7	O
)	O
,	O
whose	O
key	O
pharmacophoric	O
features	O
closely	O
matched	O
those	O
found	O
in	O
the	O
alpha2	O
-	O
agonist	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
exo	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylprop	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
exo	I-IUPAC
-	I-IUPAC
norbornyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxazoline	I-IUPAC
(	O
15	O
)	O
.	O

(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
7	O
was	O
the	O
most	O
potent	O
of	O
the	O
two	O
enantiomers	O
,	O
confirming	O
the	O
stereospecificity	O
of	O
the	O
interaction	O
with	O
alpha2	O
-	O
adrenoreceptors	O
.	O

This	O
eutomer	O
was	O
tested	O
on	O
two	O
algesiometric	O
paradigms	O
and	O
,	O
because	O
of	O
the	O
interaction	O
with	O
alpha2	O
-	O
adrenoreceptors	O
,	O
showed	O
a	O
potent	O
and	O
long	O
-	O
lasting	O
antinociceptive	O
activity	O
,	O
since	O
it	O
was	O
abolished	O
by	O
the	O
selective	O
alpha2	O
-	O
antagonist	O
RX821002	I-TRIVIALVAR
.	O

Tissue	O
and	O
serum	O
levels	O
of	O
principal	O
androgens	I-FAMILY
in	O
benign	O
prostatic	O
hyperplasia	O
and	O
prostate	O
cancer	O
.	O

Androgens	I-FAMILY
are	O
considered	O
to	O
play	O
a	O
substantial	O
role	O
in	O
pathogenesis	O
of	O
both	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
and	O
prostate	O
cancer	O
.	O

The	O
importance	O
of	O
determination	O
of	O
androgen	I-FAMILY
levels	O
in	O
tissue	O
and	O
serum	O
for	O
cancer	O
progression	O
and	O
prognosis	O
has	O
been	O
poorly	O
understood	O
.	O

The	O
aim	O
of	O
study	O
was	O
to	O
find	O
out	O
hormonal	O
differences	O
in	O
both	O
diseases	O
,	O
their	O
correlations	O
between	O
intraprostatic	O
and	O
serum	O
levels	O
and	O
predicted	O
value	O
of	O
their	O
investigation	O
.	O

Testosterone	I-TRIVIAL
,	O
dihydrotestosterone	I-TRIVIAL
,	O
androstenedione	I-TRIVIAL
and	O
also	O
epitestosterone	I-TRIVIAL
were	O
determined	O
in	O
prostate	O
tissue	O
from	O
57	O
patients	O
who	O
underwent	O
transvesical	O
prostatectomy	O
for	O
BPH	O
and	O
121	O
patients	O
after	O
radical	O
prostatectomy	O
for	O
prostate	O
cancer	O
.	O

In	O
75	O
subjects	O
with	O
cancer	O
and	O
51	O
with	O
BPH	O
the	O
serum	O
samples	O
were	O
analyzed	O
for	O
testosterone	I-TRIVIAL
,	O
dihydrotestosterone	I-TRIVIAL
and	O
SHBG	O
.	O

Significantly	O
higher	O
intraprostatic	O
androgen	I-TRIVIAL
concentrations	O
,	O
i.e.	O
8.85	O
+	O
/	O
-	O
6.77	O
versus	O
6.44	O
+	O
/	O
-	O
6.43	O
pmol	O
/	O
g	O
,	O
p	O
<	O
0.01	O
for	O
dihydrotestosterone	I-TRIVIAL
,	O
and	O
4.61	O
+	O
/	O
-	O
7.02	O
versus	O
3.44	O
+	O
/	O
-	O
4.53	O
pmol	O
/	O
g	O
,	O
p	O
<	O
0.05	O
for	O
testosterone	I-TRIVIAL
,	O
respectively	O
,	O
were	O
found	O
in	O
patients	O
with	O
prostate	O
cancer	O
than	O
in	O
BPH	O
.	O

Higher	O
levels	O
in	O
cancer	O
tissue	O
were	O
found	O
also	O
for	O
epitestosterone	I-TRIVIAL
.	O

However	O
,	O
no	O
differences	O
were	O
found	O
in	O
serum	O
levels	O
.	O

Highly	O
significant	O
correlations	O
occurred	O
between	O
all	O
pairs	O
of	O
intraprostatic	O
androgens	I-FAMILY
and	O
also	O
epitestosterone	I-TRIVIAL
as	O
well	O
as	O
between	O
serum	O
testosterone	I-TRIVIAL
and	O
dihydrotestosterone	I-TRIVIAL
(	O
p	O
<	O
0.001	O
)	O
in	O
both	O
BPH	O
and	O
cancer	O
groups	O
.	O

Correlation	O
was	O
not	O
found	O
between	O
corresponding	O
tissue	O
and	O
serum	O
testosterone	I-TRIVIAL
and	O
dihydrotestosterone	I-TRIVIAL
,	O
either	O
in	O
benign	O
or	O
cancer	O
samples	O
.	O

The	O
results	O
point	O
to	O
importance	O
of	O
intraprostatic	O
hormone	O
levels	O
for	O
evaluation	O
of	O
androgen	O
status	O
of	O
patients	O
,	O
contrasting	O
to	O
a	O
low	O
value	O
of	O
serum	O
hormone	O
measurement	O
.	O

XBMP	O
-	O
1B	O
(	O
Xtld	O
)	O
,	O
a	O
Xenopus	O
homolog	O
of	O
dorso	O
-	O
ventral	O
polarity	O
gene	O
in	O
Drosophila	O
,	O
modifies	O
tissue	O
phenotypes	O
of	O
ventral	O
explants	O
.	O

Previously	O
we	O
have	O
isolated	O
a	O
Xenopus	O
cDNA	O
homolog	O
of	O
bone	O
morphogenetic	O
protein	O
-	O
1	O
(	O
XBMP	O
-	O
1A	O
)	O
.	O

In	O
the	O
present	O
report	O
we	O
describe	O
a	O
new	O
cDNA	O
clone	O
called	O
XBMP	O
-	O
1B	O
(	O
or	O
Xtld	O
)	O
from	O
a	O
Xenopus	O
embryonic	O
library	O
.	O

Sequence	O
analysis	O
indicates	O
that	O
these	O
two	O
clones	O
share	O
an	O
indentical	O
N	O
-	O
terminal	O
sequence	O
,	O
including	O
a	O
region	O
of	O
metalloprotease	O
domain	O
,	O
three	O
copies	O
of	O
a	O
repeat	O
first	O
found	O
in	O
complement	O
proteins	O
C1r	O
/	O
s	O
and	O
an	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
-	O
like	O
sequence	O
.	O

XBMP	O
-	O
1B	O
protein	O
has	O
an	O
additional	O
copy	O
of	O
an	O
EGF	O
-	O
like	O
sequence	O
followed	O
by	O
two	O
copies	O
of	O
complement	O
1	O
r	O
/	O
s	O
repeat	O
in	O
the	O
C	O
-	O
terminus	O
.	O

The	O
overall	O
protein	O
structure	O
predicted	O
from	O
the	O
XBMP	O
-	O
1B	O
sequence	O
reveals	O
that	O
it	O
encodes	O
a	O
protein	O
homologous	O
to	O
Drosophila	O
tolloid	O
.	O

Three	O
XBMP	O
-	O
1	O
transcripts	O
(	O
2.9	O
,	O
5.2	O
and	O
6.6	O
kb	O
)	O
were	O
detected	O
by	O
northern	O
blot	O
analysis	O
.	O

However	O
,	O
the	O
2.9	O
kb	O
transcript	O
hybridized	O
specifically	O
with	O
XBMP	O
-	O
1A	O
and	O
the	O
5.2	O
and	O
6.6	O
kb	O
transcripts	O
hybridized	O
with	O
XBMP	O
-	O
1B	O
.	O

In	O
Drosophila	O
,	O
a	O
major	O
function	O
of	O
tolloid	O
is	O
to	O
augment	O
the	O
activity	O
of	O
the	O
decapentaplegic	O
gene	O
product	O
,	O
a	O
close	O
relative	O
of	O
tumor	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
superfamily	O
members	O
,	O
BMP	O
-	O
2/4	O
.	O

Although	O
XBMP	O
-	O
1	O
and	O
XBMP	O
-	O
4	O
are	O
detected	O
in	O
various	O
adult	O
tissues	O
of	O
Xenopus	O
,	O
the	O
expression	O
pattern	O
of	O
these	O
two	O
genes	O
was	O
not	O
tightly	O
correlated	O
.	O

In	O
the	O
embryo	O
,	O
the	O
expression	O
of	O
XBMP	O
-	O
1	O
increased	O
gradually	O
from	O
the	O
morula	O
to	O
the	O
swimming	O
tadpole	O
stages	O
.	O

Injection	O
of	O
XBMP	O
-	O
1B	O
RNA	O
into	O
the	O
ventral	O
blastomeres	O
at	O
the	O
4	O
-	O
cell	O
stage	O
caused	O
an	O
elongation	O
of	O
the	O
ventral	O
marginal	O
zone	O
explants	O
and	O
converted	O
globin	O
-	O
positive	O
blood	O
cells	O
to	O
mesenchymal	O
and	O
muscle	O
tissues	O
at	O
later	O
stages	O
.	O

It	O
was	O
shown	O
that	O
XBMP	O
-	O
1A	O
was	O
less	O
active	O
and	O
a	O
1A	O
mutant	O
lacking	O
the	O
signal	O
sequence	O
was	O
inactive	O
.	O

Further	O
studies	O
revealed	O
that	O
injection	O
of	O
XBMP	O
-	O
1B	O
RNA	O
into	O
the	O
ventral	O
marginal	O
zone	O
induced	O
up	O
-	O
regulation	O
of	O
dorsal	O
marginal	O
zone	O
markers	O
,	O
such	O
as	O
goosecoid	O
and	O
chordin	O
,	O
at	O
the	O
gastrulation	O
stage	O
.	O

These	O
data	O
indicate	O
that	O
XBMP	O
-	O
1	O
may	O
have	O
a	O
role	O
in	O
determining	O
dorso	O
-	O
ventral	O
patterning	O
in	O
Xenopus	O
,	O
but	O
in	O
a	O
different	O
way	O
from	O
the	O
dpp	O
/	O
tolloid	O
system	O
demonstrated	O
in	O
Drosophila	O
.	O

Spiro	O
[	O
isobenzofuran	O
-	O
1	O
(	O
3H	O
)	O
,	O
4'	O
-	O
piperidines	O
]	O
and	O
the	O
corresponding	O
benzofuran	I-TRIVIAL
and	O
benzopyran	I-TRIVIAL
derivatives	B-MODIFIER
have	O
been	O
synthesized	O
and	O
evaluated	O
as	O
sigma	O
ligands	O
.	O

The	O
compounds	O
are	O
related	O
to	O
Lu	I-TRIVIALVAR
28-179	I-TRIVIALVAR
(	O
1'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
)	O
that	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
selective	O
sigma	O
2	O
ligand	O
with	O
affinity	O
in	O
the	O
subnanomolar	O
range	O
.	O

The	O
object	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
structural	O
factors	O
governing	O
sigma	O
1	O
/	O
sigma	O
2	O
affinity	O
and	O
selectivity	O
within	O
this	O
class	O
of	O
compounds	O
.	O

The	O
N	I-PARTIUPAC
-	I-PARTIUPAC
substituent	I-PARTIUPAC
in	O
spiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidines	I-IUPAC
]	I-IUPAC
is	O
highly	O
important	O
,	O
both	O
for	O
affinity	O
and	O
selectivity	O
.	O

Spiropiperidines	I-TRIVIAL
with	O
no	O
or	O
small	O
N	I-PARTIUPAC
-	I-PARTIUPAC
substituents	I-PARTIUPAC
(	O
H	I-SUM
,	O
Me	I-ABBREVIATION
,	O
Et	I-ABBREVIATION
)	O
exert	O
very	O
low	O
affinity	O
for	O
both	O
sigma	O
1	O
and	O
sigma	O
2	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
1	O
,	O
sigma	O
2	O
)	O
&	O
gt	O
;	O
100	O
nM	O
)	O
,	O
whereas	O
medium	O
-	O
sized	O
substituents	O
(	O
e.g.	O
,	O
Pr	I-ABBREVIATION
,	O
Bu	I-ABBREVIATION
,	O
Ph	I-SUM
(	I-SUM
CH2	I-SUM
)	I-SUM
2	I-SUM
)	O
result	O
in	O
potent	O
,	O
but	O
unselective	O
compounds	O
(	O
IC50	O
(	O
sigma	O
1	O
,	O
sigma	O
2	O
)	O
=	O
2-5	O
nM	O
)	O
.	O

Increasing	O
the	O
chain	O
length	O
and	O
the	O
lipophilicity	O
of	O
the	O
N	I-PARTIUPAC
-	I-PARTIUPAC
substituent	I-PARTIUPAC
result	O
in	O
compounds	O
in	O
which	O
high	O
affinity	O
for	O
sigma	O
2	O
binding	O
sites	O
is	O
retained	O
and	O
with	O
selectivity	O
for	O
sigma	O
2	O
vs	O
sigma	O
1	O
binding	O
sites	O
(	O
e.g.	O
,	O
4	I-IUPAC
-	I-IUPAC
cyclohexyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
:	O
IC50	O
-	O
(	O
sigma	O
1	O
)	O
=	O
1.5	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.07	O
nM	O
)	O
.	O

Introduction	O
of	O
substituents	O
in	O
the	O
benzene	I-TRIVIAL
ring	O
of	O
the	O
spiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
ring	O
system	O
of	O
Lu	I-TRIVIAL
28-179	I-TRIVIAL
mainly	O
affects	O
affinity	O
for	O
sigma	O
1	O
binding	O
sites	O
.	O

Compounds	O
with	O
substituents	O
(	O
F	I-SUM
,	O
CF3	I-SUM
)	O
in	O
the	O
4	O
-	O
or	O
7	O
-	O
position	O
of	O
the	O
isobenzofuran	I-TRIVIAL
display	O
high	O
affinity	O
for	O
sigma	O
2	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.5-2	O
nM	O
)	O
and	O
very	O
low	O
affinity	O
for	O
sigma	O
1	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
1	O
)	O
&	O
gt	O
;	O
100	O
nM	O
)	O
.	O

Compounds	O
with	O
substituents	O
(	O
F	I-ABBREVIATION
,	O
CF3	I-ABBREVIATION
,	O
Me	I-ABBREVIATION
)	O
in	O
the	O
5	O
-	O
or	O
6	O
-	O
position	O
of	O
the	O
isobenzofuran	I-TRIVIAL
exert	O
increased	O
affinity	O
for	O
sigma	O
1	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
5-30	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.3-7	O
nM	O
)	O
,	O
thus	O
rendering	O
unselective	O
compounds	O
.	O

Exchanging	O
the	O
isobenzofuran	I-TRIVIAL
moiety	O
of	O
Lu	I-TRIVIALVAR
28-179	I-TRIVIALVAR
with	O
thioisobenzofuran	I-TRIVIAL
,	O
benzofuran	I-IUPAC
,	O
or	O
benzopyran	I-TRIVIAL
also	O
has	O
a	O
pronounced	O
effect	O
on	O
both	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
binding	O
sites	O
.	O

The	O
position	O
of	O
the	O
oxygen	O
atom	O
and	O
the	O
position	O
of	O
the	O
spiroconnection	O
with	O
the	O
4	O
-	O
position	O
of	O
the	O
piperidine	I-TRIVIAL
ring	O
were	O
varied	O
,	O
and	O
only	O
compounds	O
in	O
which	O
both	O
the	O
benzene	I-TRIVIAL
ring	O
and	O
the	O
heteroatom	O
are	O
attached	O
directly	O
to	O
the	O
piperidine	I-TRIVIAL
ring	O
retain	O
high	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
2	O
binding	O
sites	O
(	O
e.g.	O
,	O
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
:	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
53	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.9	O
nM	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Maitotoxin	I-TRIVIAL
-	O
induced	O
calcium	O
entry	O
in	O
human	O
lymphocytes	O
:	O
modulation	O
by	O
yessotoxin	I-TRIVIAL
,	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
channel	O
blockers	O
and	O
kinases	O
.	O

We	O
have	O
studied	O
the	O
effect	O
of	O
the	O
ciguatera	O
-	O
related	O
toxin	O
maitotoxin	I-TRIVIAL
(	O
MTX	I-ABBREVIATION
)	O
on	O
the	O
cytosolic	O
free	O
calcium	I-TRIVIAL
concentration	O
(	O
[	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
]	O
i	O
)	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
loaded	O
with	O
the	O
fluorescent	O
probe	O
Fura2	O
and	O
the	O
regulation	O
of	O
MTX	I-ABBREVIATION
action	O
by	O
different	O
drugs	O
known	O
to	O
interfere	O
in	O
cellular	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
signalling	O
mechanisms	O
and	O
by	O
the	O
marine	O
phycotoxin	O
yessotoxin	I-TRIVIAL
(	O
YTX	I-ABBREVIATION
)	O
.	O

MTX	I-ABBREVIATION
produced	O
a	O
concentration	O
-	O
dependent	O
elevation	O
of	O
[	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
]	O
i	O
in	O
a	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
-	O
containing	O
medium	O
.	O

This	O
effect	O
was	O
stimulated	O
by	O
pretreatment	O
with	O
YTX	I-ABBREVIATION
1	O
microM	O
and	O
NiCl	I-SUM
(	I-SUM
2	I-SUM
)	I-SUM
15	O
microM	O
.	O

The	O
voltage	O
-	O
independent	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
channel	O
antagonist	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
)	I-IUPAC
propoxyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazole	I-IUPAC
hydrochloride	I-IUPAC
(	O
SKF96365	I-TRIVIALVAR
)	O
blocked	O
the	O
MTX	I-ABBREVIATION
-	O
induced	O
[	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
]	O
i	O
elevation	O
,	O
while	O
the	O
L	O
-	O
type	O
channel	O
blocker	O
nifedipine	I-TRIVIAL
had	O
no	O
effect	O
.	O

Pretreatment	O
with	O
NiCl	I-SUM
(	I-SUM
2	I-SUM
)	I-SUM
or	O
nifedipine	I-TRIVIAL
did	O
not	O
modify	O
YTX	I-ABBREVIATION
-	O
induced	O
potentiation	O
of	O
MTX	I-ABBREVIATION
effect	O
,	O
and	O
SKF96365	I-TRIVIAL
-	O
induced	O
inhibition	O
was	O
reduced	O
in	O
the	O
presence	O
of	O
YTX	I-ABBREVIATION
,	O
which	O
suggest	O
different	O
pathways	O
to	O
act	O
on	O
[	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
]	O
i	O
.	O

Preincubation	O
with	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
bromocinnamylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
isoquinolinesulfonamide	I-IUPAC
.	O

2HCl	I-SUM
(	O
H	I-TRIVIALVAR
-	I-TRIVIALVAR
89	I-TRIVIALVAR
)	O
or	O
genistein	I-TRIVIAL
(	O
10	O
microM	O
)	O
also	O
had	O
no	O
effect	O
on	O
the	O
MTX	I-ABBREVIATION
-	O
induced	O
[	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
]	O
i	O
increment	O
.	O

In	O
contrast	O
,	O
the	O
PKC	O
inhibitor	O
bisindolilmaleimide	I-TRIVIAL
I	I-TRIVIAL
(	O
GF109203X	I-TRIVIALVAR
1	O
microM	O
)	O
potentiated	O
the	O
MTX	I-ABBREVIATION
effect	O
,	O
whereas	O
phosphatidylinositol	O
(	O
PI	O
)	O
3	O
-	O
kinase	O
inhibition	O
with	O
wortmannin	I-TRIVIAL
(	O
10	O
nM	O
)	O
reduced	O
the	O
MTX	I-ABBREVIATION
-	O
elicited	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
entry	O
.	O

In	O
summary	O
,	O
MTX	I-ABBREVIATION
produced	O
Ca	I-ABBREVIATION
(	I-ABBREVIATION
2+	I-ABBREVIATION
)	I-ABBREVIATION
influx	O
into	O
human	O
lymphocytes	O
through	O
a	O
SKF96365	I-TRIVIALVAR
-	O
sensitive	O
,	O
nifedipine	I-TRIVIAL
-	O
insensitive	O
pathway	O
.	O

The	O
MTX	I-ABBREVIATION
-	O
induced	O
[	O
Ca	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
]	O
i	O
elevation	O
was	O
stimulated	O
by	O
the	O
marine	O
toxin	O
YTX	I-ABBREVIATION
through	O
a	O
mechanism	O
insensitive	O
to	O
SKF96365	I-TRIVIALVAR
,	O
nifedipine	I-TRIVIAL
or	O
NiCl	I-SUM
(	I-SUM
2	I-SUM
)	I-SUM
.	O

It	O
was	O
also	O
stimulated	O
by	O
the	O
divalent	O
cation	O
Ni	I-SUM
(	I-SUM
2+	I-SUM
)	I-SUM
and	O
PKC	O
inhibition	O
and	O
was	O
partially	O
inhibited	O
by	O
PI	O
3	O
-	O
kinase	O
inhibition	O
.	O

Selective	O
protection	O
of	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxoerythromycin	I-IUPAC
A	I-IUPAC
allowed	O
for	O
elimination	O
of	O
the	O
12	I-PARTIUPAC
-	I-PARTIUPAC
hydroxyl	I-PARTIUPAC
group	I-MODIFIER
to	O
afford	O
a	O
versatile	O
12,21	I-IUPAC
-	I-IUPAC
olefin	I-IUPAC
intermediate	I-MODIFIER
.	O

Further	O
modifications	O
of	O
the	O
intermediate	O
led	O
to	O
the	O
syntheses	O
of	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxo	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
12,21	I-IUPAC
-	I-IUPAC
epoxyerythromycin	I-IUPAC
B	I-IUPAC
,	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxo	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
21	I-IUPAC
-	I-IUPAC
hydroxyerythromycin	I-IUPAC
A	I-IUPAC
,	O
and	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxo	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
21	I-IUPAC
-	I-IUPAC
hydroxyerythromycin	I-IUPAC
B	I-IUPAC
.	O

All	O
three	O
compounds	O
retained	O
antibacterial	O
activity	O
against	O
several	O
organisms	O
normally	O
susceptible	O
to	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxo	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
erythromycin	I-IUPAC
A	I-IUPAC
.	O

However	O
,	O
the	O
21	I-IUPAC
-	I-IUPAC
hydroxylated	I-IUPAC
erythromycin	I-IUPAC
A	I-IUPAC
analogue	I-MODIFIER
was	O
weaker	O
in	O
potency	O
than	O
the	O
corresponding	O
erythromycin	I-TRIVIAL
B	I-TRIVIAL
congener	I-TRIVIAL
and	O
much	O
weaker	O
than	O
the	O
epoxy	I-TRIVIAL
derivative	B-MODIFIER
.	O

This	O
suggests	O
that	O
while	O
substitution	O
of	O
a	O
polar	O
functionality	O
at	O
C	O
-	O
21	O
does	O
not	O
abolish	O
antibacterial	O
activity	O
,	O
introduction	O
of	O
vicinal	O
polar	O
groups	O
at	O
both	O
C	O
-	O
12	O
and	O
C	O
-	O
21	O
may	O
lead	O
to	O
reduction	O
in	O
potency	O
.	O

Nevertheless	O
,	O
these	O
21	O
-	O
functionalized	O
derivatives	O
of	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
erythromycylamine	I-IUPAC
provide	O
an	O
entry	O
into	O
novel	O
analogues	O
of	O
the	O
important	O
macrolide	O
antibiotic	O
erythromycin	I-TRIVIAL
.	O

Serum	O
lipid	I-FAMILY
and	O
leptin	O
concentrations	O
in	O
hypopituitary	O
patients	O
with	O
growth	O
hormone	O
deficiency	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
deficiency	O
on	O
serum	O
lipid	I-FAMILY
and	O
leptin	O
concentrations	O
in	O
hypopituitary	O
patients	O
taking	O
conventional	O
replacement	O
therapy	O
and	O
to	O
determine	O
the	O
relations	O
between	O
leptin	O
and	O
gender	O
and	O
anthropometric	O
and	O
metabolic	O
variables	O
.	O

SUBJECTS	O
:	O
Twenty	O
-	O
one	O
GH	O
deficient	O
adult	O
hypopituitary	O
patients	O
(	O
15	O
women	O
,	O
six	O
men	O
)	O
and	O
21	O
(	O
14	O
women	O
,	O
seven	O
men	O
)	O
age	O
,	O
sex	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
matched	O
healthy	O
controls	O
.	O

MEASUREMENTS	O
:	O
After	O
an	O
overnight	O
fast	O
,	O
anthropometric	O
parameters	O
were	O
measured	O
and	O
body	O
composition	O
was	O
determined	O
by	O
a	O
bioelectrical	O
impedance	O
analyser	O
.	O

Venous	O
blood	O
samples	O
were	O
obtained	O
for	O
the	O
measurements	O
of	O
glucose	I-TRIVIAL
,	O
total	O
cholesterol	I-TRIVIAL
,	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	I-TRIVIAL
,	O
triglyceride	I-FAMILY
,	O
intact	O
insulin	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
(	O
IGF	O
-	O
1	O
)	O
and	O
leptin	O
concentrations	O
.	O

Serum	O
leptin	O
and	O
hormones	O
were	O
analysed	O
by	O
radioimmunoassay	O
.	O

RESULTS	O
:	O
Hypopituitary	O
patients	O
with	O
GH	O
deficiency	O
showed	O
significantly	O
higher	O
triglyceride	I-FAMILY
,	O
total	O
and	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	I-TRIVIAL
and	O
lower	O
HDL	O
cholesterol	I-TRIVIAL
concentrations	O
on	O
conventional	O
replacement	O
therapy	O
.	O

The	O
unfavourable	O
lipid	I-FAMILY
profile	O
was	O
particularly	O
evident	O
in	O
women	O
.	O

Significantly	O
higher	O
leptin	O
concentrations	O
were	O
found	O
in	O
patients	O
compared	O
with	O
healthy	O
controls	O
with	O
similar	O
body	O
fat	O
content	O
(	O
23	O
.	O

5+	O
/	O
-	O
11.8	O
ng	O
/	O
ml	O
vs	O
11.7	O
+	O
/	O
-	O
6.9	O
ng	O
/	O
ml	O
,	O
P	O
=	O
0.01	O
)	O
.	O

This	O
difference	O
remained	O
significant	O
even	O
when	O
leptin	O
values	O
were	O
expressed	O
in	O
relation	O
to	O
fat	O
mass	O
percentage	O
(	O
0.79	O
+	O
/	O
-	O
0.40	O
vs.	O
0.42	O
+	O
/	O
-	O
0.17	O
ng	O
/	O
ml	O
%	O
,	O
P	O
<	O
0.05	O
)	O
and	O
fat	O
mass	O
kg	O
(	O
1.32	O
+	O
/	O
-	O
0.81	O
vs	O
0.66	O
+	O
/	O
-	O
0.30	O
ng	O
/	O
ml	O
kg	O
,	O
P	O
<	O
0	O
.	O

05	O
)	O
.	O

Significant	O
positive	O
correlations	O
were	O
observed	O
between	O
leptin	O
concentrations	O
and	O
body	O
fat	O
percentage	O
and	O
age	O
in	O
the	O
control	O
group	O
.	O

In	O
patients	O
the	O
sole	O
significant	O
relation	O
between	O
leptin	O
and	O
study	O
parameters	O
was	O
the	O
positive	O
correlation	O
observed	O
between	O
leptin	O
and	O
total	O
cholesterol	I-TRIVIAL
concentrations	O
.	O

Serum	O
leptin	O
concentrations	O
were	O
significantly	O
higher	O
in	O
women	O
than	O
men	O
in	O
the	O
control	O
group	O
,	O
but	O
not	O
in	O
the	O
patients	O
.	O

No	O
significant	O
gender	O
difference	O
was	O
observed	O
when	O
leptin	O
concentrations	O
were	O
expressed	O
in	O
relation	O
to	O
fat	O
mass	O
(	O
percentage	O
and	O
kg	O
)	O
.	O

CONCLUSION	O
:	O
Growth	O
hormone	O
deficient	O
hypopituitary	O
patients	O
(	O
particularly	O
women	O
)	O
on	O
conventional	O
replacement	O
therapy	O
have	O
a	O
more	O
atherogenic	O
lipid	I-FAMILY
profile	O
.	O

Leptin	O
concentrations	O
are	O
increased	O
in	O
GH	O
deficient	O
adults	O
even	O
after	O
adjustment	O
for	O
percentage	O
body	O
fat	O
and	O
body	O
fat	O
mass	O
(	O
kg	O
)	O
.	O

Although	O
the	O
nature	O
of	O
our	O
data	O
does	O
not	O
allow	O
us	O
to	O
draw	O
any	O
conclusions	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
increased	O
leptin	O
concentrations	O
in	O
GH	O
deficiency	O
,	O
decreased	O
central	O
sensitivity	O
to	O
leptin	O
and	O
increased	O
leptin	O
production	O
from	O
per	O
unit	O
fat	O
mass	O
,	O
or	O
alterations	O
in	O
leptin	O
clearance	O
,	O
might	O
be	O
operative	O
.	O

Conversion	O
of	O
the	O
8	I-IUPAC
-	I-IUPAC
phenolic	I-IUPAC
1,2,3,4,5,6	I-IUPAC
-	I-IUPAC
hexahydro	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
methano	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzazocines	I-IUPAC
to	O
the	O
corresponding	O
8	I-PARTIUPAC
-	I-PARTIUPAC
thiophenolic	I-PARTIUPAC
analogues	I-MODIFIER
was	O
achieved	O
by	O
three	O
different	O
routes	O
.	O

Diazotization	O
of	O
8	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
methano	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzazocine	I-IUPAC
(	O
2	O
)	O
followed	O
by	O
the	O
reaction	O
with	O
CH3SNa	I-SUM
afforded	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4,5,6	I-IUPAC
-	I-IUPAC
hexahydro	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
methano	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzazocine	I-IUPAC
(	O
3	O
)	O
.	O

Another	O
route	O
using	O
Grewe	O
cyclization	O
was	O
also	O
examined	O
for	O
the	O
synthesis	O
of	O
3	O
.	O

As	O
the	O
most	O
effective	O
route	O
,	O
Newman	O
-	O
Kwart	O
rearrangement	O
of	O
benzazocines	O
was	O
selected	O
and	O
closely	O
investigated	O
.	O

8	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
N	I-PARTIUPAC
,	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
Dimethylthiocarbamoyl	I-PARTIUPAC
)	I-PARTIUPAC
oxy	I-PARTIUPAC
derivatives	I-MODIFIER
(	O
6a	O
-	O
e	O
)	O
rearranged	O
to	O
8	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
N	I-PARTIUPAC
,	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
dimethylcarbamoyl	I-PARTIUPAC
)	I-PARTIUPAC
thio	I-PARTIUPAC
derivatives	I-MODIFIER
(	O
7a	O
-	O
e	O
)	O
in	O
good	O
yields	O
.	O

Reductive	O
cleavage	O
of	O
7a	O
-	O
e	O
and	O
subsequent	O
methylation	O
or	O
acylations	O
gave	O
the	O
title	O
compounds	O
(	O
3	O
,	O
8-24	O
)	O
.	O

Although	O
analgesic	O
activities	O
of	O
sulfur	O
-	O
containing	O
benzazocines	I-FAMILY
decreased	O
compared	O
to	O
the	O
corresponding	O
hydroxy	I-PARTIUPAC
compounds	B-MODIFIER
,	O
the	O
N	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
derivative	I-MODIFIER
(	O
S	I-IUPAC
-	I-IUPAC
metazocine	I-IUPAC
,	O
8	O
)	O
showed	O
potent	O
analgesic	O
activity	O
.	O

N	O
,	O
O	O
-	O
Dicarbethoxy	O
-	O
4	O
-	O
chlorobenzenesulfohydroxamate	O
(	O
1c	O
)	O
and	O
O	I-IUPAC
-	I-IUPAC
carbethoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
hydroxysaccharin	I-IUPAC
(	O
6	O
)	O
,	O
both	O
potential	O
carbethoxylating	O
agents	O
,	O
inhibited	O
yeast	O
aldehyde	O
dehydrogenase	O
(	O
AlDH	O
)	O
with	O
IC50	O
's	O
of	O
24	O
and	O
56	O
microM	O
,	O
respectively	O
.	O

The	O
esterase	O
activity	O
of	O
the	O
enzyme	O
was	O
commensurably	O
inhibited	O
.	O

AlDH	O
activity	O
was	O
only	O
partially	O
restored	O
on	O
incubation	O
with	O
mercaptoethanol	I-TRIVIAL
(	O
20	O
mM	O
)	O
for	O
1	O
h	O
.	O

On	O
incubation	O
with	O
rat	O
plasma	O
,	O
1c	O
liberated	O
nitroxyl	I-TRIVIAL
,	O
a	O
potent	O
inhibitor	O
of	O
AlDH	O
.	O

Under	O
the	O
same	O
conditions	O
,	O
nitroxyl	I-TRIVIAL
generation	O
from	O
6	O
was	O
minimal	O
,	O
a	O
result	O
compatible	O
with	O
a	O
previous	O
observation	O
that	O
nitroxyl	I-TRIVIAL
generation	O
from	O
N	I-IUPAC
-	I-IUPAC
hydroxysaccharin	I-IUPAC
(	O
7	O
)	O
,	O
the	O
product	O
of	O
the	O
hydrolysis	O
of	O
the	O
carbethoxy	I-PARTIUPAC
group	B-MODIFIER
of	O
6	O
,	O
was	O
minimal	O
at	O
physiological	O
pH	O
.	O

Since	O
chemical	O
carbethoxylating	O
agents	O
represented	O
by	O
the	O
O	I-IUPAC
-	I-IUPAC
carbethoxylated	I-IUPAC
N	I-IUPAC
-	I-IUPAC
hydroxyphthalimide	I-IUPAC
,	O
1	I-IUPAC
-	I-IUPAC
hydroxybenzotriazole	I-IUPAC
,	O
and	O
N	I-IUPAC
-	I-IUPAC
hydroxysuccinimide	I-IUPAC
(	O
8	O
,	O
9	O
,	O
and	O
10	O
,	O
respectively	O
)	O
likewise	O
inhibited	O
yeast	O
AlDH	O
,	O
albeit	O
with	O
IC50	O
's	O
1	O
order	O
of	O
magnitude	O
higher	O
,	O
we	O
postulate	O
that	O
1c	O
and	O
6	O
act	O
as	O
irreversible	O
inhibitors	O
of	O
AlDH	O
by	O
carbethoxylating	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
.	O

At	O
physiological	O
pH	O
,	O
the	O
spatial	O
arrangement	O
of	O
the	O
three	O
charges	O
of	O
DL	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ylglycine	I-IUPAC
(	O
5	O
)	O
could	O
be	O
viewed	O
as	O
similar	O
to	O
those	O
found	O
in	O
certain	O
conformations	O
of	O
the	O
two	O
excitatory	O
amino	O
acids	O
(	O
EAAs	O
)	O
-	O
-	O
aspartic	I-PARTIUPAC
and	O
glutamic	I-IUPAC
acids	I-IUPAC
.	O

Given	O
significant	O
binding	O
to	O
one	O
or	O
more	O
EAA	O
receptors	O
,	O
5	O
would	O
offer	O
unique	O
modeling	O
and	O
perhaps	O
biological	O
opportunities	O
.	O

We	O
have	O
previously	O
shown	O
it	O
to	O
be	O
the	O
most	O
potent	O
NMDA	I-ABBREVIATION
agonist	O
known	O
,	O
with	O
a	O
unique	O
and	O
marked	O
in	O
vitro	O
neutrotoxicity	O
at	O
depolarizing	O
concentrations	O
.	O

Now	O
we	O
report	O
the	O
details	O
required	O
for	O
its	O
synthesis	O
,	O
together	O
with	O
its	O
potency	O
and	O
efficacy	O
in	O
two	O
assays	O
of	O
functional	O
activation	O
of	O
the	O
NMDA	O
receptor	O
,	O
namely	O
agonist	O
-	O
influenced	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
MK801	I-IUPAC
binding	O
and	O
agonist	O
-	O
induced	O
release	O
of	O
the	O
neurotransmitter	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
norepinephrine	I-IUPAC
from	O
brain	O
slices	O
.	O

In	O
both	O
these	O
assays	O
DL	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ylglycine	I-IUPAC
proved	O
to	O
be	O
more	O
potent	O
and	O
efficacious	O
than	O
NMDA	I-ABBREVIATION
and	O
cis	I-IUPAC
-	I-IUPAC
methanoglutamate	I-IUPAC
.	O

It	O
was	O
more	O
potent	O
than	O
,	O
and	O
equally	O
efficacious	O
to	O
,	O
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
in	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
MK801	I-IUPAC
binding	O
.	O

The	O
structural	O
features	O
of	O
5	O
may	O
well	O
reflect	O
optimal	O
agonist	O
interaction	O
at	O
the	O
NMDA	O
receptor	O
site	O
.	O

(	O
We	O
considered	O
the	O
possibility	O
that	O
some	O
decarboxylation	O
of	O
DL	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ylglycine	I-IUPAC
may	O
have	O
occurred	O
during	O
testing	O
.	O

This	O
would	O
give	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
tetrazole	I-IUPAC
(	O
13	O
)	O
,	O
the	O
tetrazole	I-IUPAC
acid	I-IUPAC
analog	I-MODIFIER
of	O
glycine	I-TRIVIAL
;	O
and	O
glycine	I-TRIVIAL
is	O
involved	O
in	O
NMDA	O
receptor	O
activation	O
.	O

Compound	O
13	O
does	O
not	O
affect	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
glycine	I-IUPAC
binding	O
at	O
the	O
strychnine	I-TRIVIAL
-	O
insensitive	O
glycine	I-TRIVIAL
binding	O
site	O
,	O
and	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
MK801	I-IUPAC
binding	O
studies	O
showed	O
that	O
the	O
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
tetrazole	I-IUPAC
,	O
even	O
if	O
is	O
formed	O
,	O
would	O
probably	O
have	O
no	O
effect	O
on	O
the	O
activity	O
of	O
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ylglycine	I-IUPAC
at	O
the	O
NMDA	O
receptor	O
.	O

Oribatid	O
Mite	O
Communities	O
in	O
the	O
Canopy	O
of	O
Montane	O
Abies	O
amabilis	O
and	O
Tsuga	O
heterophylla	O
Trees	O
on	O
Vancouver	O
Island	O
,	O
British	O
Columbia	O
.	O

To	O
study	O
the	O
oribatid	O
mite	O
community	O
inhabiting	O
microhabitats	O
in	O
the	O
canopy	O
of	O
montane	O
Abies	O
amabilis	O
[	O
(	O
Douglas	O
ex	O
D	O
.	O

Don	O
)	O
Lindl	O
.	O

]	O
and	O
Tsuga	O
heterophylla	O
[	O
(	O
Raf	O
.	O

)	O
Sarg	O
]	O
tree	O
species	O
across	O
five	O
elevational	O
sites	O
,	O
we	O
collected	O
180	O
branch	O
tips	O
and	O
180	O
foliose	O
/	O
crustose	O
lichen	O
samples	O
over	O
three	O
time	O
periods	O
.	O

Thirty	O
-	O
three	O
species	O
of	O
oribatid	O
mites	O
were	O
identified	O
from	O
the	O
study	O
area	O
.	O

Mite	O
species	O
richness	O
and	O
abundance	O
was	O
significantly	O
affected	O
by	O
microhabitat	O
,	O
and	O
this	O
association	O
was	O
independent	O
of	O
sampling	O
time	O
.	O

At	O
the	O
microhabitat	O
scale	O
,	O
distinct	O
species	O
assemblages	O
were	O
associated	O
with	O
lichen	O
and	O
branch	O
tip	O
habitats	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
,	O
tree	O
species	O
.	O

Conifer	O
specificity	O
was	O
most	O
apparent	O
in	O
the	O
closely	O
related	O
species	O
of	O
Jugatala	O
,	O
where	O
Jugatala	O
tuberosa	O
Ewing	O
was	O
only	O
found	O
on	O
branch	O
tips	O
from	O
A	O
.	O

amabilis	O
and	O
Jugatala	O
sp	O
.	O

was	O
primarily	O
found	O
on	O
branch	O
tips	O
from	O
T	O
.	O

heterophylla	O
.	O

Microhabitat	O
specificity	O
was	O
most	O
pronounced	O
in	O
Dendrozetes	O
sp	O
.	O

where	O
most	O
individuals	O
were	O
found	O
on	O
branch	O
tips	O
and	O
Anachiperia	O
geminus	O
Lindo	O
et	O
al.	O
that	O
occurred	O
primarily	O
on	O
lichens	O
.	O

Principal	O
components	O
analysis	O
of	O
oribatid	O
mite	O
community	O
composition	O
further	O
showed	O
a	O
high	O
degree	O
of	O
association	O
with	O
microhabitat	O
and	O
tree	O
species	O
.	O

Habitat	O
profiles	O
are	O
difficult	O
to	O
discern	O
for	O
many	O
species	O
because	O
tree	O
,	O
microhabitat	O
,	O
and	O
elevation	O
preferences	O
confound	O
distribution	O
patterns	O
.	O

Given	O
the	O
significant	O
tree	O
-	O
microhabitat	O
associations	O
in	O
species	O
composition	O
in	O
this	O
montane	O
canopy	O
study	O
,	O
we	O
suggest	O
that	O
sampling	O
multiple	O
microhabitats	O
across	O
elevations	O
to	O
look	O
for	O
patterns	O
in	O
community	O
structure	O
offers	O
opportunities	O
to	O
explicitly	O
test	O
organizing	O
principles	O
in	O
community	O
ecology	O
.	O

Tinnitus	O
and	O
brain	O
MRI	O
findings	O
in	O
Japanese	O
elderly	O
.	O

Conclusion	O
.	O

There	O
is	O
evidence	O
of	O
an	O
inverse	O
association	O
between	O
cerebral	O
infarction	O
and	O
tinnitus	O
in	O
this	O
study	O
.	O

The	O
effects	O
of	O
cerebral	O
infarction	O
on	O
tinnitus	O
could	O
be	O
explained	O
by	O
a	O
neurophysiological	O
model	O
of	O
tinnitus	O
.	O

Objectives	O
.	O

We	O
examined	O
the	O
relationship	O
between	O
tinnitus	O
and	O
brain	O
MRI	O
findings	O
including	O
cerebral	O
infarction	O
,	O
brain	O
atrophy	O
,	O
ventricular	O
dilatation	O
,	O
and	O
white	O
matter	O
lesions	O
.	O

Subjects	O
and	O
methods	O
.	O

This	O
was	O
a	O
cross	O
-	O
sectional	O
population	O
-	O
based	O
study	O
of	O
2193	O
subjects	O
aged	O
41-82	O
years	O
living	O
in	O
Aichi	O
prefecture	O
,	O
Japan	O
.	O

Detailed	O
questionnaires	O
,	O
pure	O
tone	O
audiometry	O
,	O
and	O
brain	O
MRI	O
were	O
performed	O
.	O

Results	O
.	O

After	O
adjusting	O
for	O
potential	O
confounders	O
in	O
a	O
multiple	O
logistic	O
analysis	O
,	O
cerebral	O
infarction	O
was	O
inversely	O
associated	O
with	O
tinnitus	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0.649	O
,	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
0.477-0.884	O
)	O
.	O

Cerebral	O
infarctions	O
of	O
the	O
basal	O
ganglia	O
(	O
OR	O
=	O
0.542	O
)	O
,	O
thalamus	O
(	O
OR	O
=	O
0.441	O
)	O
,	O
and	O
pons	O
(	O
OR	O
=	O
0.319	O
)	O
were	O
especially	O
associated	O
with	O
tinnitus	O
.	O

Brain	O
atrophy	O
,	O
ventricular	O
dilatation	O
,	O
and	O
white	O
matter	O
lesions	O
had	O
no	O
significant	O
effects	O
on	O
the	O
prevalence	O
of	O
tinnitus	O
.	O

A	O
neural	O
network	O
-	O
based	O
method	O
for	O
risk	O
factor	O
analysis	O
of	O
West	O
Nile	O
virus	O
.	O

There	O
is	O
a	O
lack	O
of	O
knowledge	O
about	O
which	O
risk	O
factors	O
are	O
more	O
important	O
in	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
transmission	O
and	O
risk	O
magnitude	O
.	O

A	O
better	O
understanding	O
of	O
the	O
risk	O
factors	O
is	O
of	O
great	O
help	O
in	O
developing	O
effective	O
new	O
technologies	O
and	O
appropriate	O
prevention	O
strategies	O
for	O
WNV	O
infection	O
.	O

A	O
contribution	O
analysis	O
of	O
all	O
risk	O
factors	O
in	O
WNV	O
infection	O
would	O
identify	O
those	O
major	O
risk	O
factors	O
.	O

Based	O
on	O
the	O
identified	O
major	O
risk	O
factors	O
,	O
measures	O
to	O
control	O
WNV	O
proliferation	O
could	O
be	O
directed	O
toward	O
those	O
significant	O
risk	O
factors	O
,	O
thus	O
improving	O
the	O
effectiveness	O
and	O
efficiency	O
in	O
developing	O
WNV	O
control	O
and	O
prevention	O
strategies	O
.	O

Neural	O
networks	O
have	O
many	O
generally	O
accepted	O
advantages	O
over	O
conventional	O
analytical	O
techniques	O
,	O
for	O
instance	O
,	O
ability	O
to	O
automatically	O
learn	O
the	O
relationship	O
between	O
the	O
inputs	O
and	O
outputs	O
from	O
training	O
data	O
,	O
powerful	O
generalization	O
ability	O
,	O
and	O
capability	O
of	O
handling	O
nonlinear	O
interactions	O
.	O

In	O
this	O
article	O
,	O
a	O
neural	O
network	O
model	O
was	O
developed	O
for	O
analysis	O
of	O
risk	O
factors	O
in	O
WNV	O
infection	O
.	O

To	O
reveal	O
the	O
relative	O
contribution	O
of	O
the	O
input	O
variables	O
,	O
the	O
neural	O
network	O
was	O
trained	O
using	O
an	O
algorithm	O
called	O
structural	O
learning	O
with	O
forgetting	O
.	O

During	O
the	O
learning	O
,	O
weak	O
neural	O
connections	O
are	O
forced	O
to	O
fade	O
away	O
while	O
a	O
skeletal	O
network	O
with	O
strong	O
connections	O
emerges	O
.	O

The	O
significant	O
risk	O
factors	O
can	O
be	O
identified	O
by	O
analyzing	O
this	O
skeletal	O
network	O
.	O

The	O
proposed	O
approach	O
is	O
tested	O
with	O
the	O
dead	O
bird	O
surveillance	O
data	O
in	O
Ontario	O
,	O
Canada	O
.	O

The	O
results	O
demonstrate	O
the	O
effectiveness	O
of	O
the	O
proposed	O
approach	O
.	O

Involvement	O
of	O
the	O
incudostapedial	O
joint	O
anomaly	O
in	O
conductive	O
deafness	O
.	O

Conclusion	O
.	O

The	O
outcome	O
of	O
surgery	O
depends	O
on	O
complexities	O
of	O
middle	O
ear	O
anomalies	O
and	O
definite	O
diagnosis	O
can	O
only	O
be	O
achieved	O
during	O
exploratory	O
tympanotomy	O
.	O

We	O
must	O
be	O
aware	O
that	O
the	O
pathology	O
of	O
the	O
congenital	O
ossicular	O
anomalies	O
is	O
variable	O
and	O
careful	O
surgery	O
is	O
needed	O
for	O
hearing	O
improvement	O
.	O

Objective	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
congenital	O
ossicular	O
malformation	O
.	O

Subjects	O
and	O
methods	O
.	O

Fifteen	O
cases	O
of	O
ossicular	O
anomalies	O
without	O
external	O
ear	O
malformation	O
were	O
studied	O
.	O

The	O
anomaly	O
of	O
the	O
incus	O
-	O
stapes	O
complex	O
was	O
the	O
most	O
frequent	O
.	O

There	O
were	O
two	O
cases	O
of	O
fused	O
incudostapedial	O
(	O
IS	O
)	O
joint	O
,	O
which	O
is	O
an	O
extremely	O
rare	O
occurrence	O
.	O

Case	O
1	O
was	O
a	O
33	O
-	O
year	O
-	O
old	O
man	O
,	O
in	O
whom	O
otosclerosis	O
was	O
suspected	O
and	O
exploratory	O
tympanotomy	O
was	O
performed	O
.	O

The	O
IS	O
joint	O
was	O
fused	O
,	O
and	O
the	O
stapes	O
was	O
immobile	O
.	O

Small	O
fenestra	O
stapedectomy	O
was	O
performed	O
.	O

In	O
case	O
2	O
,	O
a	O
52	O
-	O
year	O
-	O
old	O
woman	O
,	O
otosclerosis	O
was	O
also	O
suspected	O
and	O
exploratory	O
tympanotomy	O
was	O
performed	O
.	O

The	O
IS	O
joint	O
was	O
fused	O
and	O
the	O
incus	O
was	O
fixed	O
.	O

After	O
the	O
long	O
process	O
of	O
the	O
incus	O
was	O
cut	O
,	O
the	O
stapes	O
became	O
mobile	O
.	O

However	O
,	O
since	O
the	O
incus	O
remained	O
immobile	O
,	O
it	O
was	O
removed	O
and	O
was	O
placed	O
on	O
the	O
stapes	O
.	O

In	O
both	O
cases	O
,	O
the	O
hearing	O
improved	O
after	O
surgery	O
.	O

The	O
averaged	O
hearing	O
gain	O
of	O
15	O
cases	O
was	O
28.8	O
dB	O
.	O

Combination	O
of	O
Bernouilli	O
effect	O
producing	O
maneuver	O
-	O
induced	O
pharyngeal	O
narrowing	O
rate	O
with	O
body	O
mass	O
index	O
as	O
predictive	O
tool	O
for	O
obstructive	O
sleep	O
apnea	O
syndrome	O
.	O

Conclusions	O
.	O

It	O
is	O
suggested	O
that	O
the	O
combination	O
of	O
the	O
pharyngeal	O
narrowing	O
rate	O
during	O
the	O
Bernouilli	O
effect	O
producing	O
maneuver	O
(	O
BEPM	O
)	O
with	O
the	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
might	O
be	O
a	O
promising	O
predictive	O
method	O
for	O
obstructive	O
sleep	O
apnea	O
syndrome	O
(	O
OSAS	O
)	O
.	O

Objectives	O
.	O

An	O
attempt	O
was	O
made	O
to	O
clarify	O
the	O
possibility	O
that	O
the	O
dynamic	O
narrowing	O
of	O
the	O
pharynx	O
evaluated	O
by	O
nasopharyngoscopy	O
with	O
BEPM	O
,	O
a	O
forced	O
inspiration	O
through	O
the	O
nose	O
with	O
the	O
mouth	O
closed	O
,	O
might	O
be	O
a	O
reliable	O
clinical	O
daytime	O
predictor	O
for	O
identifying	O
patients	O
at	O
risk	O
of	O
developing	O
OSAS	O
.	O

Subjects	O
and	O
methods	O
.	O

Subjects	O
were	O
57	O
patients	O
complaining	O
of	O
snoring	O
and	O
sleepiness	O
during	O
daytime	O
.	O

Endoscopic	O
images	O
of	O
the	O
retropalatal	O
pharynx	O
were	O
obtained	O
and	O
their	O
area	O
was	O
measured	O
by	O
NIH	O
imaging	O
.	O

The	O
pharyngeal	O
narrowing	O
rate	O
during	O
quiet	O
nasal	O
breathing	O
and	O
that	O
during	O
BEPM	O
were	O
compared	O
to	O
assess	O
pharyngeal	O
dynamics	O
.	O

To	O
increase	O
the	O
sensitivity	O
of	O
this	O
method	O
,	O
BMI	O
was	O
added	O
to	O
the	O
pharyngeal	O
narrowing	O
rate	O
during	O
BEPM	O
.	O

Results	O
.	O

The	O
criterion	O
of	O
BEPM	O
at	O
a	O
cut	O
-	O
off	O
value	O
of	O
50%	O
with	O
BMI	O
at	O
a	O
cut	O
-	O
off	O
value	O
of	O
25	O
kg	O
/	O
m	O
(	O
2	O
)	O
achieved	O
a	O
sensitivity	O
of	O
93%	O
,	O
while	O
the	O
specificity	O
was	O
67%	O
in	O
differentiating	O
simple	O
snorers	O
from	O
OSAS	O
patients	O
(	O
apnea	O
index	O
>	O
5	O
)	O
.	O

In	O
addition	O
,	O
the	O
likelihood	O
ratio	O
of	O
the	O
method	O
was	O
found	O
to	O
be	O
2.81	O
.	O

Frequency	O
and	O
bases	O
of	O
abnormal	O
performance	O
by	O
healthy	O
adults	O
on	O
neuropsychological	O
testing	O
.	O

The	O
frequency	O
and	O
determinants	O
of	O
abnormal	O
test	O
performance	O
by	O
normal	O
individuals	O
are	O
critically	O
important	O
to	O
clinical	O
inference	O
.	O

Here	O
we	O
compare	O
two	O
approaches	O
to	O
predicting	O
rates	O
of	O
abnormal	O
test	O
performance	O
among	O
healthy	O
individuals	O
with	O
the	O
rates	O
actually	O
shown	O
by	O
327	O
neurologically	O
normal	O
adults	O
aged	O
18-92	O
years	O
.	O

We	O
counted	O
how	O
many	O
participants	O
produced	O
abnormal	O
scores	O
,	O
defined	O
by	O
three	O
different	O
cutoffs	O
with	O
test	O
batteries	O
of	O
varied	O
length	O
,	O
and	O
the	O
number	O
of	O
abnormal	O
scores	O
they	O
produced	O
.	O

Observed	O
rates	O
generally	O
were	O
closer	O
to	O
predictions	O
based	O
on	O
a	O
series	O
of	O
Monte	O
Carlo	O
simulations	O
than	O
on	O
the	O
binomial	O
model	O
.	O

They	O
increased	O
with	O
the	O
number	O
of	O
tests	O
administered	O
,	O
decreased	O
as	O
more	O
stringent	O
cutoffs	O
were	O
used	O
to	O
identify	O
abnormality	O
,	O
varied	O
with	O
the	O
degree	O
of	O
correlation	O
among	O
test	O
scores	O
,	O
and	O
depended	O
on	O
individual	O
differences	O
in	O
age	O
,	O
education	O
,	O
race	O
,	O
sex	O
,	O
and	O
estimated	O
premorbid	O
IQ	O
.	O

Adjusting	O
scores	O
for	O
demographic	O
variables	O
and	O
premorbid	O
IQ	O
did	O
not	O
reduce	O
rates	O
of	O
abnormal	O
performance	O
.	O

However	O
,	O
it	O
eliminated	O
the	O
contribution	O
of	O
these	O
variables	O
to	O
rates	O
of	O
abnormal	O
test	O
performance	O
.	O

These	O
findings	O
raise	O
fundamental	O
questions	O
about	O
the	O
nature	O
and	O
interpretation	O
of	O
abnormal	O
test	O
performance	O
by	O
normal	O
,	O
healthy	O
adults	O
.	O

Is	O
laparoscopy	O
dying	O
for	O
radical	O
prostatectomy	O
?	O
Training	O
in	O
laparoscopic	O
urology	O
,	O
extensive	O
experimental	O
work	O
,	O
and	O
dedicated	O
surgical	O
performance	O
constitute	O
the	O
foundation	O
of	O
advanced	O
laparoscopic	O
urology	O
,	O
which	O
is	O
currently	O
a	O
reasonable	O
surgical	O
option	O
in	O
pediatrics	O
,	O
reconstructive	O
surgery	O
,	O
and	O
oncology	O
.	O

This	O
article	O
discusses	O
topics	O
related	O
to	O
laparoscopic	O
approaches	O
for	O
radical	O
prostatectomy	O
,	O
focusing	O
on	O
their	O
introduction	O
,	O
development	O
,	O
accomplishments	O
,	O
and	O
current	O
standards	O
and	O
future	O
goals	O
for	O
the	O
minimally	O
invasive	O
treatment	O
of	O
urologic	O
diseases	O
.	O

We	O
highlight	O
the	O
dynamic	O
status	O
of	O
the	O
laparoscopic	O
approach	O
for	O
radical	O
prostatectomy	O
(	O
pure	O
or	O
robotic	O
-	O
assisted	O
)	O
that	O
constitutes	O
one	O
of	O
the	O
most	O
rapidly	O
evolving	O
fields	O
in	O
urology	O
.	O

Quantitative	O
magnetic	O
resonance	O
image	O
analysis	O
of	O
the	O
cerebellum	O
in	O
macrocephalic	O
and	O
normocephalic	O
children	O
and	O
adults	O
with	O
autism	O
.	O

A	O
detailed	O
morphometric	O
analysis	O
of	O
the	O
cerebellum	O
in	O
autism	O
with	O
and	O
without	O
macrocephaly	O
.	O

Four	O
subject	O
groups	O
(	O
N	O
=	O
65	O
;	O
male	O
;	O
IQs	O
>	O
or	O
=	O
65	O
;	O
age	O
7	O
to	O
26	O
years	O
)	O
were	O
studied	O
with	O
quantitative	O
MRI	O
;	O
normocephalic	O
and	O
macrocephalic	O
individuals	O
with	O
autism	O
without	O
mental	O
retardation	O
were	O
compared	O
to	O
normocephalic	O
and	O
benign	O
macrocephalic	O
typically	O
developing	O
individuals	O
.	O

Total	O
cerebellum	O
volumes	O
and	O
surface	O
areas	O
of	O
four	O
lobular	O
midsagittal	O
groups	O
were	O
measured	O
.	O

Independent	O
t	O
-	O
tests	O
between	O
autism	O
and	O
control	O
subjects	O
matched	O
for	O
head	O
size	O
revealed	O
no	O
significant	O
differences	O
.	O

Multivariate	O
analyses	O
of	O
variance	O
were	O
also	O
performed	O
,	O
using	O
the	O
diagnostic	O
group	O
as	O
the	O
fixed	O
factor	O
,	O
cerebellar	O
measures	O
as	O
the	O
dependent	O
variables	O
and	O
total	O
intracranial	O
volume	O
,	O
total	O
brain	O
volume	O
,	O
age	O
,	O
verbal	O
IQ	O
,	O
and	O
performance	O
IQ	O
as	O
covariates	O
.	O

No	O
significant	O
differences	O
were	O
found	O
;	O
however	O
,	O
a	O
trend	O
was	O
noted	O
in	O
which	O
macrocephalic	O
individuals	O
with	O
autism	O
consistently	O
exhibited	O
slightly	O
smaller	O
cerebellar	O
volume	O
or	O
surface	O
area	O
when	O
compared	O
to	O
individuals	O
with	O
benign	O
macrocephaly	O
.	O

In	O
autism	O
,	O
with	O
and	O
without	O
macrocephaly	O
,	O
cerebellar	O
structures	O
were	O
found	O
to	O
be	O
proportional	O
to	O
head	O
size	O
and	O
did	O
not	O
differ	O
from	O
typically	O
developing	O
subjects	O
.	O

Worker	O
size	O
in	O
the	O
formosan	O
subterranean	O
termite	O
in	O
relation	O
to	O
colony	O
breeding	O
structure	O
as	O
inferred	O
from	O
molecular	O
markers	O
.	O

The	O
Formosan	O
subterranean	O
termite	O
,	O
Coptotermes	O
formosanus	O
Shiraki	O
,	O
is	O
an	O
invasive	O
species	O
that	O
originated	O
in	O
China	O
and	O
has	O
been	O
introduced	O
to	O
Hawaii	O
and	O
the	O
U	O
.	O

S	O
.	O

mainland	O
.	O

Colonies	O
are	O
headed	O
either	O
by	O
a	O
pair	O
of	O
reproductives	O
(	O
simple	O
families	O
)	O
or	O
by	O
varying	O
numbers	O
of	O
inbreeding	O
reproductives	O
(	O
extended	O
families	O
)	O
,	O
and	O
therefore	O
have	O
variable	O
degrees	O
of	O
inbreeding	O
.	O

Worker	O
size	O
also	O
varies	O
among	O
colonies	O
of	O
Formosan	O
termites	O
.	O

We	O
tested	O
whether	O
variation	O
in	O
worker	O
size	O
can	O
be	O
explained	O
by	O
the	O
breeding	O
system	O
.	O

Workers	O
were	O
collected	O
from	O
colonies	O
from	O
three	O
geographically	O
separated	O
populations	O
(	O
China	O
,	O
Hawaii	O
,	O
and	O
Louisiana	O
)	O
,	O
and	O
body	O
weight	O
and	O
head	O
size	O
were	O
measured	O
.	O

Microsatellite	O
genotyping	O
was	O
used	O
to	O
establish	O
whether	O
colonies	O
were	O
simple	O
or	O
extended	O
families	O
and	O
to	O
determine	O
the	O
heterozygosity	O
of	O
workers	O
and	O
their	O
degree	O
of	O
inbreeding	O
relative	O
to	O
their	O
colony	O
(	O
F	O
(	O
IC	O
)	O
,	O
sensitive	O
to	O
the	O
number	O
of	O
reproductives	O
)	O
.	O

All	O
Chinese	O
colonies	O
contained	O
multiple	O
inbreeding	O
neotenics	O
.	O

In	O
Hawaii	O
,	O
37%	O
of	O
the	O
colonies	O
were	O
simple	O
families	O
and	O
63%	O
were	O
extended	O
families	O
,	O
both	O
having	O
considerable	O
degrees	O
of	O
inbreeding	O
.	O

In	O
Louisiana	O
,	O
57%	O
of	O
the	O
colonies	O
were	O
simple	O
families	O
,	O
which	O
were	O
mostly	O
headed	O
by	O
unrelated	O
pairs	O
,	O
and	O
43%	O
were	O
extended	O
families	O
.	O

In	O
simple	O
families	O
,	O
size	O
and	O
body	O
weight	O
of	O
workers	O
were	O
not	O
associated	O
with	O
F	O
(	O
IC	O
)	O
or	O
heterozygosity	O
.	O

In	O
extended	O
families	O
of	O
two	O
populations	O
,	O
both	O
size	O
parameters	O
were	O
negatively	O
correlated	O
with	O
F	O
(	O
IC	O
)	O
;	O
however	O
,	O
heterozygosity	O
was	O
not	O
associated	O
with	O
worker	O
size	O
in	O
any	O
of	O
the	O
populations	O
.	O

This	O
suggests	O
that	O
the	O
number	O
of	O
reproductives	O
within	O
colonies	O
has	O
a	O
stronger	O
influence	O
on	O
worker	O
size	O
than	O
the	O
individuals	O
'	O
genetic	O
diversity	O
in	O
Formosan	O
subterranean	O
termite	O
colonies	O
.	O

Protease	O
production	O
by	O
different	O
thermophilic	O
fungi	O
.	O

A	O
comparative	O
study	O
was	O
carried	O
out	O
to	O
evaluate	O
protease	O
production	O
in	O
solid	O
-	O
state	O
fermentation	O
(	O
SSF	O
)	O
and	O
submerged	O
fermentation	O
(	O
SmF	O
)	O
by	O
nine	O
different	O
thermophilic	O
fungi	O
-	O
Thermoascus	O
aurantiacus	O
Miehe	O
,	O
Thermomyces	O
lanuginosus	O
,	O
T	O
.	O

lanuginosus	O
TO	O
.03	O
,	O
Aspergillus	O
flavus	O
1.2	O
,	O
Aspergillus	O
sp	O
.	O

13.33	O
,	O
Aspergillus	O
sp	O
.	O

13.34	O
,	O
Aspergillus	O
sp	O
.	O

13.35	O
,	O
Rhizomucor	O
pusillus	O
13.36	O
and	O
Rhizomucor	O
sp	O
.	O

13.37	O
-	O
using	O
substrates	O
containing	O
proteins	O
to	O
induce	O
enzyme	O
secretion	O
.	O

Soybean	O
extract	O
(	O
soybean	O
milk	O
)	O
,	O
soybean	O
flour	O
,	O
milk	O
powder	O
,	O
rice	O
,	O
and	O
wheat	O
bran	O
were	O
tested	O
.	O

The	O
most	O
satisfactory	O
results	O
were	O
obtained	O
when	O
using	O
wheat	O
bran	O
in	O
SSF	O
.	O

The	O
fungi	O
that	O
stood	O
out	O
in	O
SSF	O
were	O
T	O
.	O

lanuginosus	O
,	O
T	O
.	O

lanuginosus	O
TO	O
.03	O
,	O
Aspergillus	O
sp	O
.	O

13.34	O
,	O
Aspergillus	O
sp	O
.	O

13.35	O
,	O
and	O
Rhizomucor	O
sp	O
.	O

13.37	O
,	O
and	O
those	O
in	O
SmF	O
were	O
T	O
.	O

aurantiacus	O
,	O
T	O
.	O

lanuginosus	O
TO	O
.03	O
,	O
and	O
13.37	O
.	O

In	O
both	O
fermentation	O
systems	O
,	O
A	O
.	O

flavus	O
1.2	O
and	O
R	O
.	O

pusillus	O
13.36	O
presented	O
the	O
lowest	O
levels	O
of	O
proteolytic	O
activity	O
.	O

Inhomogeneity	O
of	O
Fecal	O
Flora	O
in	O
Separately	O
Reared	O
Laboratory	O
Mice	O
,	O
as	O
Detected	O
by	O
Denaturing	O
Gradient	O
Gel	O
Electrophoresis	O
(	O
DGGE	O
)	O
.	O

Laboratory	O
mice	O
were	O
divided	O
into	O
2	O
groups	O
and	O
introduced	O
to	O
different	O
rooms	O
immediately	O
after	O
being	O
transferred	O
from	O
a	O
mouse	O
farm	O
.	O

Polymerase	O
chain	O
reaction	O
followed	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
were	O
performed	O
on	O
the	O
V6	O
-	O
V8	O
regions	O
of	O
bacterial	O
16S	O
rDNA	O
obtained	O
from	O
fecal	O
samples	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
8	O
weeks	O
after	O
the	O
introduction	O
.	O

Binary	O
data	O
were	O
obtained	O
from	O
banding	O
patterns	O
,	O
and	O
Euclidean	O
distances	O
for	O
each	O
week	O
were	O
calculated	O
and	O
analyzed	O
by	O
cluster	O
analysis	O
and	O
non	O
-	O
metric	O
multidimensional	O
scaling	O
.	O

Euclidean	O
distances	O
were	O
significantly	O
higher	O
at	O
weeks	O
1	O
and	O
2	O
than	O
at	O
week	O
0	O
in	O
both	O
groups	O
,	O
although	O
the	O
distances	O
between	O
the	O
2	O
groups	O
were	O
significantly	O
higher	O
after	O
week	O
1	O
than	O
week	O
0	O
.	O

The	O
distances	O
between	O
the	O
2	O
groups	O
were	O
significantly	O
higher	O
than	O
those	O
within	O
each	O
group	O
at	O
weeks	O
4	O
and	O
8	O
.	O

Mice	O
in	O
the	O
2	O
groups	O
formed	O
clusters	O
at	O
weeks	O
2	O
and	O
3	O
respectively	O
,	O
and	O
mice	O
were	O
divided	O
into	O
2	O
clusters	O
by	O
their	O
respective	O
groups	O
at	O
weeks	O
4	O
and	O
8	O
.	O

Mice	O
in	O
the	O
2	O
groups	O
were	O
distributed	O
on	O
opposite	O
sides	O
of	O
the	O
origin	O
on	O
the	O
2	O
-	O
dimensional	O
plane	O
after	O
week	O
2	O
.	O

These	O
results	O
suggest	O
that	O
mouse	O
fecal	O
flora	O
changed	O
characteristically	O
,	O
according	O
to	O
the	O
local	O
environment	O
after	O
introduction	O
.	O

Mail	O
-	O
in	O
data	O
collection	O
at	O
SPring	O
-	O
8	O
protein	O
crystallography	O
beamlines	O
.	O

A	O
mail	O
-	O
in	O
data	O
collection	O
system	O
makes	O
it	O
possible	O
for	O
beamline	O
users	O
to	O
collect	O
diffraction	O
data	O
without	O
visiting	O
a	O
synchrotron	O
facility	O
.	O

In	O
the	O
mail	O
-	O
in	O
data	O
collection	O
system	O
at	O
SPring	O
-	O
8	O
,	O
users	O
pack	O
crystals	O
into	O
sample	O
trays	O
and	O
send	O
the	O
trays	O
to	O
SPring	O
-	O
8	O
via	O
a	O
courier	O
service	O
as	O
the	O
first	O
step	O
.	O

Next	O
,	O
the	O
user	O
specifies	O
measurement	O
conditions	O
and	O
checks	O
the	O
diffraction	O
images	O
via	O
the	O
Internet	O
.	O

The	O
user	O
can	O
also	O
collect	O
diffraction	O
data	O
using	O
an	O
automated	O
sample	O
changer	O
robot	O
and	O
beamline	O
control	O
software	O
.	O

For	O
distant	O
users	O
there	O
is	O
a	O
newly	O
developed	O
data	O
management	O
system	O
,	O
D	O
-	O
Cha	O
.	O

D	O
-	O
Cha	O
provides	O
a	O
graphical	O
user	O
interface	O
that	O
enables	O
the	O
user	O
to	O
specify	O
the	O
experimental	O
conditions	O
for	O
samples	O
and	O
to	O
check	O
and	O
download	O
the	O
diffraction	O
images	O
using	O
a	O
web	O
browser	O
.	O

This	O
system	O
is	O
now	O
in	O
routine	O
operation	O
and	O
is	O
contributing	O
to	O
high	O
-	O
throughput	O
beamline	O
operation	O
.	O

Implied	O
preference	O
for	O
seismic	O
design	O
level	O
and	O
earthquake	O
insurance	O
.	O

Seismic	O
risk	O
can	O
be	O
reduced	O
by	O
implementing	O
newly	O
developed	O
seismic	O
provisions	O
in	O
design	O
codes	O
.	O

Furthermore	O
,	O
financial	O
protection	O
or	O
enhanced	O
utility	O
and	O
happiness	O
for	O
stakeholders	O
could	O
be	O
gained	O
through	O
the	O
purchase	O
of	O
earthquake	O
insurance	O
.	O

If	O
this	O
is	O
not	O
so	O
,	O
there	O
would	O
be	O
no	O
market	O
for	O
such	O
insurance	O
.	O

However	O
,	O
perceived	O
benefit	O
associated	O
with	O
insurance	O
is	O
not	O
universally	O
shared	O
by	O
stakeholders	O
partly	O
due	O
to	O
their	O
diverse	O
risk	O
attitudes	O
.	O

This	O
study	O
investigates	O
the	O
implied	O
seismic	O
design	O
preference	O
with	O
insurance	O
options	O
for	O
decisionmakers	O
of	O
bounded	O
rationality	O
whose	O
preferences	O
could	O
be	O
adequately	O
represented	O
by	O
the	O
cumulative	O
prospect	O
theory	O
(	O
CPT	O
)	O
.	O

The	O
investigation	O
is	O
focused	O
on	O
assessing	O
the	O
sensitivity	O
of	O
the	O
implied	O
seismic	O
design	O
preference	O
with	O
insurance	O
options	O
to	O
model	O
parameters	O
of	O
the	O
CPT	O
and	O
to	O
fair	O
and	O
unfair	O
insurance	O
arrangements	O
.	O

Numerical	O
results	O
suggest	O
that	O
human	O
cognitive	O
limitation	O
and	O
risk	O
perception	O
can	O
affect	O
the	O
implied	O
seismic	O
design	O
preference	O
by	O
the	O
CPT	O
significantly	O
.	O

The	O
mandatory	O
purchase	O
of	O
fair	O
insurance	O
will	O
lead	O
the	O
implied	O
seismic	O
design	O
preference	O
to	O
the	O
optimum	O
design	O
level	O
that	O
is	O
dictated	O
by	O
the	O
minimum	O
expected	O
lifecycle	O
cost	O
rule	O
.	O

Unfair	O
insurance	O
decreases	O
the	O
expected	O
gain	O
as	O
well	O
as	O
its	O
associated	O
variability	O
,	O
which	O
is	O
preferred	O
by	O
risk	O
-	O
averse	O
decisionmakers	O
.	O

The	O
obtained	O
results	O
of	O
the	O
implied	O
preference	O
for	O
the	O
combination	O
of	O
the	O
seismic	O
design	O
level	O
and	O
insurance	O
option	O
suggest	O
that	O
property	O
owners	O
,	O
financial	O
institutions	O
,	O
and	O
municipalities	O
can	O
take	O
advantage	O
of	O
affordable	O
insurance	O
to	O
establish	O
successful	O
seismic	O
risk	O
management	O
strategies	O
.	O

X	O
-	O
ray	O
beam	O
stabilization	O
at	O
BL	O
-	O
17A	O
,	O
the	O
protein	O
microcrystallography	O
beamline	O
of	O
the	O
Photon	O
Factory	O
.	O

BL	O
-	O
17A	O
is	O
a	O
new	O
structural	O
biology	O
beamline	O
at	O
the	O
Photon	O
Factory	O
,	O
Japan	O
.	O

The	O
high	O
-	O
brilliance	O
beam	O
,	O
derived	O
from	O
the	O
new	O
short	O
-	O
gap	O
undulator	O
(	O
SGU	O
#	O
17	O
)	O
,	O
allows	O
for	O
unique	O
protein	O
crystallographic	O
experiments	O
such	O
as	O
data	O
collection	O
from	O
microcrystals	O
and	O
structural	O
determination	O
using	O
softer	O
X	O
-	O
rays	O
.	O

However	O
,	O
microcrystal	O
experiments	O
require	O
robust	O
beam	O
stability	O
during	O
data	O
collection	O
and	O
minor	O
fluctuations	O
could	O
not	O
be	O
ignored	O
.	O

Initially	O
,	O
significant	O
beam	O
instability	O
was	O
observed	O
at	O
BL	O
-	O
17A	O
.	O

The	O
causes	O
of	O
the	O
beam	O
instability	O
were	O
investigated	O
and	O
its	O
various	O
sources	O
identified	O
.	O

Subsequently	O
,	O
several	O
effective	O
countermeasures	O
have	O
been	O
implemented	O
,	O
and	O
the	O
fluctuation	O
of	O
the	O
beam	O
intensity	O
successfully	O
suppressed	O
to	O
within	O
1%	O
.	O

Here	O
the	O
instability	O
reduction	O
techniques	O
used	O
at	O
BL	O
-	O
17A	O
are	O
presented	O
.	O

Neonatal	O
pulmonary	O
tuberculosis	O
evolving	O
to	O
a	O
destroyed	O
lung	O
.	O

Tuberculosis	O
(	O
TB	O
)	O
in	O
the	O
newborn	O
is	O
infrequent	O
,	O
difficult	O
to	O
diagnose	O
and	O
often	O
devastating	O
.	O

Congenital	O
TB	O
is	O
rare	O
,	O
with	O
most	O
neonates	O
and	O
young	O
infants	O
becoming	O
infected	O
after	O
birth	O
.	O

The	O
incidence	O
of	O
neonatal	O
TB	O
might	O
increase	O
in	O
industrialised	O
countries	O
as	O
a	O
result	O
of	O
immigration	O
from	O
countries	O
with	O
higher	O
TB	O
incidence	O
among	O
women	O
of	O
childbearing	O
age	O
.	O

We	O
report	O
two	O
cases	O
of	O
post	O
-	O
natally	O
acquired	O
pulmonary	O
TB	O
in	O
newborns	O
who	O
developed	O
marked	O
lung	O
destruction	O
,	O
a	O
complication	O
of	O
TB	O
which	O
has	O
seldom	O
been	O
described	O
in	O
the	O
first	O
month	O
of	O
life	O
.	O

A	O
high	O
index	O
of	O
clinical	O
suspicion	O
is	O
required	O
when	O
evaluating	O
pregnant	O
women	O
at	O
risk	O
for	O
TB	O
and	O
their	O
ill	O
children	O
,	O
as	O
early	O
identification	O
and	O
treatment	O
can	O
prevent	O
the	O
devastating	O
consequences	O
of	O
TB	O
.	O

Visual	O
perception	O
in	O
prediagnostic	O
and	O
early	O
stage	O
Huntington	O
's	O
disease	O
.	O

Disturbances	O
of	O
visual	O
perception	O
frequently	O
accompany	O
neurodegenerative	O
disorders	O
but	O
have	O
been	O
little	O
studied	O
in	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
gene	O
carriers	O
.	O

We	O
used	O
psychophysical	O
tests	O
to	O
assess	O
visual	O
perception	O
among	O
individuals	O
in	O
the	O
prediagnostic	O
and	O
early	O
stages	O
of	O
HD	O
.	O

The	O
sample	O
comprised	O
four	O
groups	O
,	O
which	O
included	O
201	O
nongene	O
carriers	O
(	O
NG	O
)	O
,	O
32	O
prediagnostic	O
gene	O
carriers	O
with	O
minimal	O
neurological	O
abnormalities	O
(	O
PD1	O
)	O
;	O
20	O
prediagnostic	O
gene	O
carriers	O
with	O
moderate	O
neurological	O
abnormalities	O
(	O
PD2	O
)	O
,	O
and	O
36	O
gene	O
carriers	O
with	O
diagnosed	O
HD	O
.	O

Contrast	O
sensitivity	O
for	O
stationary	O
and	O
moving	O
sinusoidal	O
gratings	O
,	O
and	O
tests	O
of	O
form	O
and	O
motion	O
discrimination	O
,	O
were	O
used	O
to	O
probe	O
different	O
visual	O
pathways	O
.	O

Patients	O
with	O
HD	O
showed	O
impaired	O
contrast	O
sensitivity	O
for	O
moving	O
gratings	O
.	O

For	O
one	O
of	O
the	O
three	O
contrast	O
sensitivity	O
tests	O
,	O
the	O
prediagnostic	O
gene	O
carriers	O
with	O
greater	O
neurological	O
abnormality	O
(	O
PD2	O
)	O
also	O
had	O
impaired	O
performance	O
as	O
compared	O
with	O
NG	O
.	O

These	O
findings	O
suggest	O
that	O
early	O
stage	O
HD	O
disrupts	O
visual	O
functions	O
associated	O
with	O
the	O
magnocellular	O
pathway	O
.	O

However	O
,	O
these	O
changes	O
are	O
only	O
observed	O
in	O
individuals	O
diagnosed	O
with	O
HD	O
or	O
who	O
are	O
in	O
the	O
more	O
symptomatic	O
stages	O
of	O
prediagnostic	O
HD	O
.	O

Prospects	O
for	O
the	O
use	O
of	O
differentiation	O
-	O
modulating	O
agents	O
as	O
adjuvant	O
of	O
photodynamic	O
therapy	O
for	O
proliferative	O
dermatoses	O
.	O

Current	O
interest	O
in	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
in	O
dermatology	O
stems	O
from	O
its	O
recognized	O
success	O
in	O
dermatological	O
oncology	O
,	O
straightforward	O
approach	O
,	O
easy	O
accessibility	O
and	O
low	O
cost	O
.	O

PDT	O
is	O
a	O
photochemistry	O
-	O
based	O
modality	O
in	O
which	O
a	O
light	O
-	O
activated	O
photosensitizer	O
(	O
PS	O
)	O
destroys	O
tissue	O
through	O
oxygen	O
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
.	O

Although	O
PDT	O
has	O
been	O
used	O
in	O
dermatology	O
for	O
several	O
decades	O
,	O
its	O
application	O
has	O
still	O
not	O
extended	O
significantly	O
into	O
the	O
routine	O
management	O
of	O
neoplastic	O
and	O
proliferative	O
dermatoses	O
because	O
of	O
continuing	O
issues	O
with	O
the	O
selectivity	O
of	O
the	O
PS	O
for	O
affected	O
tissues	O
.	O

This	O
review	O
analyzes	O
prospects	O
for	O
optimization	O
of	O
PDT	O
for	O
the	O
management	O
of	O
dermatoses	O
with	O
defects	O
in	O
keratinocyte	O
proliferation	O
/	O
differentiation	O
,	O
and	O
discusses	O
the	O
use	O
of	O
differentiating	O
agents	O
that	O
redirect	O
metabolic	O
utilization	O
within	O
cells	O
and	O
lead	O
to	O
high	O
levels	O
of	O
PS	O
accumulation	O
.	O

Photodynamic	O
diagnostics	O
of	O
bladder	O
tumors	O
.	O

Approximately	O
18,000	O
new	O
cases	O
of	O
urothelial	O
cancer	O
of	O
the	O
bladder	O
occur	O
annually	O
,	O
making	O
it	O
the	O
most	O
frequent	O
urogenital	O
neoplasia	O
representing	O
nearly	O
4%	O
of	O
all	O
malignomas	O
.	O

Tumor	O
stage	O
defines	O
two	O
subgroups	O
requiring	O
specific	O
therapeutic	O
approaches	O
and	O
implying	O
distinct	O
prognoses	O
.	O

Non	O
-	O
muscle	O
-	O
invasive	O
urothelial	O
cancer	O
recurs	O
frequently	O
and	O
occasionally	O
progresses	O
to	O
muscle	O
-	O
invasive	O
stages	O
.	O

Remnant	O
tumor	O
after	O
initial	O
resection	O
is	O
seen	O
as	O
one	O
major	O
factor	O
in	O
high	O
recurrence	O
rates	O
.	O

Although	O
photodynamic	O
diagnostics	O
improving	O
detection	O
and	O
increasing	O
recurrence	O
-	O
free	O
survival	O
has	O
been	O
introduced	O
to	O
broad	O
application	O
,	O
it	O
has	O
yet	O
not	O
been	O
established	O
as	O
standard	O
procedure	O
.	O

This	O
article	O
reviews	O
the	O
current	O
literature	O
and	O
discusses	O
controversial	O
aspects	O
.	O

Thalamic	O
atrophy	O
and	O
cognition	O
in	O
unilateral	O
temporal	O
lobe	O
epilepsy	O
.	O

This	O
study	O
examined	O
quantitative	O
magnetic	O
resonance	O
volumes	O
of	O
the	O
thalamus	O
and	O
hippocampus	O
and	O
determined	O
their	O
relationship	O
with	O
cognitive	O
function	O
and	O
clinical	O
seizure	O
characteristics	O
in	O
a	O
sample	O
of	O
46	O
unilateral	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
subjects	O
(	O
20	O
left	O
and	O
26	O
right	O
)	O
and	O
29	O
controls	O
.	O

The	O
hippocampus	O
and	O
thalamus	O
exhibited	O
different	O
patterns	O
of	O
volume	O
abnormality	O
,	O
different	O
associations	O
with	O
clinical	O
seizure	O
characteristics	O
,	O
and	O
different	O
patterns	O
of	O
relationship	O
with	O
cognitive	O
measures	O
.	O

Hippocampal	O
volume	O
reduction	O
was	O
primarily	O
ipsilateral	O
to	O
the	O
seizure	O
focus	O
,	O
and	O
thalamic	O
volume	O
reduction	O
was	O
bilateral	O
.	O

Ipsilateral	O
hippocampal	O
volume	O
was	O
significantly	O
correlated	O
with	O
both	O
early	O
neurodevelopmental	O
features	O
(	O
age	O
of	O
seizure	O
onset	O
)	O
and	O
disease	O
characteristics	O
(	O
duration	O
of	O
epilepsy	O
)	O
,	O
whereas	O
thalamus	O
integrity	O
was	O
related	O
only	O
to	O
disease	O
variables	O
.	O

Hippocampal	O
volume	O
showed	O
a	O
selective	O
association	O
with	O
verbal	O
memory	O
performance	O
.	O

In	O
contrast	O
,	O
both	O
left	O
and	O
right	O
thalamic	O
volumes	O
were	O
significantly	O
correlated	O
with	O
performance	O
on	O
both	O
memory	O
and	O
nonmemory	O
cognitive	O
domains	O
.	O

These	O
findings	O
underscore	O
the	O
importance	O
of	O
thalamic	O
atrophy	O
in	O
chronic	O
TLE	O
and	O
its	O
potential	O
implications	O
for	O
cognition	O
.	O

Unilateral	O
hearing	O
disturbance	O
could	O
be	O
an	O
isolated	O
manifestation	O
prior	O
to	O
ipsilateral	O
anterior	O
inferior	O
cerebellar	O
artery	O
infarction	O
.	O

A	O
50	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
a	O
sudden	O
onset	O
of	O
right	O
-	O
sided	O
hearing	O
disturbance	O
.	O

His	O
hearing	O
disturbance	O
improved	O
gradually	O
,	O
however	O
,	O
dysarthria	O
,	O
right	O
-	O
sided	O
facial	O
weakness	O
and	O
dysesthesia	O
,	O
and	O
gait	O
disturbance	O
was	O
developed	O
11	O
days	O
after	O
the	O
onset	O
of	O
hearing	O
disturbance	O
.	O

MR	O
imaging	O
revealed	O
fresh	O
infarctions	O
of	O
the	O
right	O
dorsolateral	O
pons	O
and	O
middle	O
cerebellar	O
peduncle	O
localized	O
in	O
the	O
territory	O
of	O
anterior	O
inferior	O
cerebellar	O
artery	O
.	O

Unilateral	O
hearing	O
disturbance	O
could	O
be	O
an	O
isolated	O
manifestation	O
prior	O
to	O
ipsilateral	O
anterior	O
inferior	O
cerebellar	O
artery	O
infarction	O
.	O

An	O
OLETF	O
Allele	O
of	O
Hyperglycemic	O
QTL	O
Nidd3	O
/	O
of	O
Is	O
Dominant	O
.	O

The	O
OLETF	O
rat	O
is	O
a	O
well	O
-	O
established	O
model	O
for	O
the	O
study	O
of	O
type	O
2	O
diabetes	O
associated	O
with	O
obesity	O
and	O
has	O
been	O
shown	O
to	O
possess	O
multiple	O
hyperglycemic	O
alleles	O
in	O
its	O
genome	O
.	O

Here	O
we	O
focused	O
on	O
and	O
carefully	O
characterized	O
one	O
of	O
the	O
previously	O
reported	O
congenic	O
strains	O
,	O
F	O
.	O

O	O
-	O
Nidd3	O
/	O
of	O
that	O
carries	O
the	O
OLETF	O
allele	O
of	O
the	O
Nidd3	O
/	O
of	O
locus	O
(	O
also	O
known	O
as	O
Niddm21	O
in	O
the	O
Rat	O
Genome	O
Database	O
)	O
in	O
the	O
normoglycemic	O
F344	O
genetic	O
background	O
.	O

A	O
prominent	O
finding	O
was	O
that	O
the	O
F1	O
progeny	O
between	O
the	O
congenic	O
and	O
the	O
F344	O
stain	O
,	O
whose	O
genotype	O
is	O
heterozygote	O
at	O
the	O
Nidd3	O
/	O
of	O
locus	O
,	O
showed	O
mild	O
hyperglycemia	O
equal	O
to	O
the	O
parental	O
congenic	O
rat	O
,	O
suggesting	O
that	O
the	O
OLETF	O
allele	O
is	O
dominant	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
in	O
which	O
a	O
diabetic	O
QTL	O
has	O
been	O
directly	O
demonstrated	O
to	O
be	O
dominant	O
by	O
using	O
congenic	O
strains	O
.	O

Implementation	O
of	O
remote	O
monitoring	O
and	O
diffraction	O
evaluation	O
systems	O
at	O
the	O
Photon	O
Factory	O
macromolecular	O
crystallography	O
beamlines	O
.	O

Owing	O
to	O
recent	O
advances	O
in	O
high	O
-	O
throughput	O
technology	O
in	O
macromolecular	O
crystallography	O
beamlines	O
,	O
such	O
as	O
high	O
-	O
brilliant	O
X	O
-	O
ray	O
sources	O
,	O
high	O
-	O
speed	O
readout	O
detectors	O
and	O
robotics	O
,	O
the	O
number	O
of	O
samples	O
that	O
can	O
be	O
examined	O
in	O
a	O
single	O
visit	O
to	O
the	O
beamline	O
has	O
increased	O
dramatically	O
.	O

In	O
order	O
to	O
make	O
these	O
experiments	O
more	O
efficient	O
,	O
two	O
functions	O
,	O
remote	O
monitoring	O
and	O
diffraction	O
image	O
evaluation	O
,	O
have	O
been	O
implemented	O
in	O
the	O
macromolecular	O
crystallography	O
beamlines	O
at	O
the	O
Photon	O
Factory	O
(	O
PF	O
)	O
.	O

Remote	O
monitoring	O
allows	O
scientists	O
to	O
participate	O
in	O
the	O
experiment	O
by	O
watching	O
from	O
their	O
laboratories	O
,	O
without	O
having	O
to	O
come	O
to	O
the	O
beamline	O
.	O

Diffraction	O
image	O
evaluation	O
makes	O
experiments	O
easier	O
,	O
especially	O
when	O
using	O
the	O
sample	O
exchange	O
robot	O
.	O

To	O
implement	O
these	O
two	O
functions	O
,	O
two	O
independent	O
clients	O
have	O
been	O
developed	O
that	O
work	O
specifically	O
for	O
remote	O
monitoring	O
and	O
diffraction	O
image	O
evaluation	O
.	O

In	O
the	O
macromolecular	O
crystallography	O
beamlines	O
at	O
PF	O
,	O
beamline	O
control	O
is	O
performed	O
using	O
STARS	O
(	O
simple	O
transmission	O
and	O
retrieval	O
system	O
)	O
.	O

The	O
system	O
adopts	O
a	O
client	O
-	O
server	O
style	O
in	O
which	O
client	O
programs	O
communicate	O
with	O
each	O
other	O
through	O
a	O
server	O
process	O
using	O
the	O
STARS	O
protocol	O
.	O

This	O
is	O
an	O
advantage	O
of	O
the	O
extension	O
of	O
the	O
system	O
;	O
implementation	O
of	O
these	O
new	O
functions	O
required	O
few	O
modifications	O
of	O
the	O
existing	O
system	O
.	O

Direct	O
Comparison	O
between	O
ICSI	O
-	O
Mediated	O
DNA	O
Transfer	O
and	O
Pronuclear	O
DNA	O
Microinjection	O
for	O
Producing	O
Transgenic	O
Rats	O
.	O

Production	O
efficiency	O
of	O
transgenic	O
rats	O
was	O
compared	O
directly	O
between	O
the	O
routine	O
pronuclear	O
microinjection	O
of	O
exogenous	O
DNA	O
solution	O
(	O
PNMI	O
-	O
Tg	O
method	O
)	O
and	O
the	O
ooplasmic	O
injection	O
of	O
sperm	O
cells	O
exposed	O
to	O
exogenous	O
DNA	O
solution	O
(	O
ICSI	O
-	O
Tg	O
method	O
)	O
using	O
six	O
DNA	O
constructs	O
.	O

The	O
overall	O
production	O
efficiency	O
per	O
treated	O
oocyte	O
in	O
the	O
ICSI	O
-	O
Tg	O
method	O
(	O
mean	O
1.1%	O
,	O
range	O
0.2	O
to	O
3.1%	O
)	O
was	O
similar	O
to	O
that	O
in	O
the	O
PNMI	O
-	O
Tg	O
method	O
(	O
mean	O
1.1%	O
,	O
range	O
0	O
to	O
2.4%	O
)	O
.	O

An	O
advantage	O
of	O
the	O
ICSI	O
-	O
Tg	O
method	O
in	O
the	O
production	O
of	O
transgenic	O
rats	O
is	O
noted	O
in	O
cases	O
in	O
which	O
a	O
low	O
yield	O
of	O
pronuclear	O
zygotes	O
is	O
an	O
inevitable	O
fate	O
of	O
the	O
rat	O
strain	O
.	O

EEG	O
observations	O
in	O
a	O
case	O
with	O
thalamic	O
syndrome	O
.	O

A	O
case	O
of	O
thalamic	O
syndrome	O
of	O
the	O
D	O
ÃÂ	O
ÃÂ©	O
jerine	O
-	O
Roussy	O
type	O
is	O
presented	O
.	O

EEG	O
studies	O
reveal	O
that	O
although	O
bilaterally	O
symmetrical	O
rhythmic	O
activity	O
may	O
be	O
present	O
when	O
the	O
patient	O
is	O
awake	O
,	O
during	O
drowsiness	O
and	O
deeper	O
sleep	O
a	O
marked	O
asymmetry	O
often	O
appears	O
with	O
early	O
disappearance	O
of	O
alpha	O
activity	O
and	O
reduction	O
or	O
abolition	O
of	O
spindles	O
on	O
the	O
side	O
involved	O
.	O

Thalamic	O
integration	O
in	O
the	O
sleep	O
mechanism	O
is	O
briefly	O
discussed	O
.	O

Distinct	O
cognitive	O
profiles	O
and	O
rates	O
of	O
decline	O
on	O
the	O
Mattis	O
Dementia	O
Rating	O
Scale	O
in	O
autopsy	O
-	O
confirmed	O
frontotemporal	O
dementia	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Neuropsychological	O
studies	O
have	O
shown	O
that	O
patients	O
with	O
Frontotemporal	O
dementia	O
(	O
FTD	O
)	O
perform	O
worse	O
than	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
on	O
tests	O
of	O
conceptualization	O
and	O
verbal	O
fluency	O
,	O
but	O
better	O
on	O
tests	O
of	O
memory	O
and	O
visuospatial	O
functions	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
if	O
these	O
distinct	O
cognitive	O
profiles	O
are	O
robust	O
enough	O
to	O
be	O
detected	O
using	O
a	O
relatively	O
brief	O
dementia	O
screening	O
instrument	O
such	O
as	O
the	O
Mattis	O
Dementia	O
Rating	O
Scale	O
(	O
MDRS	O
)	O
.	O

To	O
address	O
this	O
issue	O
,	O
the	O
MDRS	O
subscale	O
profiles	O
of	O
patients	O
with	O
autopsy	O
-	O
confirmed	O
FTD	O
(	O
n	O
=	O
17	O
)	O
or	O
AD	O
(	O
n	O
=	O
34	O
)	O
were	O
compared	O
.	O

Results	O
showed	O
distinct	O
cognitive	O
profiles	O
in	O
which	O
FTD	O
patients	O
performed	O
worse	O
than	O
AD	O
patients	O
on	O
the	O
Initiation	O
/	O
Perseveration	O
and	O
Conceptualization	O
subscales	O
while	O
performing	O
better	O
on	O
the	O
Memory	O
and	O
Construction	O
subscales	O
.	O

The	O
distinct	O
subscale	O
profiles	O
correctly	O
classified	O
85%	O
of	O
AD	O
patients	O
and	O
76%	O
of	O
FTD	O
patients	O
.	O

Profiles	O
were	O
maintained	O
in	O
a	O
subset	O
of	O
mildly	O
-	O
to	O
-	O
moderately	O
demented	O
patients	O
(	O
MDRS	O
>	O
or	O
=	O
105	O
)	O
and	O
correctly	O
classified	O
89%	O
of	O
these	O
patients	O
.	O

In	O
addition	O
,	O
FTD	O
patients	O
(	O
mean	O
=	O
30.0	O
points	O
/	O
year	O
)	O
declined	O
faster	O
than	O
AD	O
patients	O
(	O
mean	O
=	O
14.8	O
points	O
/	O
year	O
)	O
on	O
MDRS	O
total	O
and	O
specific	O
subscale	O
scores	O
.	O

These	O
results	O
suggest	O
that	O
the	O
MDRS	O
may	O
be	O
a	O
useful	O
adjunct	O
to	O
other	O
clinical	O
measures	O
for	O
distinguishing	O
FTD	O
from	O
AD	O
and	O
tracking	O
the	O
progression	O
of	O
the	O
disorder	O
.	O

Households	O
'	O
perceived	O
personal	O
risk	O
and	O
responses	O
in	O
a	O
multihazard	O
environment	O
.	O

This	O
study	O
proposed	O
and	O
tested	O
a	O
multistage	O
model	O
of	O
household	O
response	O
to	O
three	O
hazards	O
-	O
flood	O
,	O
hurricane	O
,	O
and	O
toxic	O
chemical	O
release	O
-	O
in	O
Harris	O
County	O
Texas	O
.	O

The	O
model	O
,	O
which	O
extends	O
Lindell	O
and	O
Perry	O
's	O
(	O
1992	O
,	O
2004	O
)	O
Protective	O
Action	O
Decision	O
Model	O
,	O
proposed	O
a	O
basic	O
causal	O
chain	O
from	O
hazard	O
proximity	O
through	O
hazard	O
experience	O
and	O
perceived	O
personal	O
risk	O
to	O
expectations	O
of	O
continued	O
residence	O
in	O
the	O
home	O
and	O
adoption	O
of	O
household	O
hazard	O
adjustments	O
.	O

Data	O
from	O
321	O
households	O
generally	O
supported	O
the	O
model	O
,	O
but	O
the	O
mediating	O
effects	O
of	O
hazard	O
experience	O
and	O
perceived	O
personal	O
risk	O
were	O
partial	O
rather	O
than	O
complete	O
.	O

In	O
addition	O
,	O
the	O
data	O
suggested	O
that	O
four	O
demographic	O
variables	O
-	O
gender	O
,	O
age	O
,	O
income	O
,	O
and	O
ethnicity	O
-	O
affect	O
the	O
basic	O
causal	O
chain	O
at	O
different	O
points	O
.	O

An	O
exploratory	O
evaluation	O
of	O
the	O
contribution	O
of	O
personality	O
and	O
childhood	O
sexual	O
victimization	O
to	O
the	O
development	O
of	O
sexually	O
abusive	O
behavior	O
.	O

Scores	O
on	O
the	O
Millon	O
Adolescent	O
Clinical	O
Inventory	O
(	O
MACI	O
)	O
and	O
the	O
Childhood	O
Trauma	O
Questionnaire	O
(	O
CTQ	O
)	O
were	O
collected	O
from	O
two	O
samples	O
of	O
incarcerated	O
delinquent	O
males	O
:	O
74	O
adjudicated	O
sexual	O
abusers	O
and	O
53	O
nonsexual	O
abusers	O
.	O

In	O
comparison	O
to	O
non	O
-	O
sexually	O
abusive	O
youths	O
,	O
a	O
larger	O
percentage	O
of	O
the	O
sexually	O
abusive	O
youths	O
indicated	O
a	O
history	O
of	O
childhood	O
sexual	O
victimization	O
.	O

The	O
scores	O
were	O
then	O
entered	O
into	O
a	O
logistic	O
regression	O
to	O
assess	O
the	O
contribution	O
of	O
personality	O
characteristics	O
to	O
a	O
social	O
learning	O
"	O
victim	O
-	O
to	O
-	O
victimizer	O
"	O
etiological	O
model	O
.	O

After	O
controlling	O
for	O
time	O
in	O
treatment	O
,	O
the	O
model	O
correctly	O
classified	O
76.6%	O
of	O
the	O
youths	O
.	O

The	O
variables	O
that	O
contributed	O
significantly	O
to	O
the	O
social	O
learning	O
model	O
were	O
the	O
CTQ	O
Sexual	O
Abuse	O
and	O
Physical	O
Neglect	O
scales	O
and	O
the	O
Submissive	O
and	O
Forceful	O
scales	O
on	O
the	O
MACI	O
.	O

Research	O
and	O
treatment	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

